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ABSTRACT 
 
Lyme disease is a significant and re-emerging disease that impacts the 
public health, particularly in endemic regions. The causative agent of Lyme 
disease, Borrelia burgdorferi, is transmitted to humans by Ixodes ticks. During tick 
feeding, B. burgdorferi is injected into the skin, and quickly adapts to mammalian 
environment by differentially expressing a number of genes, many of which 
encode lipoproteins and contribute to borrelial infectivity. Identification and 
characterization of these host specific proteins should provide insight into 
important steps in regard to B. burgdorferi colonization as well as borrelial 
pathogenesis. 
In the first part of this study, we identified a previously uncharacterized 
borrelial lipoprotein designated BBA33. We showed that a bba33 mutant failed to 
establish infection in mice and was cleared early in the infectious process, in a 
manner that could be rescued by genetic complementation with intact bba33. In 
terms of the protein function, we found that BBA33 specifically bound to human 
type IV and VI collagen in vitro. Our findings demonstrated that BBA33 functions 
as an essential adhesin in experimental infection via its interaction in collagen-
enriched tissues.  
Previous observation showed that B. burgdorferi resists the classical 
complement-dependent killing; however, the mechanisms of resistance were not 
described. In the second part of this study, we asked how surface exposed 
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lipoproteins might promote resistance to the classical complement pathway. 
Through the use of far-Western immunoblots, we found that the previously 
identified fibronectin binding protein BBK32 mediates binding to the classical 
complement C1 complex. Subsequent surface plasmon resonance assays 
showed that the BBK32 C-terminal domain bound to both C1 and C1r with high 
affinity. This binding was found to inhibit the activation of C1r. Furthermore, the 
production and surface localization of BBK32 in a non-virulent, serum-sensitive 
B. burgdorferi isolate increased the bacterial binding to C1 and C1r, and partially 
promoted bacterial resistance to the classical pathway-dependent killing. This 
study demonstrated a novel mechanism utilized by B. burgdorferi to evade 
complement system activation and survive in the mammalian host. In addition, we 
identified a new function of B. burgdorferi lipoprotein BBK32 in blocking the 
classical complement pathway. Given that several pathologies are associated 
with uncontrolled activation of C1, it is possible that inhibition of this activity by 
BBK32 derivatives/mimetics may provide therapeutic potential. 
Taken together, this study deciphered novel functions of borrelial surface 
lipoproteins. It also provided insight into the mechanisms of how different surface 
proteins of B. burgdorferi mediate the colonization of host tissues and the evasion 
of complement-dependent killing. As such, these studies provide additional insight 
into the role of borrelial surface proteins in the infectivity and pathogenesis of B. 
burgdorferi during experimental infection. 
  iv 
DEDICATION 
 
 
 
 
 
To my family 
  v 
ACKNOWLEDGEMENTS 
 
I would like to express my deepest gratitude to my dissertation committee 
chair and mentor, Dr. Jon Skare, for all his support and guidance throughout the 
entire course of my PhD period, not only in research, but also in my life. His 
selfless time and care were sometimes all that kept me going on my scientific 
journey. I would like to thank my committee members, Dr. James Samuel, Dr. 
David McMurray and Dr. Rajesh Miranda, for their endless guidance in classes, 
assistance, support, and patience in research for all these years. In addition, 
gratitude is extended to Dr. Magnus Höök, Dr. Brandon Garcia, Dr. Magda Barbu, 
Dr. Yaping Ko and Xiaowen Liang for their advice, feedback and collaboration in 
regard to my PhD project. 
We thank Beau Wager for helpful discussions and Sunita Seemanapalli for 
the initial purification of rBBA33. We are grateful to R. Gilmore, J. Seshu and S. 
Bergström for providing us with antiserum to OspC, PncA, and P66, respectively. 
We also wish to thank Katherine Biancardi and Brian Bordelon for excellent 
technical assistance. We gratefully acknowledge the assistance of Texas A&M 
University’s Comparative Medicine Program with antibody production against 
rBBA33. We thank Tom Schwan for generously providing us with strain B314 and 
Seppo Meri for the monoclonal antibody against BBK32. This work was supported 
by Public Health Service grant R01-AI042345, R01-AI058086, and a Texas A&M 
Health Science Center College of Medicine Training Grant Award.  
  vi 
Thanks also go to my friends, colleagues, the faculty and staff in the 
Microbial Pathogenesis and Immunology department for making my time at Texas 
A&M University Health Science Center a great experience.  
Finally, I want to thank all my family members for their unconditional and 
endless love, support and encouragement through my entire PhD period. 
  vii 
NOMENCLATURE 
 
NHS Normal Human Serum 
TLR4 Toll Like Receptor 4 
CDC Centers for Disease Control and Prevention 
LB Lyme Borreliosis 
ORFs Open Reading Frames 
DMC Dialysis Membrane Chambers 
ECM  Extracellular Matrix  
FN Fibronectin 
GAGs Glycosaminoglycans 
MAC Membrane attack complex 
SPR Surface Plasmon Resonance  
CP Classical Pathway  
AP Alternative Pathway 
LP Lectin Pathway 
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
Borrelia burgdorferi, the causative agent of Lyme disease 
Lyme disease was first identified clinically in 1976, when a cluster of 
children residing in the area of Lyme, Connecticut experienced a mysterious 
rheumatoid arthritis-like condition (Steere et al., 1977). Subsequently a causal link 
was established between a tick-based infection and the juvenile arthritis observed. 
In 1981, in the midgut of hard-body Ixodes ticks, Dr. Willy Burgdorfer and 
colleagues discovered a spirochete, which was designated Borrelia burgdorferi 
and was subsequently identified as the etiologic agent of Lyme disease 
(Burgdorfer et al., 1982; Johnson et al., 1984). Since then, Lyme disease has 
transitioned into a significant public health issue in the U.S. and is often plagued 
by difficulty in treatment particularly in the late stage disease, characterized by 
fatigue, muscle pain, and arthritis. Lyme disease is the leading vector-borne 
illness in the United States with approximately 300,000 diagnosed cases per year, 
according to the Centers for Disease Control and Prevention (CDC) (Hinckley et 
al., 2014), indicating that Lyme borreliosis is a significant, re-emerging infectious 
disease. 
Phylogenetic analyses categorized Lyme borreliosis (LB) spirochetes into 
several species, three of which are known to cause Lyme disease in humans The 
three species are collectively referred to as Borrelia burgdorferi senso lato (s.l.) 
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and include B. burgdorferi sensu stricto, B. garinii, and B. afzelii (Baranton et al., 
1992; Margos et al., 2011). B. burgdorferi senso stricto (s.s.), referred to as B. 
burgdorferi herein, is found primarily in the United States and western Europe. 
Normally infection by B. burgdorferi results in the formation of a painless rash 
following the bite of an infected tick, termed erythema migrans, which occurs 3-
32 days after infection (Brisson et al., 2012; Radolf et al., 2012). If no treatment is 
sought, patients can develop neurological illness, arthritis, and carditis (Shapiro, 
2014). In Europe and Asia, most tick-borne dermatological manifestations are 
attributed to B. afzelii (Stanek and Strle, 2008). Likewise, neuroborreliosis is 
associated with B. garinii (Stanek and Strle, 2008).  
 
Manifestation and treatment of Lyme disease 
 Following the bite of an infected tick, B. burgdorferi can transmit to the 
human host resulting in a multi-stage illness characterized by localized, 
disseminated, and persistent Lyme disease (Steere, 2001). The most common 
sign of localized Lyme disease is the erythema migrans lesion (Shapiro, 2014; 
Wormser et al., 2006). Erythema migrans usually appears at the site of the tick 
bite within 1 to 2 weeks in the form of a small erythematous papule, which 
subsequently enlarges and persists for 3 to 4 weeks if untreated (Nadelman et al., 
1996; Smith et al., 2002; Steere and Sikand, 2003). The typical “bull’s eye rash” 
appearance of the erythema migrans is attributed by the flux of immune cells 
including macrophages, dendritic cells and T cells with pro-inflammatory cytokines 
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(Interleukin-6 and Interferon-γ) (Weis and Bockenstedt, 2010) in response to the 
dissemination of spirochetes (Salazar et al., 2003). In some patients, erythema 
migrans is often the sole symptom encountered, but many patients have 
nonspecific symptoms, including headache, myalgia, arthralgia, fatigue, and, less 
often, low-grade fever (Nadelman et al., 1996; Smith et al., 2002; Steere and 
Sikand, 2003). 
 In the dissemination stage, B. burgdorferi is able to migrate 
hematogenously to other sites in the skin and to extracutaneous sites (Shapiro, 
2014). In addition, multiple, often smaller, erythema migrans, are seen at this 
stage of infection (Shapiro, 2014; Smith et al., 2002). Later, the bacteria spread 
to multiple tissues and infected individuals can develop musculoskeletal pain, 
carditis, and neurological symptoms (Duray and Steere, 1988; Steere, 2001; 
Steere et al., 2004). If untreated, the disease may progress to persistent infection 
characterized by the aforementioned symptoms. Late, untreated infection is 
sometimes seen in the form of difficult to treat Lyme arthritis, debilitating 
neurological symptoms, and chronic fatigue (Halperin, 1998; Logigian et al., 1990; 
Oschmann et al., 1998; Steere et al., 1987, 1994).  
The currently recommended treatment for B. burgdorferi includes 
doxycycline, amoxicillin or cefuroxime axetil, with the clearance being about 90% 
(Shapiro, 2014; Wormser et al., 2006). It is worth noting that Lyme disease is still 
highly responsive to antibiotic treatment with early diagnosis in the first two stages 
of disease (Shapiro, 2014). However, when the infection progresses to the late 
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phase, treatment can become more difficult. Such patients may suffer from 
refractory Lyme arthritis, which refers to the inflammation in a large joint (usually 
the knee) for months or even several years after the spirochetal bacterium is 
cleared (Feder et al., 2007). Because of these complications and the lack of 
commercially available vaccines, the best defense is to prevent the initial B. 
burgdorferi transmission or, if infected, to seek antibiotic therapy early in the 
infectious process. 
  
The enzootic life cycle of B. burgdorferi 
The enzootic life cycle of B. burgdorferi involves hard ticks of the Ixodes 
complex and a diverse species of vertebrates. B. burgdorferi is transmitted 
principally by four species of hard ticks including Ixodes ricinus in Europe, I. 
persulcatus in Asia, Ixodes scapularis in eastern North America and I. pacificus in 
western North America (Kurtenbach et al., 2006; Radolf et al., 2012). Larvae and 
nymphal Ixodes ticks feed on several small rodent species, such as the white-
footed mouse and chipmunk (Levine et al., 1985; LoGiudice et al., 2003), whereas 
the adult Ixodes ticks feed on large mammals, most notably deer. There are three 
feeding periods during their 2-year life cycle. The larvae ticks are free of B. 
burgdorferi when they hatch, as there is no vertical transmission (Nefedova et al., 
2004). The tick species acquire B. burgdorferi after feeding on an infected 
reservoir host, followed by molting into a nymphal tick. Subsequently, the nymph 
form of the tick seeks a blood meal and, in that process, transmits the pathogen 
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to the animal or human, usually in the late spring or early summer of the second 
year. Following the final molt, the adult ticks feed on large animals such as the 
white-tailed deer during the fall and lay eggs, which are able to persist through the 
winter and hatch in the following spring or summer into uninfected larvae (Wilson 
and Spielman, 1985). While the white-tailed deer is required for the life cycle of 
Ixodes ticks, given that they serve as a site for the adult ticks to mate, they are 
not directly involved in the enzootic life cycle of B. burgdorferi as the bacteria do 
not survive within an infected deer. Humans are an accidental host and there is 
no documentation of human to human transmission. Most human infections occur 
in the late spring and early summer, which overlaps with the nymphal feeding 
period (Radolf et al., 2012). 
 
The basic biology of B. burgdorferi 
Borrelia spp. are organized similar to Gram-negative bacteria such as 
Escherichia coli with a two-membrane envelope ultrastructure (Samuels, 2010). 
Unlike conventional Gram-negative bacteria, B. burgdorferi lacks 
lipopolysaccharide in their outer membranes (Takayama et al., 1987) and, as such, 
do not activate the innate immune response via the toll-like receptor 4 (TLR4) 
(Hirschfeld et al., 1999; Oosting et al., 2010) . In regard to B. burgdorferi envelope 
structure, a fragile outer membrane overlays the lower protoplasmic cylinder, 
which consists of peptidoglycan along with a cytoplasmic membrane and the 
enclosed cytoplasm (Barbour and Hayes, 1986; Johnson et al., 1984). Borrelia 
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burgdorferi is approximately 0.2 to 0.3 µm in diameter by 15 to 20 µm in length 
and is actively motile with a collection of 7-11 subsurface flagellar organelles 
located in the periplasmic space (Radolf et al., 2012). The flagella are attached to 
the poles and wrap around the cell cylinder and, in addition to providing motility, 
provide the cell with its characteristic flat wave shape (Samuels, 2010).  
To date, 28 complete and draft genome sequences of Lyme borreliosis 
spirochetes have been released (Di et al., 2014; Wattam et al., 2014). Among 
those, the B. burgdorferi strain B31 was the first and probably the most widely 
used (Casjens et al., 2012; Fraser et al., 1997). The complete strain B31 genome 
consists of a single linear chromosome of approximately 910 kilobases (kb), and 
21 linear and circular plasmids, which represent an additional 600 kb of genetic 
material. Many of the plasmids are indispensable for in vitro growth and infection 
(Fraser et al., 1997). The chromosome is relatively small compared to other 
bacteria and B. burgdorferi lacks many metabolic synthesis pathways related 
genes. As such, the Lyme disease spirochete is an obligate parasite. Specifically, 
B. burgdorferi does not synthesize any nucleotides, amino acids, and fatty acids 
(Fraser et al., 1997). Therefore, the organism is only able to survive by utilizing 
metabolites provided by its tick vector or mammalian hosts via direct scavenging.  
On the other hand, B. burgdorferi produces a large number of surface 
exposed lipoproteins that respond to the environmental changes during its life 
cycle and interact with different host proteins. The B. burgdorferi strain B31 
genome is well known for its large number of open reading frames (ORFs) 
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encoding putative lipoproteins, including 5% of the chromosomal ORF’s, and in 
total 14.5% to 17% of the ORFs located on the plasmids (Fraser et al., 1997). In 
contrast, Helicobacter pylori encodes a total of 20 putative lipoproteins in its 1.67 
million base pair genome (1.3% of its coding sequences) (Fraser et al., 1997; 
Tomb et al., 1997). Borrelial lipoproteins are distributed throughout the inner and 
outer leaflets of the outer-membrane and the outer leaflet of the inner-membrane 
(Kenedy et al., 2012). The abundance of lipoproteins as well as their surface 
exposure suggests that these proteins play an important role in the life cycle of B. 
burgdorferi. The expression of many lipoprotein-encoding genes is augmented in 
feeding ticks and in mammalian hosts, in response to elevated temperature, 
nutrient availability, as well as reduced pH (Liang et al., 2002; Samuels, 2011), 
suggesting that many play an important part in the transmission from the tick 
vector to the mammalian host. A large number of lipoproteins encoded by these 
up-regulated genes are related to mammalian infection, such as ospC, dbpBA, 
and bbk32, and many are required for optimal mammalian infection (Radolf et al., 
2012; Weening et al., 2008; Seshu et al., 2006; Grimm et al., 2004; Pal et al., 
2004a; Hyde et al., 2009; Samuels, 2011). In addition to the identified 
pathogenesis-associated genes, several additional uncharacterized genes are 
regulated in a similar manner (Caimano et al., 2007; Kumar et al., 2010), 
suggesting that they may serve a function within the context of mammalian 
infection. Thus, deciphering these “genes of unknown function” in B. burgdorferi 
infection may provide new insight into B. burgdorferi pathogenesis.  
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Transmission of B. burgdorferi from ticks to mammalian hosts 
Tick attachment starts by inserting the saw-like chelicerae into the 
epidermis of the host to create an entrance wound (Richter et al., 2013). During 
attachment, Ixodes ticks inject saliva, which contains a mixture of bioactive 
chemicals, including histamine binders, cytokine and complement inhibitors, and 
anticoagulants (Nuttall and Labuda, 2008). These chemicals facilitate the tick’s 
ability to ingest blood by providing an anti-coagulant and concomitantly benefit the 
survival and dissemination of B. burgdorferi in mammalian host by muting the host 
innate immune response (Nuttall and Labuda, 2008).  
The Ixodes tick engorges on the vertebrate host for 4 to 8 days until it feeds 
to repletion (Cupp, 1991). During the blood meal, B. burgdorferi migrate from the 
midgut to the salivary gland and then transmit to the epidermal/dermal layer of 
mammalian host. When an Ixodes tick starts feeding on a mammal, the tick midgut 
environment goes through a dramatic alteration. The ingestion of blood alters the 
temperature, pH, and availability of nutrients in the midgut and exposes the 
bacteria to host immune factors such as antibodies and complement proteins, as 
well as reactive oxygen and nitrogen intermediates as a byproduct of increased 
tick respiration. Despite these potential inhibitory factors, B. burgdorferi rapidly 
replicates in the midgut during tick feeding (Piesman et al., 1990). In infected 
nymphs, the number of B. burgdorferi increases from fewer than 1000 per midgut 
prior to feeding to approximately 6000 following 72 hours of attachment (Piesman 
et al., 2001). Meanwhile, the spirochetes in the tick salivary glands increase >17-
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fold, yielding approximately 20 spirochetes per salivary gland pair at 72 h post-
attachment when infectivity is at its peak, from approximately 1 per salivary gland 
pair before feeding. (Ohnishi et al., 2001; Piesman et al., 2001). These 
observations suggest that feeding ticks provide a stable site for B. burgdorferi 
replication, which is followed by activation and transmission. This process is 
mediated in part by borrelial surface lipoproteins since the profile of these proteins 
is dramatically altered during this process (Caimano et al., 2007; Kumar et al., 
2010; Ohnishi et al., 2001). 
Before the blood meal, B. burgdorferi lies in a quiescent state within the 
tick midgut. At this point, the borrelial cells produce OspA on their surface that 
serves as an adhesin to the tick protein designated TROSPA (Pal et al., 2004b). 
Once the blood-meal begins, the B. burgdorferi begins to down-regulate ospA and 
express OspC (Ohnishi et al., 2001). Within the overall population the per cell 
response is variable in this regulation, resulting in some variation of surface 
exposed OspA and OspC, i.e., some cells are OspA- and OspC-, some are OspA+ 
and OspC-, while others are OspA- and OspC+. Those that fall into latter category 
are more readily transmitted to mammals (Ohnishi et al., 2001), based on mutant 
ospC strain analysis (Grimm et al., 2004; Pal et al., 2004a).  
 
Gene regulation in B. burgdorferi 
To quickly adapt to the altered environment and survive in the mammalian 
host, B. burgdorferi regulates its gene expression during transmission (Liang et 
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al., 2002; Samuels, 2011), including genes that encode infection-associated 
lipoproteins (Grimm et al., 2004; Hyde et al., 2011a; Maruskova et al., 2008; Pal 
et al., 2004a; Seshu et al., 2006; Weening et al., 2008; Zhang et al., 1997; Zhi et 
al., 2015). The Rrp2-RpoN-RpoS regulatory pathway, along with BosR (Hyde et 
al., 2009; Ouyang et al., 2009), plays a critical role in this process as this 
regulatory cascade is required for the expression of virulence related genes, 
including ospC, dbpBA, and bbk32 (Radolf et al., 2012; Weening et al., 2008; 
Seshu et al., 2006; Grimm et al., 2004; Pal et al., 2004a; Hyde et al., 2009, 2010; 
Samuels, 2011; Ouyang et al., 2009; Hubner et al., 2001). To better understand 
the transition in gene expression between in vitro culture and in vivo conditions, 
Akins et al. developed a new animal model for studying spirochetes in a 
mammalian host-adapted state (Akins et al., 1998). To accomplish this, B. 
burgdorferi was placed within dialysis membrane chambers (DMC) and implanted 
into the peritoneal cavity of rats (Akins et al., 1998). After several days the DMCs 
were removed and the cells evaluated for protein content relative to organisms 
grown under various in vitro conditions (Caimano et al., 2007). These studies 
showed that, in addition to the aforementioned genes (e.g., ospC, dbpBA, and 
bbk32), a large number of hypothetical genes were regulated in a similar RpoS-
dependent manner (Caimano et al., 2007; Kumar et al., 2010).  
RpoS is an alternative RNA polymerase σ-factor, which is transcribed by 
another alternative σ-factor, RpoN (also known as σ54). Regulation of the B. 
burgdorferi rpoS locus is a remarkably elaborate process. The borrelial rpoS gene 
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is expressed as both temperature and CO2 levels increases and pH decreases, a 
condition believed to mimic the tick feeding to mammalian transmission step 
(Carroll et al., 1999; Hyde et al., 2007; Samuels, 2011; Stevenson et al., 1995). 
These environmental changes result in an increase in rpoS transcripts and 
subsequent RpoS protein production (Burtnick et al., 2007; Caimano et al., 2004; 
Hubner et al., 2001; Hyde et al., 2007, 2009; Lybecker and Samuels, 2007; 
Samuels, 2011; Yang et al., 2000). RpoN-dependent transcription of rpoS is 
mediated by the formation of an rpoS promoter complex, including a 
phosphorylated version of the response regulatory protein 2 (Rrp2) and a 
Fur/PerR orthologue known as the Borrelia oxidative stress regulator or BosR 
(Boylan et al., 2003; Hyde et al., 2009; Ouyang et al., 2009; Samuels, 2011). BosR 
acts as a transcriptional activator by binding to the rpoS promoter at three regions 
including one immediately upstream of the RpoN-dependent promoter (Ouyang 
et al., 2014). Besides Rrp2 and BosR, BadR (BB0693) is also identified as a 
negative regulator that controls growth phase-dependent induction of rpoS and 
bosR in B. burgdorferi (Miller et al., 2013; Ouyang and Zhou, 2015). Once badR 
is inactivated, rpoS and bosR expression is induced only during the early stages 
of bacterial growth, but not during the stationary growth phase (Ouyang and Zhou, 
2015).  
Taken together, substantial evidence demonstrates that gene regulation in 
B. burgdorferi is complex at the interface of the tick vector and the mammalian 
host during transmission (Samuels, 2011). The complicated gene regulation 
  12 
network in B. burgdorferi indicates that borrelial gene expression is strictly 
controlled and dynamically altered during the enzootic cycle. In addition, these 
data suggest that differentially regulated genes may play spatial and temporal 
specific roles during the infection. Therefore, by analogy, determining the 
functions of additional RpoS-regulated genes of unkown function may provide 
futher insight into the pathogenic potential of B. burgdorferi.  
 
The role of borrelial lipoproteins in colonization and dissemination within 
the mammalian host 
After infection, B. burgdorferi colonizes connective tissue in the skin and 
penetrates deep into the dense irregular connective tissue of the dermis, as well 
as the dense regular structures within tendons (Barthold et al., 1991, 2006; 
Cadavid et al., 2003; Pachner et al., 1995). In this process, B. burgdorferi interacts 
with different structural targets within the extracellular matrix (ECM), mediated by 
borrelial surface proteins (Cabello et al., 2007). For instance, BmpA and ErpX 
engage laminin (Brissette et al., 2009a; Verma et al., 2009); P66 and BBB07 
adhere to integrin proteins (Behera et al., 2008; Ristow et al., 2012); and CspA 
and CspZ bind to complement proteins, fibronectin (Fn), laminin, and collagens 
(Hallström et al., 2010, 2013; Kenedy et al., 2009; Rogers and Marconi, 2007). 
Several additional ECM binding proteins are associated with borrelial 
pathogenesis. For example, the lipoproteins DbpA and DbpB bind decorin and 
glycosaminoglycans (GAG’s) (Blevins et al., 2008; Fischer et al., 2003; Guo et al., 
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1995; Weening et al., 2008). The importance of DbpB/A in borrelial pathogenesis 
was established when a deletion of dbpBA resulted in reduced infectivity in mice 
(Weening et al., 2008). In addition, a fibronectin and GAG binding protein, 
designated BBK32, is required for the initial tethering of the bacterium to the 
endothelium via Fn binding (Fischer et al., 2006; Kim et al., 2004; Norman et al., 
2008; Probert and Johnson, 1998; Seshu et al., 2006). This transient interaction 
results in more stable interactions between BBK32 and GAGs, leading to the 
dragging of the bacterium along the endothelium, followed by stationary adhesion 
(Moriarty et al., 2012). More recently, it was shown that BBK32 promotes joint 
colonization via GAG binding, indicating an additional critical role for BBK32 in 
borrelial pathogenesis (Lin et al., 2014).  
B. burgdorferi is also known to align with host collagen (Barthold et al., 
1991; Zambrano et al., 2004). Collagens are ubiquitous within a vertebrate host. 
For instance, collagen type I and IV are mainly found in skin, while collagen type 
II is enriched in cartilage, both of which are a preferred colonization niche for B. 
burgdorferi (Lindblad and Kormos, 1991; Shoulders and Raines, 2009). Collagen 
type VI is another important extracellular matrix protein. It is enriched in skeletal 
muscle, papillary dermis immediately below the dermal-epidermal junction, and 
around blood vessels (Watson et al., 2001). Intriguingly, after B. burgdorferi 
infection, the bacteria are extensively found enriched in all the aforementioned 
tissues of different mammalian hosts (Barthold et al., 1991, 2006; Cadavid et al., 
2003; Pachner et al., 1995). Binding to collagen enriched tissues would 
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presumably not only benefit borrelial colonization, but may also facilitate other 
aspects of borrelial pathogenesis. For example, the colonization of B. burgdorferi 
around the blood vessels may promote dissemination into the circulatory system 
(Barthold et al., 1991, 2006; Cadavid et al., 2003; Pachner et al., 1995). 
Collectively, these findings suggest that the ability to recognize specific collagen 
types by individual B. burgdorferi proteins may contribute to borrelial tissue 
tropism, promote dissemination, and enhance long-term survival. However, the 
mechanism of interaction between B. burgdorferi and mammalian collagens is not 
defined. Therefore, the identification of borrelial proteins that bind to particular 
collagen types may provide important insight into borrelial infectivity strategies 
and pathogenic correlates. 
In addition to the previously described pathogenesis-associated genes 
such as ospC, dbpBA, and bbk32, several other B. burgdorferi genes are known 
to be regulated in a similar manner (Caimano et al., 2007; Kumar et al., 2010; 
Yang et al., 2003). However, the function of the proteins encoded by these genes 
is not known. One such RpoS-dependent gene is bba33, which is found on the 54 
kilobase (kb) plasmid of B. burgdorferi strain B31 (Fraser et al., 1997). Caimano 
et al. showed that bba33 was up-regulated 29-fold in implanted dialysis 
membrane chambers (DMC) and 8 fold in vitro in an RpoS-dependent manner 
(Caimano et al., 2007), suggesting that BBA33 is involved in the mammalian side 
of the infectious lifecycle. Consistent with this contention, bba33 is also induced 
during a blood meal in ticks and expressed in infected mouse skin (Kumar et al., 
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2010). Furthermore, microarray and RT-PCR experiments from infected non-
human primates revealed that bba33 was significantly up-regulated in heart 
tissue, but poorly expressed in the central nervous system (Narasimhan et al., 
2003), suggesting that bba33 expression is regulated spatially and thus may 
contribute to the dissemination and secondary colonization of B. burgdorferi at 
distinct sites within mammalian hosts. Taken together, these data suggested that 
the B. burgdorferi BBA33 protein was involved in some, as yet unknown, 
mammalian host specific step in borrelial colonization and/or pathogenesis.  
 
The mammalian complement system  
The complement cascade represents an important part of the mammalian 
innate immune response and serves as a first line of defense against pathogens. 
It also serves as a functional bridge between the innate and adaptive immune 
responses (Ricklin et al., 2010). One important role of the complement system is 
to recognize and clear invading pathogens. In this regard, some complement 
factors are able to opsonize the pathogen, others enhance phagocytosis, while 
others promote leukocyte chemotaxis. The complement system consists of the 
classical, the alternative, and the lectin pathways, all of which lead to the formation 
of the membrane attack complex (MAC) in the cellular membrane and result in 
the lysis of the organism. The complement system is summarized in Fig. 1 
(Dunkelberger and Song, 2010).  
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Different complement pathways are activated by recognizing distinct 
ligands on pathogens. Initiation of the classical pathway is dependent on the C1 
complex activation by binding to pathogen-bound immunoglobulins and serum 
components such as serum amyloid P (SAP) and C-reactive protein (CRP) (Brown 
et al., 2002; Clas and Loos, 1982; Yuste et al., 2007). The C1 complex consists 
of one molecule of C1q, two of C1r and two of C1s (C1q/C1r2/C1s2). The C1q 
molecule is a 460 kDa glycoprotein composed of six globular “heads”, which are 
held together by their six collagen-like “stalks”. Each head includes three distinct 
chains of polypeptide A, B and C that form a collagen-like strand with a triple-
helical fibril structure. C1r and C1s are both serine proteases and share similar 
overall structural organizations. Both proteins contain dual CUB modules, an 
epidermal growth factor (EGF)-like module, two contiguous complement control 
protein (CCP) domains, and a chymotrypsin-like serine protease (SP) motif 
(Morikis and Lambris, 2005). Dimers of the C1r and C1s subcomponents amplify 
the enzymatic activities associated with the C1 complex and form a tetrameric 
proenzyme structure around the collagen-like strands of C1q. The binding of C1 
with its activators leads to a conformational change of C1q, which triggers the 
auto-activation of C1r. Subsequently, C1r activates C1s and the latter cleaves C2 
and C4 to form the activation products C2a, C2b, C4a, and C4b. C2a and C4b 
bind to the surface and form the C3 convertase of the classical pathway, deemed 
C4b2a. C4b2a subsequently cleaves C3 into the anaphylatoxin C3a and the 
opsonin C3b (Ricklin et al., 2010).  
  17 
 
 
 
 
Figure 1. A chematic representation of the complement pathway. The complement 
system can be activated through three pathways: (1) the classical, (2) the lectin, and (3) 
the alternative. This figure is reprinted with permission from Dunkelberger and Song, 
2010.  
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The activation of the lectin pathway relies upon binding of the mannose-
binding lectin (MBL) or ficolins (FCNs) to highly glycosylated pathogen-associated 
molecular patterns (PAMPS) on the surface of the pathogen. MASPs 1, 2 and 3 
form a complex with MBL or FCNs and become autoactivated after ligand binding. 
Similar to C1s, activated MASP2 cleaves C2 and C4, to form C3 convertase 
C4bC2a (Ricklin et al., 2010).  
The activation of the alternative pathway (AP) is mechanistically distinct in 
comparison to the lectin and classical pathways activation. On all cell surfaces, a 
low level initiation of the alternative pathway occurs spontaneously and 
continuously through hydrolysis of C3 to C3b(H2O). Factor B binds to C3b(H2O) 
and is subsequently cleaved by factor D to form an initial solvent-based C3 
convertase C3bBb, which then cleaves C3 to generate C3b on the cell surface. 
The C3 convertase is further stabilized by properdin, which helps to amplify the 
activation of the alternative pathway . As a consequence, the activation of the 
complement system is exponentially amplified due to the formation of a feedback 
amplification loop. All three pathways converge at the level of C3, which is cleaved 
by C3 convertase to generate C3b. C3b covalently binds to the pathogen surface 
near the activation site to form the C5 convertase and eventually leads to the 
formation of membrane attack complex (MAC) and lysis of the cell via recruitment 
of the C6, C7, and C8 proteins and the assembly of multiple C9 proteins.  
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Regulation of complement activation 
Complement activities need to be controlled to the surface of invading 
organisms, and strictly regulated to prevent collateral damage to host tissues, 
because of the potential destructive side-effect of complement activation. Hence, 
multiple steps involved in complement activation are regulated by various 
inhibitors such that the whole complement system maintains an intricate, 
homeostatic balance between the minimization of tissue damage and 
opsonization and destruction of pathogens (Mollnes et al., 2002).  
Complement regulators are categorized into soluble and membrane-bound 
regulators (Cho, 2015). Soluble regulators include factor H, factor H-like proteins, 
factor H-related protein 1, properdin, C1 inhibitor (C1-INH), C4 binding protein 
(C4BP), and vitronectin, and are distributed in the plasma and other body fluids 
(Cho, 2015). Some of these soluble regulators can also attach to cell surfaces and 
cell membranes to control complement activation in tissues (Rodríguez de 
Córdoba et al., 2004).  
One important soluble regulator of the complement cascade are proteins 
that belong to the factor H family. This family includes factor H, complement factor 
H like protein 1 (CFHL1), and five factor-H related proteins (Rodríguez de 
Córdoba et al., 2004). Factor H is a 150-kDa single-chain plasma glycoprotein 
that specifically regulates the alternative pathway. Factor H regulates the 
activation of complement by three different mechanisms: 1) factor H inhibits the 
interaction of C3b and factor B, thereby blocking the formation of C3bBb; 2) it 
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contributes to the dissociation of the C3 convertase; and 3) it is a cofactor for 
factor I, which cleaves C3b (Rodríguez de Córdoba et al., 2004). Properdin is 
another soluble regulator which serves as an activator of the alternative pathway 
by binding to C3b to stabilize the complement convertase and prevent its cleavage 
by factor I (Lesher et al., 2013; Zipfel and Skerka, 2009).  
C1-INH and C4BP are two other fluid-phase regulators specifically 
associated with the classical and lectin pathways. C1-INH is a member of the 
serine protease inhibitor family. It irreversibly inhibits the classical pathway by 
disassembling the C1 complex and inactivates MASP1 and MASP2 to block the 
lectin pathway. C1-INH has been proposed to be useful in animal models to 
control unnecessary and harmful inflammation, such as Gram-negative sepsis, 
myocardial reperfusion injury, and hyperacute transplantation rejection (Cho, 
2015). 
C4BP is a 570kDa soluble glycoprotein that protects many host tissues 
from damage by complement. C4BP and factor H have similar action (Blom et al., 
2004; Zipfel and Skerka, 2009). Like factor H, it has both cofactor and decay-
accelerating activity (Gigli et al., 1979). Instead of C3, however, the primary target 
of C4BP is C4bC2a, although C4BP has also been reported as a cofactor for 
factor I for C3b cleavage (Blom et al., 2004). In addition, other soluble complement 
regulators, including vitronectin, clusterin, and CFHR1, target the terminal steps 
of the pathway, and thus inhibit the formation of MAC on the cell surface. (Heinen 
et al., 2009; Preissner and Seiffert, 1998; Schwarz et al., 2008). 
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Host cells also express membrane-associated factors that protect them 
from the detrimental activation of complement. For example, CD46 is a 
ubiquitously expressed protein that serves as a co-effector of factor I to cleave 
C3b and C4b (Andrews et al., 1985). CD59 is a widely expressed small (20 kDa) 
glycosylphosphatidylinositol (GPI) anchored complement regulator, which blocks 
C9 from incorporating into the C5b-8 complex as well as C9 polymerization in a 
pre-formed C5b-9 complex (Meri et al., 1991; Morgan et al., 2005). All of these 
complement regulators are involved in regulating the activation of the complement 
system, keeping the balance between destroying foreign cells and minimizing host 
tissue damage. However, they can also be utilized by pathogens to manipulate 
and evade host immune systems for optimal infection. 
 
Bacterial evasion strategies against complement activation 
Microbes are often recognized and cleared by the immune system of the 
human host in part via the action of complement. However, some pathogens can 
survive in an immune-competent human host based on their ability to efficiently 
inactivate or evade the innate immune response. To successfully infect, 
pathogenic microbes often utilize numerous, sometimes redundant, and highly 
complicated strategies to control, modulate, and block complement activation, as 
well as other innate and adaptive immune responses of the hosts they infect (Blom 
et al., 2009; Lambris et al., 2008; Rooijakkers and van Strijp, 2007; Zipfel et al., 
2007). 
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Pathogenic microbes interfere with complement activation at different 
levels. For instance, some bacteria bind plasminogen, the human pre-protease, 
on their surface and utilize either bacteria-encoded or host activators like 
urokinase-type plasminogen activator (uPA) to produce the proteolytically active 
plasmin, which then can cleave and degrade C3 to block its functions (Barthel et 
al., 2012; Lähteenmäki et al., 2001; Zipfel et al., 2013). Streptococcus pyogenes 
expresses at least five plasminogen binding proteins to promote the evasion of 
complement activation (Berge and Sjobring, 1993; Pancholi and Fischetti, 1998; 
Ringdahl and Sjöbring, 2000; Sanderson-Smith et al., 2007). Of note, several 
borrelial proteins bind to plasminogen as well and may contribute to complement 
evasion. For example, BBA70-bound plasmin was able to degrade the central 
complement proteins C3b and C5 (Koenigs et al., 2013). ErpP, ErpA, and ErpC 
also bind to human plasminogen (Brissette et al., 2009b), but the contribution of 
this interaction to complement evasion is still not clear.  
Infectious bacteria may also directly block the activation of complement 
early in the cascade. The collagen binding protein, Cna, of Staphylococcus aureus 
binds to C1q and disassembles the C1 complex (Kang et al., 2013). In addition, 
some Gram-negative bacteria are able to recruit serum amyloid P (SAP) on the 
cell surface to interfere with LPS mediated activation of the classical pathway 
(Haas et al., 2000).  
The most common soluble complement regulators recruited by different 
pathogens include factor H, other members of the factor H-like protein family, and 
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C4BP (Blom et al., 2009; Lambris et al., 2008; Simon et al., 2013; Zipfel et al., 
2007). These complement regulators attach to the microbial surface to control the 
activity of C3 convertase, as well as the amplification loop, eventually leading to 
complement inactivation (Zipfel et al., 2007, 2013). Alternatively, other pathogens 
use other strategies to neutralize complement-dependent inactivation/killing. For 
example, instead of binding to factor H and C4BP, Bordetella pertussis binds to 
C1-INH and neutralizes both the classical and the lectin pathways (Marr et al., 
2007). In addition, a large set of pathogenic microbes, including Gram-positive 
and Gram-negative bacteria, as well as the pathogenic yeast C. albicans, bind to 
vitronectin (Singh et al., 2010). Vitronectin is used by those pathogens to inhibit 
the terminal steps of complement, which blocks the formation of the membrane 
attack complex (MAC) on the cell surface, thereby preventing lysis and cell death 
(Singh et al., 2010).  
 
Complement evasion strategies of B. burgdorferi 
B. burgdorferi is an extracellular pathogen that can disseminate through 
both the circulation and lymphoid systems. During the process of dissemination, 
it is presumed that B. burgdorferi must combat the lethal effect of complement to 
survive. It would then follow that B. burgdorferi requires strategies to evade or 
block complement activation in order to establish and maintain infection.  
All of the three complement pathways are involved in complement activation 
by B. burgdorferi (de Taeye et al., 2013). However, different genospecies of Lyme 
  24 
disease spirochetes differ in their ability to resist complement dependent killing in 
normal human serum in vitro and are categorized as either serum-sensitive or 
serum-resistant isolates (Breitner-Ruddock et al., 1997; Dam et al., 1997). For 
instance, B. burgdorferi, B. afzelii, and B. garinii serotype 4 (also known as B. 
bavariensis) are moderately resistant to complement dependent killing in vitro, 
whereas B. garinii serotype 5 and 6 are susceptible. Although it is still not clear 
why different Lyme disease spirochetes confer distinct levels of resistance to 
human serum, it is postulated that borrelial adaptation to a variety of vertebrate 
hosts provide a different array of surface proteins that contribute to the variable 
serum sensitivities observed (de Taeye et al., 2013). In this regard, ticks feed on 
different vertebrate animals including birds, rodents, and large mammals and 
transmit B. burgdorferi to those animals. In Europe, bird species are the main host 
for B. garinii, whereas B. afzelii and B. bavariensis infect rodents species 
(Kurtenbach et al., 2002). B. burgdorferi is carried by both birds, rodents, and 
some larger animals including dogs (Kurtenbach et al., 2002). Correspondingly, 
B. garinii strains, although sensitive to most mammalian serum, are resistant to 
the killing by bird serum. B. afzelii strains are resistant to killing in rodent, human, 
dog, and cat serum, but are sensitive to the serum from birds. In contrast, B. 
burgdorferi strains are intermediately resistant to serum from humans, rodents, 
birds, dogs, cats, and horses (Bhide et al., 2005; Kurtenbach et al., 1998, 2002). 
The pattern of in vitro serum sensitivity of different Borrelia species mentioned 
above reflects the reservoir status of many vertebrate species. (Bhide et al., 2005; 
  25 
Kurtenbach et al., 1998, 2002). For example, large animals, such as deer and 
cows, are dead-end hosts for all Borrelia species, probably due to the spirochetes’ 
inability to prevent complement-dependent killing (Bhide et al., 2005). These 
observations imply that different Lyme disease spirochetes have evolved to adapt 
to their main host reservoirs in a manner that avoids complement dependent killing. 
When these spirochetes are transmitted to humans, an accidental host, the 
resistance to serum-killing is seen as variable. Further analysis is required to 
determine how Borrelia species specific factors contribute to these variable serum 
sensitive phenotypes. 
A set of borrelial genes that are up-regulated during mammalian infection are 
involved in resistance to complement dependent killing (de Taeye et al., 2013). 
Studies of the serum dependent killing first led to the identification of B. burgdorferi 
proteins that bind factor H (FH), factor H-like protein-1 (FHL-1), and FH related 
protein 1 (FHR-1) (Kraiczy et al., 2001, 2002). These proteins are also referred to 
as complement regulator-acquiring surface proteins (CRASPs), which include 
CspA (CRASP1), CspZ (CRASP2), and OspE-related proteins (CRASP-3, -4, and 
-5) (Hartmann et al., 2006; Hellwage et al., 2001; Kraiczy et al., 2004). To better 
understand how CspA contributes to serum resistance in B. burgdorferi, Brooks 
et al. and Kenedy et al. generated B. burgdorferi cspA mutants and showed that 
they were susceptible to human serum-dependent killing in vitro (Brooks et al., 
2005; Kenedy et al., 2009). Furthermore, production of CspA in B. garinii 50, a 
serum sensitive strain, restored the serum resistance to a level indistinguishable 
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from wild-type B. burgdorferi (Brooks et al., 2005). These studies showed that 
cspA mutants do not efficiently bind human FH on their surface, which led to 
enhanced binding of C3, C6 and C5b-9 onto the surface of the cspA mutant 
relative to that of the wild-type strain (Kenedy et al., 2009). Clearly, CspA 
contributes to serum-resistance of B. burgdorferi, but there are few studies directly 
showing that CspA specifically inhibits the activation of the alternative pathway. In 
addition, the importance of the alternative pathway in controlling B. burgdorferi 
infection is controversial as well. In the presence of C1-inhibitor (C1-INH), which 
inhibits both the classical and lectin pathways but not the alternative pathway, 
human-serum dependent killing of serum-sensitive B. garinii strain was 
completely abrogated (Schuijt et al., 2011). This results suggest that the 
alternative pathway may only be important for amplification of complement 
activation (de Taeye et al., 2013).  
 In addition to recruiting factor H on the borrelial surface, some Borrelia 
species also develop other strategies to evade complement-dependent killing. For 
instance, B. burgdorferi and the relapsing fever spirochetes B. recurrentis and B. 
duttonii recruit C4BP and C1-INH through the interaction of specific surface 
lipoproteins (Grosskinsky et al., 2010; Meri et al., 2006; Pietikäinen et al., 2010). 
Also, B. burgdorferi expresses a CD59-like protein that inhibits the formation of 
the lytic MAC (Pausa et al., 2003). In addition to binding to factor H, CspA of B. 
burgdorferi also binds to complement protein C7, which inhibits the terminal 
complement pathway (Hallström et al., 2013). 
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Taken together, Borrelia evades complement system in various ways to 
generate serum-resistance to promote infection in mammalian hosts. However, 
details needed to understand B. burgdorferi-complement interactions are still 
vague due to the lack of in vivo data that supports the utility of specific complement 
proteins in B. burgdorferi infectivity and pathogenesis. Of note, complement killing 
of serum sensitive B. garinii is mediated by the activation of the classical pathway 
given that B. garinii survives in C1q depleted human serum or anti-C1q treated 
serum (Dam et al., 1997). This observation suggests that differences between the 
serum sensitive B. garinii and the serum resistant B. burgdorferi strains may be 
useful in identifying proteins that provide serum resistant phenotypes to sensitive 
species. 
 
Summary 
The causative agent of Lyme disease, B. burgdorferi, is very different from 
most pathogenic bacteria both biologically and physiologically. One of the unique 
features of B. burgdorferi is the large number of lipoproteins that are produced on 
the bacterial surface in response to different environmental cues. The Rrp2-RpoN-
RpoS regulatory pathway plays an important role for B. burgdorferi at the interface 
of tick vector and mammalian host (Boardman et al., 2008; Hubner et al., 2001; 
Radolf et al., 2012; Samuels, 2011) as this regulatory cascade up-regulates a 
large number of genes encoding lipoproteins such as ospC, dbpBA, and bbk32, 
which are important in mammalian infection (Grimm et al., 2004; Pal et al., 2004a; 
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Radolf et al., 2012; Samuels, 2011; Seshu et al., 2006; Weening et al., 2008). 
These surface lipoproteins are involved in various aspects of borrelial 
pathogenesis, including colonization, dissemination and immune suppression.  
In addition to those lipoproteins, other uncharacterized borrelial 
lipoproteins are up-regulated in the mammalian host. Previous studies indicate 
that a putative lipoprotein, BBA33, is produced in an RpoS-dependent manner 
(Boardman et al., 2008; Caimano et al., 2007; Kumar et al., 2010). However, the 
significance and function for BBA33 was not identified. Given its linkage to the 
BosR/Rrp2-RpoN-RpoS regulatory cascade, we hypothesized that BBA33 
facilitates B. burgdorferi infection in the mammalian host. In Chapter II, we report 
that the deletion of bba33 eliminates B. burgdorferi infectivity in C3H mice, in a 
manner that could be rescued by genetic complementation with intact bba33. In 
regard to BBA33 function, a combinatorial peptide approach, coupled with 
subsequent in vitro binding assays, indicated that BBA33 binds to collagen type 
VI and, to a lesser extent, collagen type IV. Whole cell binding assays 
demonstrated BBA33-dependent binding to human collagen type VI. Taken 
together, these results suggest that BBA33 interacts with collagenous structures 
and may function as an adhesin in a process that is required to establish B. 
burgdorferi colonization. The striking phenotype of the bba33 mutant in mice led 
us to ask if BBA33 interferes with the innate immune response by interacting with 
immune-response related proteins that may share a structure similar to collagens. 
C1q, the first protein involved in the activation of the classical complement 
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pathway, contains a collagen-like triple helical domain that we hypothesized might 
be recognized by BBA33. As such, we were interested in determining whether 
BBA33 interacts with C1q and asked if BBA33 was capable of inhibiting the 
activation of the classical complement pathway.      
The human complement system is a connected network of blood proteins 
capable of recognizing and eliminating microbial intruders. B. burgdorferi sensu 
lato genospecies (i.e., B. burgdorferi, B. afzelii, and B. garinii) differ in their ability 
to survive in the presence of human complement (Breitner-Ruddock et al., 1997; 
Dam et al., 1997). Complement killing of serum sensitive B. garinii is mediated by 
the activation of the classical pathway (Dam et al., 1997), indicating that evasion 
of the classical pathway may be the key for serum-resistant Borrelia species to 
survive in human blood. However, the mechanisms of how B. burgdorferi evades 
the activation of classical pathway are still not well-understood. To answer this 
question, we tested if BBA33 inhibited the activation of the classical pathway. In 
a classical pathway dependent hemolysis assay, we found that BBA33 did not 
affect complement activation. However, surprisingly, we found that another B. 
burgdorferi surface exposed lipoprotein, BBK32, showed a very potent inhibitory 
effect on classical pathway activation. 
In Chapter III, we investigated further the mechanism of how B. burgdorferi 
BBK32 blocks the activation of the classical complement pathway. We found that 
BBK32, a previously identified fibronectin-binding protein, targets and inhibits the 
first component of complement, C1 (Garcia et al., 2016). Upon binding to human 
  30 
C1, BBK32 traps the C1 protease complex in an inactive state, and prevents the 
downstream proteolytic events of the pathway by direct binding to C1r. We further 
mapped this inhibitory function to the previously uncharacterized C-terminal 
domain of BBK32. This study defines a new mechanism by which microbes are 
able to escape the human innate immune system and identifies the complement 
protease C1r as a new target of bacterial complement inhibition. Thus, the 
discovery of the complement inhibitory activity of BBK32 may serve as a 
foundation to identify other related proteins from other Borrelia species and may 
serve as the basis for the development of therapeutically useful mimetics that 
mirror this BBK32-specific function (i.e, inhibit the activation of C1). 
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CHAPTER II  
THE Borrelia burgdorferi BBA33 LIPOPROTEIN IS A COLLAGEN BINDING 
ADHESIN THAT IS REQUIRED FOR BORRELIAL PATHOGENESIS∗ 
 
Introduction 
The spirochetal bacterium Borrelia burgdorferi, the etiologic agent of Lyme 
disease, infects mammalian hosts via the bite of Ixodes spp. ticks (Radolf et al., 
2012; Samuels, 2011). When humans become infected, they present with non-
descript flu-like symptoms with most developing a characteristic skin lesion referred 
to as a erythema migrans (recently reviewed in (Shapiro, 2014)). If untreated, the 
infection can progress to a multi-stage disorder as the spirochete disseminates to 
distant organ sites, resulting in carditis, neurological disorders, and arthritis. 
Recently the CDC reported that more than 300,000 cases of Lyme disease are 
diagnosed annually in the United States, indicating that Lyme borreliosis is a 
significant, re-emerging infectious disease (Hinckley et al., 2014). Furthermore, the 
lack of an effective vaccine underscores the need to better understand factors that 
contribute to the pathogenic potential of B. burgdorferi.  
                                                
∗ Part of this chapter is reprinted with permission from “The BBA33 lipoprotein 
binds collagen and impacts Borrelia burgdorferi pathogenesis” by Hui Zhi, Eric H. 
Weening, Elena Magda Barbu, Jenny A. Hyde, Magnus, Höök, Jon T. Skare, 
2015. Molecular Microbiology, Volume 96, p.68–83. Copyright 2015 by John Wiley 
& Sons, Inc. 
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B. burgdorferi establishes infection by interaction with connective tissue of 
the skin and disseminates to deeper tissues following colonization (Cabello et al., 
2007). Early in the infectious process, B. burgdorferi is known to align with host 
collagen (Barthold et al., 1991) and interact with other structures found within the 
extracellular matrix (ECM) in a process that involves the function of borrelial 
adhesins. Known surface exposed adhesins that recognize host structures found 
in the ECM include: the lipoproteins DbpA and DbpB that bind decorin and 
glycosoaminoglycans (GAG’s) (Blevins et al., 2008; Fischer et al., 2003; Guo et al., 
1995; Weening et al., 2008); BBK32 that interacts with fibronectin and GAG’s 
(Fischer et al., 2006; Kim et al., 2004; Norman et al., 2008; Probert and Johnson, 
1998; Seshu et al., 2006); BmpA and ErpX that engage laminin (Brissette et al., 
2009a; Verma et al., 2009); P66 and BBB07 that adhere to integrin proteins (Behera 
et al., 2008; Ristow et al., 2012); and CspA and CspZ that bind to complement 
proteins, fibronectin, laminin, and collagens (Hallström et al., 2010, 2013; Kenedy 
et al., 2009; Rogers and Marconi, 2007). Several of these proteins are categorized 
as MSCRAMMs (for microbial surface component that recognize adhesive matrix 
molecules) (Patti et al., 1994) and some (Dbp’s, BBK32, and P66) are linked to 
borrelial pathogenesis (Lin et al., 2012; Ristow et al., 2012; Seshu et al., 2006; 
Weening et al., 2008).  
It is well established that B. burgdorferi modulates its gene expression as it 
cycles between the tick vector and the mammalian hosts they infect (Akins et al., 
1998; Brooks et al., 2003; Liang et al., 2002; Narasimhan et al., 2003; Ohnishi et 
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al., 2001; Ojaimi et al., 2003; Revel et al., 2002; Samuels, 2011), including genes 
that encode infection-associated lipoproteins (Grimm et al., 2004; Pal et al., 2004a; 
Radolf et al., 2012; Seshu et al., 2006; Weening et al., 2008; Zhang et al., 1997). 
For mammalian infection, the Rrp2-RpoN-RpoS regulatory pathway plays an 
important role in this process (Boardman et al., 2008; Hubner et al., 2001; Radolf 
et al., 2012; Samuels, 2011) as this regulatory cascade is required for the 
expression of ospC, dbpBA, and bbk32, all of which are required for optimal 
mammalian infection (Grimm et al., 2004; Pal et al., 2004a; Radolf et al., 2012; 
Samuels, 2011; Seshu et al., 2006; Weening et al., 2008). In addition to these 
pathogenesis-associated genes, several additional genes are regulated in a similar 
manner; however, the importance and function of the proteins they encode are not 
known. One such gene that is RpoS-dependent is bba33, which is found on the 54 
kb plasmid of B. burgdorferi strain B31 (Fraser et al., 1997). Previous studies 
showed that bba33 was up-regulated 29-fold in implanted dialysis membrane 
chambers and 8.2-fold in vitro in an RpoS-dependent manner (Caimano et al., 
2007), and required Rrp2 for maximal expression (Boardman et al., 2008), 
suggesting that BBA33 is produced under mammalian-like conditions. In support of 
this contention, Kumar et al. found that bba33 is induced during a blood meal in 
ticks and is expressed in infected mouse skin (Kumar et al., 2010). Furthermore, 
microarray and RT-PCR experiments revealed that bba33 transcripts were 
significantly up-regulated in heart tissue, but poorly expressed in the central 
nervous system in B. burgdorferi infected non-human primates (Narasimhan et al., 
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2003), suggesting that bba33 expression is spatially regulated and thus may 
contribute to the dissemination and secondary colonization of B. burgdorferi to 
targeted organs. Taken together, these data suggested that BBA33 was linked to 
B. burgdorferi virulence; however, its function was unknown.  
By analogy to other infection-associated lipoprotein-encoding genes that are 
regulated in a similar manner (e.g., dbpA or bbk32 (Blevins et al., 2008; Seshu et 
al., 2006; Weening et al., 2008)), we hypothesized that the protein encoded by 
bba33 could contribute to pathogenesis-associated functions. We now report that 
the loss of bba33 renders B. burgdorferi essentially non-infectious. A combinatorial 
peptide approach suggested that BBA33 recognizes a sequence that maps to 
human collagen type VI. Given its abundance in the skin and other sites colonized 
by B. burgdorferi, as well as the known association of B. burgdorferi with collagen 
(Barthold et al., 1991), we evaluated the ability of BBA33 to bind collagen and 
mediate bacterial attachment to collagen substrates. The results presented herein 
demonstrate that BBA33 plays an important role in early stages of borrelial infection 
due presumably to its ability to interact with collagenous substrates. 
 
Results 
Molecular analysis of bba33  
Given the significance of several RpoS-regulated B. burgdorferi genes in 
mammalian infection (Blevins et al., 2008; Hubner et al., 2001; Pal et al., 2004a; 
Radolf et al., 2012; Weening et al., 2008), including several that map to the 54 kb 
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plasmid (lp54) of B. burgdorferi strain B31 (Blevins et al., 2008; Gilmore et al., 
2010; Kumar et al., 2010; Weening et al., 2008), we sought to determine whether 
RpoS-dependent BBA33 contributed to borrelial pathogenesis. As a first step, we 
genetically deleted B. burgdorferi bba33 as depicted in Fig. 2A. Briefly, a 
construct that replaced the entire bba33 locus with a streptomycin resistant (StrR) 
cassette was made and designated pHZ001. This construct was transformed into 
strain ML23 and transformants were screened by PCR for allelic exchange of the 
native bba33 gene with the StrR marker (Fig. 2B). ML23 is a strain that lacks the 
25 kb linear plasmid that encodes a restriction/modification gene (bbe02); as 
such, this strain is more readily transformable via allelic exchange (Seshu et al., 
2006; Weening et al., 2008), but is also non-infectious since the bbe22/pncA locus 
is essential for survival following experimental infection (Labandeira-Rey and 
Skare, 2001; Purser and Norris, 2000; Purser et al., 2003). Infectivity can be 
restored via trans complementation of bbe22/pncA on the shuttle vector pBBE22 
(Purser et al., 2003).  
To assess the status of the StrR transformants relative the parent strain, 
PCR was employed. Consistent with the deletion of bba33, a 1296 bp PCR 
product was amplified from the putative ∆bba33 strain using primers 1 and 4, 
relative to the expected 841 bp fragment from the parent strain (Fig. 2B). As 
predicted, primers 4 and 5 failed to amplify any fragment from the parent strain 
ML23 pBBE22luc whereas a StrR-cassette containing 995 bp fragment was 
amplified from the putative ∆bba33 mutant (Fig. 2B). Furthermore, primers 2 and 
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Figure 2. A schematic representation of the bba33 deletion strategy. A. The bba33 locus 
and its flanking region was replaced by a PflgB-StrR cassette by homologous 
recombination. B. Primer pairs P1/P4 and P4/P5 (Table 3) were used to confirm the 
presence of PflgB-StrR cassette in the bba33 deletion mutant strain HZ001 (M, Δbba33 
mutant) relative to its parent strain ML23 (P, parent) by PCR. Likewise, PCR with the 
primer pair P2/P3 (Table 3) confirmed that HZ001 carried the Δbba33::StrR allele (M). 
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3 amplified a 672 bp fragment from the parent, but not from the putative ∆bba33 
mutant (Fig. 2B). The resulting ∆bba33 mutant strain was designated HZ001 and 
then transformed with pBBE22luc to both complement mammalian infectivity with 
bbe22, which is necessary in strains lacking lp25 (Purser et al., 2003), and provide 
a constitutively expressed borrelial codon optimized luciferase (luc) gene (Blevins 
et al., 2007). 
To genetically complement the bba33 deletion in trans, intact bba33 with 
both upstream (210 bp) and downstream (129 bp) sequences included, was 
cloned into pBBE22luc (Hyde et al., 2011). The resulting construct, designated 
pHZ300, was transformed into the bba33 deletion strain HZ001. PCR analysis of 
the transformed deletion strain (Fig. 3B) showed a 672 bp fragment similar to that 
seen for the initial parent strain (Fig. 2B). B. burgdorferi plasmid profiles of all 
strains were evaluated to ensure no further loss of plasmid DNA (Labandeira-Rey 
and Skare, 2001) (data not shown). All three strains made PncA/BBE22 protein 
and produced light, consistent with the presence of the pncA locus and firefly luc 
on pBBE22luc, respectively (data not shown). Furthermore, all isolated strains 
grew at the same rate indicating that the loss of bba33 did not alter B. burgdorferi 
replication in vitro (Fig. 4). 
 
Conditions that mimic the mammalian host environment induce bba33  
To determine whether BBA33 was produced in the deletion strain HZ001 
pBBE22luc relative to its parent (ML23 pBBE22luc) and genetic complement 
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(HZ001 pHZ300), we subjected protein lysates to Western immunoblot analysis. 
Prior studies indicated that temperature, pH, and CO2 content affected gene 
expression in B. burgdorferi (Carroll et al., 1999; Hyde et al., 2007; Samuels, 
2011; Stevenson et al., 1995). Furthermore, bba33 was induced under conditions 
that result in the production of several virulence-associated proteins, including 
OspC, BBK32, and DbpA, which require Rrp2/RpoS for their induction (Grimm et 
al., 2004; Pal et al., 2004a; Seshu et al., 2006; Weening et al., 2008). To assess 
whether the aforementioned variables contributed to bba33 induction, we 
subjected the aforementioned three strains to growth at either 32˚C, 1% CO2, pH 
7.6 (our conventional growth conditions) or 37˚C, 5% CO2, pH 6.8 to mimic the 
mammalian host conditions in vitro. When equivalent amounts of B. burgdorferi 
proteins from these conditions were resolved by SDS-PAGE, lp54-encoded 
BBA33 was detected in the parent strain ML23 pBBE22luc grown at 37˚C, 5% 
CO2, pH 6.8 (Fig. 5, bottom panel, right), consistent with the induction of 
mammalian-induced proteins, including OspC (Fig. 5, middle panel). In contrast, 
lp54-encoded BBA33 was not detectable in ML23 pBBE22luc when grown at 
32˚C, 1% CO2, pH 7.6 (Fig. 5, bottom panel, left). In fact, BBA33 levels were only 
observed at 37˚C, 5% CO2, pH 6.8; no other combination of temperature, CO2 
content, or pH resulted in detectable levels of BBA33 (data not shown). As 
expected, BBA33 was not detected in the ∆bba33 mutant HZ001 pBBE22luc, 
regardless of growth condition (Fig. 5, lower panel). In contrast, when bba33 was 
expressed from a shuttle vector in the genetic complement strain HZ001 pHZ300 
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Figure 3. A schematic presentation of the bba33 complementation strategy. A. 
Schematic presentation of the bba33 complementation construct pHZ300B. PCR using 
primer pairs P2/P3 confirmed the presence of bba33 in the complemented strain HZ001 
pHZ300 (C; complement) relative to the Δbba33 strain HZ001 pBBE22luc (M; Δbba33 
mutant).S 
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Figure 4. In vitro growth of the B. burgdorferi strains used in this study. The B. burgdorferi 
Parent strain (ML23/pBBE22luc), the Δbba33 mutant (HZ001/pBBE22luc), and the bba33 
complemented strain (HZ001/pHZ300; bba33 Comp.) were grown in triplicate in BSK-II 
media at 37˚C, 5% CO2, pH 6.8 and enumerated by dark field microscopy daily out to day 
6. Similar growth kinetics between these 3 strains were observed when the cells were 
grown at 32˚C, 1% CO2, pH 6.8, as well as other growth conditions (not shown). Data 
points shown reflect average value with standard error. No significant differences in 
growth were observed. 
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(Fig. 5, lower panel), the levels of BBA33 produced were high independent of the 
conditions imposed, presumably due to the increased copy number of the 
episomal DNA relative to its native location on lp54, which may titrate out 
regulatory components that regulate bba33 expression. In support of this premise, 
previous studies estimated the copy number of cp9 at 5-10 per cell relative to 
linear replicons (Beaurepaire and Chaconas, 2007; Tilly et al., 2006). In addition, 
a similar effect was seen when dbpBA was complemented in trans; that is, shuttle-
vector encoded DbpA was produced at levels that were approximately 8-fold 
greater than the lp54 encoded version (Weening et al., 2008). Given that dbpBA 
and bba33 are similarly regulated (Blevins et al., 2008; Weening et al., 2008), it 
is not surprising that in trans encoded BBA33 is produced at a similarly high level. 
 
BBA33 is a surface exposed lipoprotein  
The primary sequence of B. burgdorferi BBA33 predicts a lipoprotein with 
a leader peptidase II signal peptide at its amino terminus. To provide supporting 
evidence that BBA33 was surface exposed, we subjected intact B. burgdorferi 
strain ML23 pBBE22luc to proteinase K treatment. These cells were grown at 
37˚C, 5% CO2, pH 6.8, to induce detectable levels of BBA33 (Fig. 5). The data 
showed that BBA33 was degraded in intact B. burgdorferi cells under conditions 
where P66 was accessible to protease (producing a known 50 kDa stable product; 
(Bunikis et al., 1998)) but subsurface endoflagella (FlaB) was not (Fig. 6). The 
addition of detergent Triton X-100 together with proteinase K resulted in the loss  
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Figure 5. BBA33 is produced under conditions that mimic the mammalian-like 
environment. Equivalent amount of protein were loaded for the B. burgdorferi parent 
strain ML23 pBBE22luc (P for parent), the Δbba33 strain HZ001 pBBE22luc (M for 
mutant), and the genetic complement HZ001 pHZ300 (C for complement) from cells that 
were either grown in media under “non-induced” (32˚C, 1% CO2, pH 7.6; left 3 lanes) or 
“induced” conditions (37˚C, 5% CO2, pH 6.8; right 3 lanes), separated by SDS-PAGE, 
and stained with Coomassie blue (top panel) or immunoblotted with anti-OspC (middle 
panel), or anti-BBA33 serum (bottom panel). Note that the only condition where the parent 
strain made BBA33 is shown; no other combination of temperature, CO2 content, or pH 
resulted in the detection of BBA33. The numbers on the side panel depict the molecular 
mass of protein markers (in kDa). 
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Figure 6. BBA33 is surface exposed. B. burgdorferi strain ML23 pBBE22luc was 
cultivated at 37˚C, 5% CO2, pH 6.8 (inducing conditions) and harvested. The cells were 
then either resuspended in buffer (PBS), incubated with Proteinase K (P), or treated with 
both Proteinase K and Triton X-100 (P+TX). Following processing, the resulting samples 
were subjected to SDS-PAGE and immunoblotted with antiserum directed against either 
BBA33, the outer membrane P66 protein, or the subsurface FlaB protein.  
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of all antigens tested providing further support that the cells treated with PBS or 
proteinase K alone were intact (Fig. 6). Additional studies confirmed that BBA33 
partitioned with Triton X-114, consistent with its predicted status as a lipoprotein 
(not shown). Taken together, these results demonstrate that BBA33 is a surface 
exposed outer membrane lipoprotein of B. burgdorferi. 
 
The loss of bba33 results in the rapid clearance of B. burgdorferi 
Next, we asked if B. burgdorferi cells lacking bba33 were attenuated using 
the murine infection model. To track the active infection of cells lacking BBA33, 
we infected C3H/HeN mice with the parent strain (ML23 pBBE22luc), the ∆bba33 
strain (HZ001 pBBE22luc), and the bba33 complement strain (HZ001 pHZ300), 
all containing borrelial codon optimized firefly luciferase at doses of 103 and 105 
cells and measured light emission from these cells over time (Fig. 7 and 8). At 
the lower inoculum dose, a signal is not detected above background levels for any 
of the strains prior to day 4. At day 4 a clear signal is observed in mice infected 
with the parent and complement strain (Fig. 7). The signal expanded with a peak 
at day 7 and then began to wane commensurate with the development of the 
adaptive immune response (Fig. 7 and 8). At the low dose, the ∆bba33 mutant 
did not emit light above background for any of the time points tested (Fig. 7). For 
the high dose, an equivalent light signal was detected at 24 hours following 
infection for all strains tested (Fig. 7 and 8). However, at day 4 and beyond, no 
signal above background was detected in the ∆bba33 strain HZ001 pBBE22luc  
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Figure 7. Temporal and spatial tracking of B. burgdorferi strains following infection with 
103 and 105 spirochetes. C3H mice were infected with the parent (Parent; 
ML23/pBBE22luc), the Δbba33 mutant (Δbba33; HZ001/pBBE22luc), or the bba33 
complemented strain (bba33 Com., HZ001/pHZ300) at a dose of 103 (A) and 105 (B). 
Mice denoted with “+” were treated with D-luciferin and imaged at the times listed on the 
left. For each image shown the mouse on the far left (denoted as “-”) was infected with B. 
burgdorferi but did not receive D-luciferin to serve as a background control. All images 
were normalized to the same scale (shown on the right).  
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Figure 8. Quantification of in vivo luminescence images of mice infected at a dose of 103 
(A) and 105 (B) as previously described. B. burgdorferi ML23/pBBE22luc is depicted as 
circles, the Δbba33 derivative HZ001/pBBE22luc as squares, and the genetic 
complement HZ001/pHZ300 as triangles. Each time point represents the average value 
from the three mice given luciferin. ***P < 0.001; **** P < 0.0001. 
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(Fig. 7). Conversely, the parent and bba33 complement strains exhibited similar  
light emission and dissemination profiles (Fig. 7 and 8). After 21 days, the mice 
infected with the parent, ∆bba33, and bba33 complement, at both inoculum doses, 
were sacrificed and organs were harvested for cultivation and quantitative PCR 
analysis. Consistent with the imaging data, the absence of bba33 resulted in the 
inability of B. burgorferi to survive or colonize mice from any organ site tested at 
any inoculum dose tested including up to an infection dose of 107 ∆bba33 B. 
burgdorferi (Table 1). This is in stark contrast to the parent and complement 
strains, which were recovered from all organs independent of dose (Table 1).  
To quantify the bacterial burden, quantitative PCR (qPCR) was performed 
on total DNA extracted from the skin, lymph node, tibiotarsal joint, and heart from 
mice infected with the parent, the ∆bba33 mutant, and bba33 complemented 
strains harvested at the same time as the in vitro cultivated samples. Consistent 
with the cultivation data shown in Table 1, few genomic equivalents were detected 
in tissues infected with the ∆bba33 mutant HZ001 pBBE22luc at a 103 or 105 
inoculum (Fig. 9A and 9B, respectively). Also in line with the prior infection data 
(Fig. 7 and Table 1), the parent and complemented strains exhibited similar 
colonization phenotypes indicating that the defect observed in the mutant was 
due to the loss of BBA33 and not a secondary mutation (Fig. 9A and 9B). 
Interestingly, the overproduction of BBA33 in complemented strains resulted in 
lower colonization in joint tissue relative to the parent strain independent of 
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Table 1. Infectivity of the ∆bba33 mutant strain relative to its parent and genetic 
complement. 
 
 Number of culture positive/total number 
  
Strain 
Inoculum 
dose 
Lymph 
node 
  
Skin 
  
Heart 
  
Spleen 
  
Bladder 
  
Joint 
All 
sites 
ML23/pBBE22luc  103 4/4 4/4 4/4 4/4 4/4 4/4 24/24 
(parent) 105 4/4 4/4 4/4 4/4 4/4 4/4 24/24 
 
HZ001/pBBE22luc  103 0/4 0/4 0/4 0/4 0/4 0/4 0/24 
(Δbba33) 105 0/4 0/4 0/4 0/4 0/4 0/4 0/24 
  107 0/3 0/3 0/3 0/3 0/3 0/3 0/18 
 
HZ001/pHz300 
(Δbba33/bba33 
Comp) 
103 4/4 4/4 4/4 4/4 4/4 4/4 24/24 
105 4/4 4/4 4/4 4/4 4/4 4/4 24/24 
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infectious dose, yet exhibited similar bacterial burden in heart tissue (Fig. 9A and 
9B). Taken together, these data indicate that BBA33 is required for infectivity. 
Furthermore, the absence of BBA33 from the surface of B. burgdorferi leads to 
rapid clearance, suggesting that BBA33 is required for the establishment of a 
localized infection and resistance to the host innate immune response.  
 
Recombinant BBA33 mediates binding to collagens  
Given that BBA33 was an infectivity-associated surface exposed 
lipoprotein, we were next interested in identifying a function for this protein. To 
this end, we screened random cyclic peptide phage display libraries to identify 
peptide sequences that would selectively recognize recombinant BBA33 
(rBBA33) (Barbu et al., 2010; Mullen et al., 2006; Sergeeva et al., 2006). We 
found that the number of phage binding to immobilized rBBA33 increased relative 
to background after several rounds of panning (based on BSA binding), 
suggesting a specific enrichment for BBA33. After the aforementioned panning, 
the DNA corresponding to the peptide insert from 100 randomly selected plaques 
was sequenced. An alignment of the deduced amino acids revealed enrichment 
for the sequence PGEPGLN, which is found in the human collagen type VI alpha 
3 chain. However, in collagen this sequence is present in the triple helix 
collagenous domains and it is unlikely that all residues identified in the cyclic 
peptide would be available for interactions in the structurally restricted triple helix. 
To explore the possibility that BBA33 can bind collagens we used an ELISA-type  
  50 
 
 
Figure 9. Quantitative assessment of B. burgdorferi infection in C3H mice. Real-time PCR 
(qPCR) of the parental strain B. burgdorferi ML23/pBBE22luc (Circles), the Δbba33 
derivative HZ001/pBBE22luc (Squares), and the genetic complement HZ001/pHZ300 
(Triangles) was used to enumerate borrelial genomic equivalents from mouse tissues. 
Mice were infected with either 103 (A) or 105 (B) B. burgdorferi strains for 21 days before 
total DNA was obtained from skin (SK), lymph nodes (LN), joints (JT) and heart (HT) 
tissues. The results are represented as the number of borrelial genome copies per 106 
mouse β-actin copies. The horizontal line depicts the mean value. Each data point shown 
represents an independent sample from a single mouse tissue assayed in triplicate and 
averaged. * P<0.05; ** P<0.01; *** P<0.001. 
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binding assay where increasing concentrations of purified rBBA33 protein were 
incubated in wells coated with different collagen types and other extracellular 
matrix proteins. A concentration dependent binding of BBA33 to type VI collagen 
was noted with saturation at 2 µM and half maximum binding (e.g., apparent KD) 
at approximately 350 nM (Fig 10A). In contrast, purified OspC did not bind to 
collagen type VI at any concentration tested (Fig. 10A) indicating that the 
BBA33::collagen type VI interaction is specific. BBA33 showed dose-dependent 
binding to collagen type IV but not to human collagen type I, fibronectin, and 
murine laminin, indicating specificity for a subset of targets (Fig 10B). When 
BBA33 was subjected to heat inactivation, the binding to collagen observed was 
eliminated suggesting that the native conformation was required for dose-
dependent binding (not shown). 
 
Native BBA33 binds to type VI collagen  
We next sought to determine whether native BBA33, presented on the 
surface of B. burgdorferi cells, could promote bacterial attachment to the identified 
BBA33 targets. A significant difference in borrelial cell attachment was observed 
to collagen type VI when the bba33 complement (HZ001 pHZ300; designated C) 
was compared to the parent strain ML23 pBBE22luc (designated P) and ∆bba33 
strain HZ001 pBBE22luc (designated M) when the cells are grown at 32˚C, 1% 
CO2, pH 7.6 (Fig. 11, left); under these conditions no difference was seen in the 
attachment to laminin to any of the strains tested (Fig. 11). Under these conditions  
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Figure 10. BBA33 binds to human type VI collagen and mouse type IV collagen in a dose-
dependent manner. A. Various concentrations of purified BBA33 were incubated with type 
VI collagen. Identical concentrations of OspC were tested for type VI collagen interaction 
as well and served as a negative control. B. Binding of BBA33 to collagens types I, IV, 
and VI, as well as fibronectin and laminin, was evaluated as in panel A. Binding to 
collagens type VI and IV was dose dependent, whereas binding to fibronectin and laminin 
did not demonstrate specific binding to BBA33. All assays were done independently three 
times, each time in duplicate. **P < 0.01; ****P < 0.0001. 
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the levels of BBA33 are low in the parent strain (Fig. 5); therefore, the low level 
of binding observed for the parent strain ML23 pBBE22luc is consistent with the 
lack of BBA33 produced when the parent is grown under non-inducing conditions 
and thus, not surprisingly, comparable to the ∆bba33 mutant (Fig. 11, left). 
However, when the cells were grown under conditions that promote the 
production of BBA33 (Fig. 5; e.g., 37˚C, 5% CO2, pH 6.8), a significant difference 
in collagen type VI binding was observed between the parent ML23 pBBE22luc 
and the ∆bba33 mutant HZ001 pBBE22luc. No significant differences to laminin 
binding were noted (Fig. 11, right). As expected, the bba33 complement HZ001 
pHZ300 strain bound collagen type VI under inducing conditions (Fig. 11, right) 
since shuttle vector encoded BBA33 is synthesized at high levels independent of 
growth parameters (Fig. 5). These data are consistent with the induction of bba33 
under the “mammalian-like” induction conditions and provide further support that 
surface-exposed, native BBA33 specifically recognizes collagen type VI. 
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Figure 11. B. burgdorferi whole cells that produce surface exposed BBA33 mediate 
specific binding to human type VI collagen. B. burgdorferi strain ML23/pBBE22luc (P; 
parent), HZ001/pBBE22luc (M; bba33 mutant), and HZ001/pHZ300 (C; complement) 
were grown either under “non-inducing” conditions (32˚C, 1% CO2, pH 7.6; left side) or 
“inducing” conditions (37˚C, 5% CO2, pH 6.8; right side) and incubated on cover slips 
containing either mouse laminin (filled circles or squares) or human type VI collagen 
(open circles or squares). B. burgdorferi cells binding was scored via dark field 
microscopy. Each data point represents the average number of spirochetes visualized in 
10 random fields. Each strain was tested a minimum of 3 times, with each sample 
assayed in duplicate. ***P < 0.001; ****P < 0.0001; ns, non-significant difference. 
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Discussion 
Interaction with the host extracellular matrix (ECM) is an essential part of 
the pathogenic process of B. burgdorferi. B. burgdorferi is transmitted from ticks 
to a mammalian host during a blood meal and, as a result, is deposited within the 
dermal layer of the skin where collagen and other components of the ECM reside 
(Cabello et al., 2007; Radolf et al., 2012). Some of the first micrographs of B. 
burgdorferi from infected tissue showed spirochetal bacteria aligned with collagen 
fibrils (Cabello et al., 2007; Barthold et al., 1991). Subsequent infectivity studies 
demonstrated that the association of B. burgdorferi with ECM tissue is required 
for persistence (Brissette and Gaultney, 2014; Cabello et al., 2007), although the 
basis for all B. burgdorferi-ECM interactions was not completely defined.  
In this study we describe a collagen binding lipoprotein from B. burgdorferi, 
designated BBA33, which is required for experimental Lyme borreliosis. To date, 
the only data associated with bba33 is its dependence on the BosR/Rrp2-RpoN-
RpoS regulatory pathways for expression (Caimano et al., 2007). Despite the 
observation that bba33 was subject to the same degree of regulation observed 
for other borrelial virulence determinants (Boardman et al., 2008; Caimano et al., 
2007; He et al., 2007; Hubner et al., 2001; Yang et al., 2003), notably ospC, 
dbpBA, and bbk32 (He et al., 2007; Hubner et al., 2001), no function was known 
for BBA33. Using phage display, we identified a sequence found in type VI 
collagen as a target for BBA33. To biochemically validate the predicted BBA33-
collagen interaction we used an ELISA-based assay and found that BBA33 binds 
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to collagen types IV and VI in a dose-dependent manner, but does not bind to 
collagen I, laminin, or fibronectin (Fig. 10B). To address the ability of surface 
exposed native BBA33 to recognize ECM proteins, we incubated whole cells 
producing BBA33 with human collagen type VI and laminin. The results in Fig. 11 
show that the genetic complement strain HZ001 pHZ300, which produces large 
amounts of BBA33, significantly enhances the ability of the spirochete to adhere 
to collagen type VI relative to the parent strain (ML23 pBBE22luc) and ∆bba33 
strain (HZ001 pBBE22luc) that are grown under conditions where BBA33 is not 
produced (Fig. 5). These data appears to contradict earlier findings that saw no 
binding of B. burgdorferi to collagens (Guo et al., 1995). However, upon reflection, 
this observation may be consistent with our findings since lp54-encoded bba33 is 
only expressed in the parent strain under conditions that mimic mammalian host 
adapted conditions (Fig. 5). The prior work was done using conventionally grown 
B. burgdorferi (Guo et al., 1995), which represent experimental conditions that do 
not yield detectable levels of BBA33 (Fig. 5). In addition, when the parent strain 
ML23 pBBE22luc is grown under inducing conditions, the level of collagen type 
VI binding increases significantly consistent with the production of BBA33 within 
this same environment (Fig. 5). 
The ability of bacteria to adhere to collagen type VI is known for a few 
pathogens, including Legionella and some Staphylococcus spp. (Bober et al., 
2010; Liu et al., 2004; Wagner et al., 2007), but is still poorly characterized relative 
to other pathogen-collagen interactions (Liu et al., 2007; Zong et al., 2005). It is 
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important to note that, in the case of collagen type VI binding by the 
Staphylococcus capitis protein SdrX, the recombinant protein bound to several 
types of collagens in ELISA-based binding assays but only type VI collagen when 
S. capitis cells were used to query collagen binding (Liu et al., 2004). As such, 
the ability of B. burgdorferi cells to bind to collagen type VI provides similar 
support for BBA33-type VI collagen interactions.  
The recognition of collagen type VI by BBA33 is of further interest given 
the recent reports demonstrating the ability of activated macrophages to secrete 
this particular collagen in a non-fibrillar form as is normally seen in fibroblasts 
(Schnoor et al., 2008). Two molecules that stimulate the production and secretion 
of type VI collagen include IL-10 and TGF-β1, both of which are induced early in 
B. burgdorferi infection (Codolo et al., 2008; Lazarus et al., 2008). In addition, 
both of these cytokines negate the inflammatory response of cells, including 
activated macrophages (Bogdan and Nathan, 1993; Oosting et al., 2014) and, by 
virtue of their ability to secrete collagens, notably type VI collagen (Schnoor et al., 
2008), might create an additional platform for B. burgdorferi to bind. Based on the 
concurrent deactivation of previously activated macrophages, this 
microenvironment may promote localized colonization of B. burgdorferi and assist 
in the dissemination of spirochetes to distal sites. Based on our current data it is 
unclear if this is operative in vivo; however, the dramatic attenuation of cells 
lacking BBA33 suggests that this lipoprotein plays an important role early in B. 
burgdorferi infection. 
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Type VI collagen also interacts with both biglycan and decorin, two 
proteoglycans that B. burgdorferi recognizes via the surface exposed lipoproteins, 
DbpA and DbpB (Brown et al., 1999; Fischer et al., 2003). It is tempting to 
speculate that B. burgdorferi infection stimulates the production of type VI 
collagen locally within the skin via innate immune cells and fibroblasts to generate 
a scaffold that borrelial cells can actively engage via a number of adhesins that 
bind to ECM targets. Further experimentation is required to test this hypothesis.  
Perhaps the more striking result presented herein is the absolute loss of 
infectivity seen for the ∆bba33 mutant strain HZ001 pBBE22luc. From our imaging 
data of bioluminescent spirochetes (Fig. 7), it is clear that the ∆bba33 mutant is 
cleared early in the infectious process at time points where the parent and genetic 
complement are replicating in vivo, suggesting that BBA33 may assist in the 
resistance to innate immune clearance. It is curious that the complement protein, 
C1q, contains a collagen-like motif (Kishore and Reid, 2000). Although C1q is 
involved in the classical pathway of complement, a serum sensitive B. burgdorferi 
sensu lato isolate, B. garinii, is resistant to serum when C1q is selectively depleted 
(Dam et al., 1997), suggesting that the interaction of C1q and Borrelia isolates is 
key for innate survival. Our evaluation of BBA33::C1q interactions indicated that 
BBA33 does recognize and bind strongly to C1q (not shown). When we tested 
whether BBA33 could inhibit classical complement activation, no inhibitory activity 
was observed. However, surprisingly (and serendipitously), we did find that the 
fibronectin-binding protein, BBK32, was able to inhibit the classical pathway at a 
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Kd value of approximately 20 nM, indicating a high affinity interaction. This 
interaction serves as the basis for the next section of this dissertation, i.e., 
Chapter III. 
A diverse set of pathogens are known to bind to mammalian collagen-rich 
tissues to promote colonization (Bober et al., 2010; Foster et al., 2014; Umemoto 
et al., 1997). The structure of several of these interactions has been resolved 
yielding important insight into the binding process (Zong et al., 2005). The best 
characterized is the Cna collagen binding protein from Staphylococcus aureus, 
which uses a collagen-hug mechanism to bind host collagen (Zong et al., 2005). 
This interaction is important for pathogenesis, as Cna is required for several 
pathogenic features associated with experimental S. aureus infections, including 
ocular keratitis, osteomyelitis, and arthritis (Foster et al., 2014). The portion of 
Cna that mediates collagen binding is composed of two sub-domains, each 
adopting an IgG-like fold (Zong et al., 2005). This same beta pleated sheet rich 
structure is seen or presumed for the homologous collagen binding protein from 
Streptococcus and Enterococcus spp (Lannergard et al., 2003; Liu et al., 2007). 
Several algorithms predict that BBA33 is devoid of beta pleated sheet structure 
and instead is largely alpha helical in nature. If this is true, then the mechanisms 
that BBA33 employs to bind collagen are likely to be novel relative to that seen 
for Cna and related collagen binding proteins.  
In summary, herein we demonstrate that B. burgdorferi BBA33 is a surface 
exposed lipoprotein that is expressed preferentially under conditions that mimic 
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the mammalian host environment. In addition, we show that BBA33 mediates 
specific interaction of B. burgdorferi with collagen substrates, i.e., human collagen 
type VI and murine type IV collagen. Despite a long history of B. burgdorferi-
collagen interactions, to our knowledge BBA33 represents the first B. burgdorferi 
protein that recognizes human collagens in a dose-dependent manner. Imaging 
of bioluminescent ∆bba33 B. burgdorferi showed that the loss of BBA33 results 
in rapid clearance, which suggests a role in resistance to innate immune 
mechanisms. Further studies are warranted to investigate the significance of this 
interaction in vivo. 
 
Experimental procedures  
Bacterial strains and culture conditions  
Bacterial strains and plasmids used in this study are described in Table 2. 
Escherichia coli strains were grown with aeration in Luria broth (LB) media at 
37°C. Concentrations of antibiotics used in E. coli for selective pressure are as 
follows: kanamycin, 50 µg ml-1; spectinomycin, 50 µg ml-1. B. burgdorferi B31 
ML23 (Labandeira-Rey and Skare, 2001) and derivative strains were grown in 
BSK-II media supplemented with 6% normal rabbit serum (Pel-Freez Biologicals, 
Rogers, AR) under either conventional microaerobic conditions at 32°C, at pH 6.8 
or pH 7.6, under a 1% or 5% CO2 atmosphere, or at 37°C, pH 6.8 or pH 7.6, under 
a 1% or 5% CO2 atmosphere. For most experiments, B. burgdorferi cultures were 
grown at either 32°C, 1% CO2, pH 7.6 (non-inducing or conventional conditions) 
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or at 37°C, 5% CO2, pH 6.8 (inducing conditions). Growth was scored daily by 
dark field microscopy. Antibiotics used for the selective pressure in B. burgdorferi 
are as follows: kanamycin at 300 µg ml-1 and/or streptomycin at 50 µg ml-1, 
depending on genetic composition. The use of infectious B. burgdorferi in this 
study was reviewed and approved by the Institutional Biosafety Committee at 
Texas A&M University.  
 
Genetic modification of B. burgdorferi  
B. burgdorferi deleted for bba33 was generated via homologous 
recombination by replacing all of bba33 with a PflgB-aadA (StrR) antibiotic cassette 
(Frank et al., 2003). To accomplish this, a 1526 bp fragment upstream of bba33 
was amplified using the primer pairs BamHI-A33us-recF and flgB-A33us-recR 
(Table 3) that created a 5’ overhang to pCR2.1 with the BamHI site and a 3’ 
overhang homologous to PflgB sequences from pKFSS1 (Table 3). An additional 
1527 bp PCR product, which was directed to sequences downstream from bba33, 
was engineered with primers aadA-A33ds-recF and A33ds-XhoI-recR (Table 3) 
with overlapping sequences to sequences downstream to the stop codon of the 
aadA locus (StrR) at the 5’ end, and sequences homologous to pCR2.1, including 
the XhoI site. Finally, a PCR product containing the PflgB-StrR cassette was 
amplified from plasmid pKFSS1 using primer set FlgB-F and aadA-R (Table 3). 
All 3 PCR products, each containing homologous sequences, along with pCR2.1 
digested with BamHI and XhoI, were combined and subjected to Gibson 
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assembly as outlined by the manufacturer (New England Biolabs). The resulting 
construct was designated pHZ001 (Table 3). Transformation of strain ML23 with 
linearized pHZ001 was done as previously described (Samuels, 1995; Weening 
et al., 2008; Hyde et al., 2011). Transformants were selected for their resistance 
to streptomycin and screened by PCR to confirm the deletion of bba33 using 
primers listed in Table 3 and as depicted in Fig. 2. Candidates were screened for 
borrelial plasmid content as before (Labandeira-Rey and Skare, 2001) and those 
that mirrored strain ML23 were transformed with pBBE22luc and transformants 
were selected for resistance to kanamycin (Hyde et al., 2011). Putative 
transformants were screened for the presence of pBBE22luc and total borrelial 
plasmids using methods described previously (Labandeira-Rey and Skare, 2001; 
Hyde et al., 2011). 
For genetic complementation, bba33 and 210 bp 5’ to the translation start 
site were cloned into the BamHI and SalI sites in the pBBE22luc shuttle vector to 
yield the final construct, pHZ300, using the oligonucleotides used are listed in 
Table 3. HZ001 was then made competent and electroporated with pHZ300 as 
described (Samuels, 1995). Transformants were selected for resistance to 
kanamycin and candidates were confirmed by PCR as indicated in Fig. 3. As 
before, borrelial plasmid DNA was accounted for using previously published 
methods (Labandeira-Rey and Skare, 2001). Only strains that contained the DNA 
profile of transformed ML23 were used for subsequent analyses. 
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Table 2. Strains and plasmid constructs used in this study. 
 
Strain or plasmid Genotype and/or characteristics Source 
 
E. coli strains 
 
Mach-1TM-T1R 
 
 
 
BL21 Star™ (DE3) 
 
BL21 Star™ (DE3) pLysS 
 
 
Top10  
φ80lacZ∆M15 ∆lacX74 hsdR (rK-, mk+) 
∆recA1498 endA1 tonA 
F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) 
 
F- ompT hsdSB (rB-mB-) gal dcm rne131 (DE3) 
pLysS (CamR) 
 
F- mcrA Δ(mrr-hsdRMS-mcrBC) φ80lacZΔM15 
ΔlacX74 recA1 araD139, Δ(ara leu)7697 galU 
galK rpsL (StrR) endA1 nupG 
Invitrogen 
 
 
Invitrogen 
 
Invitrogen 
 
 
Invitrogen 
 
B. burgdorferi strains 
 
ML23 B. burgdorferi strain B31 clonal isolate missing 
lp25 
(Labandeira-Rey and 
Skare, 2001) 
 
ML23/pBBE22luc Clonal isolate of strain B31 lacking lp25 
containing bbe22 and B. burgdorferi codon 
optimized luc gene under the control of a strong 
borrelial promoter (PflaB-luc); parent strain 
 
(Hyde et al., 2011) 
HZ001 ML23 Δbba33::StrR 
 
This study 
HZ001/pBBE22luc ML23 Δbba33::StrR, containing bbe22 and the B. 
burgdorferi codon optimized luc gene under the 
control of a strong borrelial promoter (PflaB-luc) 
 
This study 
HZ001/pHZ300 ML23 Δbba33::StrR, containing bbe22, bba33, 
both under the control of their native promoters, 
and the B. burgdorferi codon optimized luc gene 
under the control of a strong borrelial promoter 
(PflaB-luc) 
 
This study 
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Table 2. Continued 
 
Strain or plasmid Genotype and/or characteristics Source 
 
Plasmids    
pCR2.1 
 
pKFSS1 
 
 
 
pBBE22Gate 
 
 
 
pBBE22luc 
 
pCR™2.1-TOPO® vector; AmpR, KanR 
 
B. burgdorferi shuttle vector containing PFlgB-
StrR cassette; SpcR in E. coli, StrR in B. 
burgdorferi 
 
pBBE22 modified to be a Gateway destination 
vector containing attL and attR sites; CamR, 
KanR 
 
Borrelial shuttle vector containing bbe22 and B. 
burgdorferi codon optimized luc gene under the 
control of a strong borrelial promoter (PflaB-luc) 
 
Invitrogen 
 
(Frank et al., 2003) 
 
 
(Weening et al., 2008) 
 
 
(Hyde et al., 2011) 
 
pCR2.1Bactin β-actin gene cloned into pCR2.1 vector; KanR (Hyde et al., 2011) 
 
pCR2.1recA 
 
1119 bp fragment, containing the recA gene, 
cloned into pCR2.1 vector; KanR 
 
(Hyde et al., 2011) 
 
pET15b 
 
 
pSS008 
 
 
 
 
pHZ001 
 
 
 
 
 
 
pHZ300 
 
Cloning vector for overexpression of genes to 
generate His-tagged recombinant protein; AmpR 
 
bba33 lacking its leader peptide (including the 
cysteine residue) was cloned into the NdeI and 
BamHI sites of pET15b in order to produce His-
tagged recombinant BBA33  
 
PCR amplicons containing sequences 1526 bp 
upstream of the start of B. burgdorferi bba33, the 
PflgB-StrR cassette from pKFSS1, and 
sequences 1527 bp downstream of the bba33 
stop codon, as well as pCR2.1, were specifically 
configured using Gibson assembly 
 
Intact bba33 containing sequences 210 bp 
upstream and 129 bp downstream were cloned 
into the BamHI and SalI sites of pBBE22luc 
EMD Millipore 
 
 
This study 
 
 
 
 
This study 
 
 
 
 
 
 
This study 
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Infectivity studies and bioluminescent imaging  
Infectivity studies were performed as previously described (Hyde et al., 
2009). Briefly, 8-week-old C3H/HeN mice were inoculated with either 103 or 105 
organisms of the B. burgdorferi parent strain ML23/pBBE22luc, the ∆bba33 strain 
HZ001/pBBE22luc, or the genetic complement strain HZ001/pHZ300 by 
intradermal injection. For each dose and strain used, 4 mice were infected per 
group. Imaging of infected mice to detect bioluminescence in the aforementioned 
B. burgdorferi strains was done as described (Hyde et al., 2011). After 21 days, 
the mice were sacrificed and inguinal lymph node, skin, heart, spleen, bladder 
and tibiotarsal joint tissues from each mouse were aseptically collected for in vitro 
cultivation and qPCR analysis of B. burgdorferi burden as described (Weening et 
al., 2008; Hyde et al., 2011). All animal experiments were performed in 
accordance to the Association for Assessment and Accreditation of Laboratory 
Animal Care (AAALAC) guidelines. The Texas A&M University Institutional 
Animal Care and Use Committee (IACUC) approved all animal procedures used 
in this study. 
 
DNA extraction of B. burgdorferi from infected tissues and qPCR analysis  
Total DNA was isolated from mice skin, lymph node, heart and tibiotarsal 
joint samples using Roche High Pure PCR template preparation kit as previously 
described (Weening et al., 2008). Approximately 100 ng of total DNA was used  
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Table 3. Oligonucleotides used in this study. 
 
Oligonucleotide Sequence (5’ to 3’) Description 
BamHI-A33us-recF 
 
 
flgB-A33us-recR 
 
 
CCAAGCTTGGTACCGAGCTCGGATCCACAC
GCGCTAGCATCCTTTAAATT 
 
TAGGAAATCTTCCACGCCAATTGTTAAAGCT
TTCTGTTTCTACGATATCG 
 
 
Primer pair used to amplify 
1526 bp region upstream of 
bba33 with a 22 bp 5’ flanking 
region homologous to pCR2.1 
upstream of the BamHI site 
and a 3’ flanking region 
homologous to the 5’ region of 
the flgB promoter (PflgB) 
 
 
aadA-A33ds-recF 
 
 
 
A33ds-XhoI-recR 
 
 
 
 
 
flgB-F 
 
aadA-R 
 
 
 
 
GTGAAAAAGTTTAAAAATCAGTTATTCTTCT
ATAGGTTTTATTTCTG 
 
CGAATTGGGCCCTCTAGATGCATGCTCGAG
CGGGTGTTGGAATTGGAAACGAACC 
 
 
 
 
 
CAATTGGCGTGGAAGATTTCC 
 
CTGATTTTTAAACTTTTTCACAAATAGG 
 
 
 
Primer pair used to amplify the 
1527 bp region downstream 
from bba33 with a 21 bp 5’ 
flanking region homologous to 
the aadA 3’ end and a 32 bp 3’ 
flanking region homologous to 
sequences downstream of the 
XhoI site of pCR2.1 
 
 
Primer pair used to amplify 
PflgB-StrR cassette from 
pKFSS1 
 
 
 
P1 
 
P2 
 
 
P3 
 
P4 
 
P5 
 
GCCAGAGAGCGATATCGTAGAAAC 
 
AATAATAGGTTCATGAAAAATTTGTATG 
 
 
CACAAATAGGGTCAAAATTTTGACC 
 
TGCCCTATCAGAAATAAAACCTATAGAAG 
 
GAAGTGCCTGGCAGTAAGTTG 
 
 
Primers P1 through P5 were 
used to confirm the bba33 
deletion in B. burgdorferi as 
well as complementation 
construct (see Fig. 2 and 3). 
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Table 3. Continued 
 
Oligonucleotide Sequence (5’ to 3’) Description 
 
 
A33-NdeI-5’F 
 
 
A33-BamHI-3’R 
 
 
 
ACGCCATATGTATTTAAATGATTTTTCTGGT
ATG 
 
ACGCGGATCCTTATTTTTGAATTAGTGCTAA
AGCAC 
 
 
Primer pair used to amplify 
bba33 lacking sequences that 
encode its leader peptide 
through the stop codon with 
NdeI (underlined) and BamHI 
(bold) sites engineered for 
cloning into pET15b 
expression vector 
   
 
A33up210-BamHI-F 
 
 
A33dn129-SalI-R 
 
ACGCGGATCCGCCAGAGAGCGATATCGTA
GAAAC 
 
ACGCGTCGACAAATGGCTAGGGTGGAATAC
AAAC 
 
Primer pair used to amplify a 
region from 210 bp upstream 
and 129 downstream of bba33 
with BamHI (bold) and SalI 
(underlined) sites; cloned into 
pBBE22luc 
 
β-Actin-F 
 
β-Actin-R 
 
ACGCAGAGGGAAATCGTGCGTGAC 
 
ACGCGGGAGGAAGAGGATGCGGCAGTG 
 
Primer pair used for 
enumerating copies of mouse 
β -actin via qPCR (Pal et al., 
2008) 
 
nTM17FrecA 
 
 
nTM17RrecA 
 
GTGGATCTATTGTATTAGATGAGGCT 
 
GCCAAAGTTCTGCAACATTAACACCT 
 
Primer pair used for 
enumerating copies of 
B.burgdorferi recA via qPCR 
(Liveris et al., 2002; Weening 
et al., 2008) 
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for each qPCR reaction. Quantitative real-time PCR analysis was conducted 
using the Applied Biosystems ABI 7900 HT system. B. burgdorferi genome copies 
and mammalian cell equivalents were determined using either the 
oligonucleotides nTM17FRecA and nTM17RRecA (Liveris et al., 2002; Weening 
et al., 2008) and primer set βactin-F and βactin-R (Pal et al., 2008), respectively. 
The bacterial burden was depicted as the number of B. burgdorferi recA per 106 
β-actin copies. 
 
Purification of recombinant BBA33  
To overproduce and purify rBBA33, a construct lacking the first 51 bp of 
the bba33 open reading frame (corresponding to the leader peptide) was 
amplified from B. burgdorferi genomic DNA using primer set A33-NdeI-5’F and 
A33-BamHI-3’R (Table 3) and cloned in-frame into pET15b following its digestion 
with NdeI and BamHI. The resulting construct, designated pSS008, encodes an 
amino terminal His-tagged version of BBA33. To affinity purify His-tagged BBA33, 
pSS008 was transformed into BL21 Star™(DE3) pLysS, grown to early log phase, 
and the His-tagged BBA33 produced following induction with 0.2 mM IPTG for 16 
hrs at 15°C. The cells were harvested by centrifugation, the pellet frozen, and 
lysed via French pressure cell treatment. The soluble fraction, containing the His-
tagged BBA33 protein, was applied to HisPur Cobalt resin (Thermo scientific) and 
affinity purified as outlined by the manufacturer.  
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Rabbit polyclonal antiserum to BBA33 was obtained following 
immunization of New Zealand white rabbits via an IACUC approved regimen at 
the Comparative Medicine Program, Texas A&M University.  
 
SDS-PAGE and immunoblotting  
B. burgdorferi protein lysates were resolved by SDS–PAGE (Laemmli, 
1970) and gels were either stained with Coomassie Brilliant Blue R-250 (Sigma 
Aldrich, St Louis, MO, USA) or transferred to PVDF membranes and 
immunoblotted as described (Weening et al., 2008). Primary antibodies were 
used at the following dilutions: anti-BBA33 at 1:2000; anti-His6 (GE Healthcare) 
at 1:6000; anti-OspC at 1:4 x 106 (a kind gift from R. Gilmore); anti-PncA at 1:1500 
(generously provided by J. Seshu); anti-P66 at 1:1000 (kindly provided by Sven 
Bergström); or anti-FlaB at 1:20,000 (Affinity Bioreagent, Golden, CO). Prior to its 
use for Western immunoblotting, the BBA33 antiserum was adsorbed against 
HZ001 borrelial lysates to reduce the amount of non-specific antibodies, as 
reported previously (Skare et al., 1999). Appropriate secondary antibodies, with 
horseradish peroxidase (HRP) conjugates [anti-mouse HRP (Invitrogen, 
Carlsbad, CA) or anti-rabbit HRP (Amersham, Piscataway, NJ), both diluted 
1:4000] were used to detect immune complexes, the membranes washed 
extensively in PBS, 0.2% Tween-20, and developed using the Western Lightning 
Chemiluminescent Reagent plus system (Perkin Elmer, Waltham, MA, USA). 
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Proteinase K accessibility assay  
B. burgdorferi strain ML23 pBBE22luc was grown under inducing 
conditions (37˚C, 5% CO2, pH 6.8) and harvested by centrifugation at 5,800 x g, 
and washed twice with PBS. The cell pellet was re-suspended in 0.5 ml of either 
PBS alone, PBS with proteinase K (to a final concentration of 200 µg ml-1), or 
PBS/proteinase K with 0.05% Triton X-100. All samples were incubated at 20°C 
for 40 min. Reactions were terminated by the addition of phenylmethylsulfonyl 
fluoride (PMSF) to a final concentration of 1 mM. Cells were again pelleted by 
centrifugation (9,000 x g for 10 min at 4°C), washed twice with PBS containing 1 
mM PMSF, and re-suspended in Laemmli sample buffer (Laemmli, 1970). 
Samples were run on SDS-PAGE gel and probed with anti-BBA33, anti-P66, and 
anti-FlaB antibodies, respectively.  
 
Triton X-114 phase partitioning  
B. burgdorferi strain ML23 pBBE22luc was grown under inducing 
conditions (37˚C, 5% CO2, pH 6.8) and subjected to Triton X-114 phase 
partitioning as previously described (Skare et al., 1995).  
 
Solid-phase phage display screening  
A phage library displaying random cyclic 8-mer peptides (CX8C; X is any 
amino acid) was used for the screening against rBBA33 immobilized onto 
microtiter wells overnight at 4˚C (at 1 µg/well in PBS). After the wells were washed 
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twice with PBS and blocked with PBS containing 3% BSA for 1 hr at 23˚C, 109 
PFU in 50 µl PBS containing 2% BSA were added to the wells (Barbu et al., 2010). 
After 2 hours at 23˚C, the wells were washed 6 times with PBS containing 0.1% 
Tween 20 and 3 times with PBS, and phage were recovered by bacterial infection 
as described (Smith and Scott, 1993). Phage recovered after the second and third 
round of selection were subjected to dideoxy sequencing and the resulting 
deduced amino acid sequences compared in the existing NCBI protein database.  
 
In vitro ECM binding assay  
Maxinunc microtiter plates (eBiosciences) were coated with 0.5 μg human 
collagen I (Corning), human collagen VI (Abcam), bovine fibronectin (Corning), 
mouse collagen IV (Corning), and mouse laminin (Corning) at 4°C for overnight, 
and blocked with 3% BSA for 1 hour at 37 °C. Recombinant His-tagged BBA33 
protein was serially diluted 1:2 starting from 4 µM down to 62.5 nM in PBS, 0.1% 
Tween-20, and added to coated wells in triplicate and incubated for 1 hour at 37 
°C. After 5 washes in PBS, 0.1% Tween-20, a 1:6000 dilution of monoclonal 
antibody directed against poly-His (His6) was added to each well and incubated 
for 1 hr at 37 °C. Following 5 washes in PBS, 0.1% Tween-20, a 1:4000 dilution 
of horseradish peroxidase (HRP) conjugated anti-mouse IgG was added to each 
well and incubated for 1 hr at 37 °C. The wells were then washed in PBS, 0.1% 
Tween-20, after which 3,3’,5,5’–tetramethylbenzidine (TMB) was added as 
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substrate. The enzymatic reaction was stopped after 3 min using 0.16 M sulfuric 
acid (Thermo scientific) and the absorbance at 450 nm was determined. 
 
B. burgdorferi whole cell adherence assay  
Poly-D-lysine pre-coated coverslips (Corning Biocoat) were coated with 2 
µg human collagen VI or mouse laminin and incubated at 4°C overnight. The 
coverslips were washed thoroughly in PBS to remove excess unbound proteins. 
The coverslips were then blocked with 3% BSA at 37 °C for 1 hr. The B. 
burgdorferi parent strain ML23 pBBE22luc, the ∆bba33 strain HZ001/pBBE22luc, 
and the genetic complement strain HZ001/pHZ300 were all grown to exponential 
phase at either 32°C, 1% CO2, pH 7.6 (non-inducing conditions) or 37°C, 5% CO2, 
pH 6.8 (inducing conditions). The resulting cells were then harvested by 
centrifugation at 5,800 × g and washed with BSK-II medium without serum three 
times, and diluted to 107 organisms/ml in BSK-II medium without serum. The 
resulting B. burgdorferi cells, in 0.1 ml volumes, were applied onto the coverslips 
and incubated for 2 hr at 32°C. Unbound bacteria were removed from the 
coverslips by gentle washing with PBS; this wash step was repeated 10 times. 
The coverslips were applied to a glass slide and attached bacteria were counted 
by dark field microscopy. Binding was scored as the average number of bacteria 
bound per field based on 10 random fields per slide. 
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Statistical analysis  
For real-time qPCR analysis, a one-tailed Mann–Whitney’s t-test was 
performed between the strains indicated. For ELISA and bioluminescent assays, 
Two-way analyses of variance (ANOVA) were performed respectively among 
variables. Tukey’s post-test was used to determine P-values between coated 
proteins. Statistical significance was accepted when the P values were less than 
0.05 for all statistical analyses employed. 
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CHAPTER III  
Borrelia burgdorferi BBK32 INHIBITS THE CLASSICAL PATHWAY BY 
BLOCKING ACTIVATION OF THE C1 COMPLEMENT COMPLEX∗ 
 
Introduction 
In the prior Chapter, we determined that BBA33 bound to collagen. 
Proteins that bind to collagens often also recognize the classical complement 
protein C1q, which is a component of the C1 complex. Microbial proteins from 
pathogens that bind C1q can also interfere with complement dependent killing 
mechanisms by inhibiting classical complement activation. As such, given the 
profound phenotype in borrelial cells lacking BBA33, we were interested in 
determining if BBA33 could bind C1q and block C1 activation. We determined (in 
collaboration with Magnus Höök’s group) that BBA33 did bind to C1q but did not 
inhibit the classical complement pathway. However, we did find that the BBK32 
protein, the known fibronectin adhesin (Fischer et al., 2006; Kim et al., 2004; 
Norman et al., 2008; Probert and Johnson, 1998; Seshu et al., 2006), which was 
added initially as a control, was able to potently inhibit the classical pathway at a 
                                                
∗ Part of this chapter is reprinted from “Borrelia burgdorferi BBK32 Inhibits the 
Classical Pathway by Blocking Activation of the C1 Complement Complex” by 
Brandon L. Garcia, Hui Zhi, Beau Wager, Magnus Höök, Jon T. Skare, 2016. 
PLoS Pathogens, Volume 12, Issue 1, p. e1005404. Copyright 2016 by Garcia 
et al. This is an open access article distributed under the terms of the Creative 
Commons Attribution License, which permits unrestricted use, distribution, and 
reproduction in any medium, provided the original author and source are 
credited. 
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low Kd value. The characterization of the BBK32::C1 interaction serves as the 
basis for this Chapter of the dissertation. 
Blood-borne pathogens, or those that traffic in interstitial fluid or lymphatics, 
which lack endogenous regulators of complement activity, must adopt strategies 
to successfully evade complement attack. One such pathogen, Borrelia 
burgdorferi, is the etiologic agent of Lyme disease and is the leading cause of 
vector-borne illness in the United States according to the Centers for Disease 
Control and Prevention (CDC). Lyme disease is often accompanied by a local 
erythema migrans lesion and can lead to severe clinical outcomes such as 
carditis, neurological dysfunction, and arthritis (Radolf et al., 2012; Stanek et al., 
2012). B. burgdorferi is transmitted to humans via the bite of infected hard ticks. 
During the tick’s blood meal, spirochetes enter the mammalian host and 
subsequently disseminate to remote tissues (Radolf et al., 2012; Stanek et al., 
2012). If therapeutic intervention is not sought, B. burgdorferi is able to persistently 
colonize a large number of tissues including joint, skin, heart, and the central 
nervous system (Radolf et al., 2012; Stanek et al., 2012). B. burgdorferi appears 
to avoid complement-mediated killing from the alternative pathway by expressing 
a group of virulence factors known as Csp proteins (CspA and CspZ) and those 
from the OspE/F family (Alitalo et al., 2002; Hellwage et al., 2001; Kenedy and 
Akins, 2011; Kenedy et al., 2009; McDowell et al., 2003a; Rogers and Marconi, 
2007; Rogers et al., 2009). These proteins are also referred to as complement 
regulator-acquiring surface proteins (CRASPs) (Bykowski et al., 2008; de Taeye 
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et al., 2013). These bacterial surface proteins recruit human factor H, factor H-like 
protein 1, and factor H-related proteins, which serve as the major endogenous 
negative regulators of the alternative pathway (Brooks et al., 2005; Hallström et 
al., 2013; Kenedy et al., 2009; Kraiczy et al., 2000; McDowell et al., 2003a; de 
Taeye et al., 2013). In addition, human factor H is also recruited to the surface of 
relapsing fever Borrelia spp. where similar alternative pathway inhibition would 
occur (Hovis et al., 2004; McDowell et al., 2003b). By hijacking these key host 
complement regulatory molecules, B. burgdorferi, as well as other B. burgdorferi 
sensu lato isolates, subverts the deleterious effects of alternative pathway 
activation.  
Activation of the classical pathway has previously been shown for Lyme 
disease spirochetes (Dam et al., 1997; Kochi and Johnson, 1988) and studies 
employing mouse models deficient in factor H, factor B, or C3 have shown that 
the classical pathway and/or lectin pathway play significant roles in controlling 
early stages of borrelial infection (Woodman et al., 2007). Indeed, the importance 
of spirochetal strategies to subvert classical pathway activation is underscored by 
the ability of B. burgdorferi as well as the relapsing fever spirochetes B. recurrentis 
and B. duttonii to recruit the host classical pathway regulators C4b-binding protein 
and/or C1 esterase inhibitor (C1-INH) to their surface via interactions with specific 
borrelial lipoproteins (Grosskinsky et al., 2010; Meri et al., 2006; Pietikäinen et al., 
2010). Our studies with BBA33 binding to collagen (Chapter II) led us to look at 
the ability of this protein to recognize C1q, the classical complement protein with 
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collagen-like motifs, and ask whether BBA33 could inhibit the activation of the 
C1q-containing C1 complex. Although BBA33 does bind to C1q, it did not affect 
C1 activation. However, in this analysis, we found that BBK32 functions as a 
potent and specific inhibitor of the classical pathway capable of forming a high-
affinity interaction with C1. We then localized the anti-complement activity of 
BBK32 to the C-terminal region and demonstrated a molecular mechanism by 
which BBK32 non-covalently inactivates the central classical pathway initiating 
serine protease C1r. To our knowledge, BBK32 represents the first example of a 
C1r specific inhibitor of biomolecular origin and is the first noncovalent protein 
inhibitor of the C1 complex to be described. Thus, this work significantly expands 
our knowledge of how pathogens recognize and evade human innate immunity 
by defining a new mechanism by which the pathogen B. burgdorferi prevents 
activation of the classical pathway of complement.  
 
Results 
The Borrelia burgdorferi lipoprotein BBK32 interacts with the first 
component of human complement, C1  
In light of the apparent ability of B. burgdorferi to suppress the classical 
pathway (discussed above), we hypothesized that novel interactions exist 
between B. burgdorferi surface proteins and the classical pathway initiating 
enzyme complex, complement C1. To explore this hypothesis we adopted a Far 
Western immunoblot approach designed to probe for interaction of B. burgdorferi 
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B31 lysate proteins with C1. The initial profile showed that biotinylated C1 
specifically recognizes borrelial proteins with apparent molecular masses of 17, 
28, and 48 kDa (Fig. 12A). We also tested the reactivity of lysates harvested from 
cultures grown under conditions that require the Rrp2-RpoN-RpoS regulatory 
system for their induction (Boardman et al., 2008; Caimano et al., 2007; Hubner 
et al., 2001; Yang et al., 2003) (e.g., pH 6.8 relative to conventional growth 
conditions of pH 7.6) and thus mimic, in part, some aspects of the mammalian 
host environment (Boardman et al., 2008; Burtnick et al., 2007; Caimano et al., 
2007; Hubner et al., 2001; Yang et al., 2000, 2003). Given that the 48-kDa band 
was near the known SDS-PAGE migration position of the borrelial lipoprotein 
BBK32 (Probert and Johnson, 1998), we also tested lysates originating from cells 
that lacked an intact bbk32 locus (bbk32::StrR; (Seshu et al., 2006)) (Fig. 12A). 
These experiments show that the 48-kDa band is inducible under mammalian 
host-like conditions and is also completely absent from bbk32::StrR lysates. The 
two lower molecular weight bands did not change in intensity in response to 
altered growth conditions and remained present in the B. burgdorferi lacking intact 
bbk32, indicating that they were not proteolytic fragments of BBK32 and instead 
are distinct protein species (Fig. 12A). Immunoblot analysis also confirmed that 
the 48-kDa C1-reactive species co-migrated with BBK32 in the parent strain and 
was missing in the bbk32::StrR mutant (Fig. 12B). 
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Figure 12. B. burgdorferi expresses surface-exposed proteins that bind complement C1. 
Far Western Blot analysis of B. burgdorferi cell lysates probed with complement C1. (A) 
Biotinylated C1 was used to probe cell lysates from B. burgdorferi B31 strain ML23 grown 
under conventional (pH 7.6) or induced (pH 6.8) conditions. Proteins of apparent 
molecular weights 17, 28, and 48 kDa were capable of binding C1, while the 48-kDa band 
alone was inducible. Lysates from a strain lacking an intact bbk32 locus (bbk32::StrR) 
lacked the 48-kDa band. (B) Immunoblot analysis with anti-BBK32 demonstrated that the 
48-kDa protein co-migrates with the C1 reactive species in the parent strain (lane 1) and 
is missing from the bbk32::StrR mutant (lane 2) providing further support that it is BBK32. 
Both strains shown here were grown at 37˚C, pH 6.8, e.g., under inducing conditions. (C) 
To determine if the C1 binding proteins present in borrelial lysates were surface exposed, 
a proteinase K assay was employed. All three bands are absent from proteinase K treated 
samples. (D) The subsurface endoflagellar protein FlaB are identical between mock and 
protease treated cells, indicating that the B. burgdorferi cells retained structural integrity. 
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Next, we were interested in determining if the C1-binding proteins were 
surface exposed in B. burgdorferi. To this end, we used a proteinase K 
accessibility assay that serves as a readout for the surface localization of borrelial 
proteins (Barbour et al., 1984; Probert et al., 1995). The results indicated that all 
three C1 reactive proteins were eliminated following protease treatment 
suggesting that they are all on the outer surface of B. burgdorferi (Fig. 12C). To 
address the integrity of the B. burgdorferi cells, we tested whether the subsurface 
endoflagellar structural protein FlaB was affected by the addition of proteinase K. 
The levels of FlaB between mock and protease treated cells were not different 
(Fig. 12D), indicating that the B. burgdorferi cells used in this experiment were 
structurally intact.  
 
The C-terminal globular domain of BBK32 binds C1 with high-affinity in a 
calcium-dependent manner  
The identity of the 17 and 28-kDa proteins targeted by biotinylated C1 in 
the Far Western assay remain unclear at this time. However, in addition to gel 
migratory position, three lines of evidence suggested that the identity of the 48-
kDa band was indeed BBK32; (i) it is induced under mammalian-like conditions 
(Fig. 12A), (ii) it is surface exposed (Fig. 12C), and (iii) it is not detected in 
samples containing the bbk32::StrR allele (Fig. 12A and 12B). To further 
investigate a potential C1::BBK32 interaction we next produced a recombinant 
form of BBK32 (residues 21 to 354) which lacks only the 20 residue signal peptide 
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(Probert and Johnson, 1998), and immobilized this “full-length” BBK32 (referred 
to as BBK32-FL hereafter) protein on the surface of a Biacore sensor chip. Surface 
plasmon resonance (SPR) was used to quantitatively measure the interaction of 
purified C1 with immobilized BBK32-FL in a running buffer of HBS-T-Ca2+. Strong 
and dose-dependent binding was observed (Fig. 13A) and kinetic evaluation of 
the resulting sensorgrams indicates that BBK32-FL binds C1 with high affinity, as 
a dissociation constant (KD) of 3.9 nM (Table 4) was calculated.  
BBK32 has long been known for its ability to bind the extracellular matrix 
glycoprotein fibronectin (Fn) (Fischer et al., 2006; Probert and Johnson, 1998; 
Probert et al., 2001). The Fn/BBK32 interaction is primarily mediated by anti-
parallel β-strand addition of residues 126-190 originating from the intrinsically 
disordered N-terminal region of BBK32 with Fn type I domains along an extended 
region of Fn (Probert et al., 2001; Raibaud et al., 2005). In addition to Fn, 
glycosaminoglycans (GAGs) also act as a mammalian host ligand for BBK32 and 
are recognized by a distinct N-terminal binding site (BBK32 residues 45-68) (Lin 
et al., 2014). In contrast, the C-terminal region of BBK32 (residues 206-354 and 
hereafter referred to as BBK32-C) is a highly basic globular domain rich in α-
helical secondary structure (Kim et al., 2004), which to date has not been ascribed 
a specific function. To determine if the binding site for C1 on BBK32 could be 
localized to the N-terminal region of BBK32 (residues 21-205, and hereafter 
referred to as BBK32-N) or the globular C-terminal region, we next immobilized 
recombinant versions of BBK32-N and BBK32-C on the surface of an SPR sensor 
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Figure 13. The C-terminal domain of BBK32 mediates a high-affinity and calcium-
dependent interaction with complement C1. SPR was used to measure the direct binding 
of C1 to BBK32 proteins. A twofold dilution series of C1 (0.2 – 100 nM) was injected over 
immobilized (A) BBK32-FL, (B) BBK32-C, or (C) BBK32-N in a running buffer of HBS-T-
Ca2+ and the SPR response was recorded (black lines). BBK32-FL and BBK32-C bind 
C1 with high affinity while BBK32-N exhibits no detectable response. Kinetic analysis of 
the resulting sensorgrams was performed and fits are represented as red traces. The 
derived binding constants and fitting statistics are reported in Table 1. Sensorgrams from 
a representative injection series are shown and all experiments were conducted in 
triplicate. BBK32/C1 interaction is strongly calcium dependent as evidenced by greatly 
diminished binding in the presence of the calcium chelator EGTA (D-F). 
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Table 4. SPR: BBK32/C1 and C1r binding parameters. 
 
Immobilized 
Ligand 
Analyte KD 
(nM) 
ka 
(M
-1
s
-1
) 
kd 
(s
-1
) 
BBK32-FL C1 3.9 ± 0.31 (7.2 ± 0.24) x 10
4
 (2.8 ± 0.14) x 10
-4
 
  C1r 
enzyme 
15 ± 7.5 (1.9 ± 1.1) x 10
4
 (2.2 ± 0.85) x 10
-4
 
BBK32-C C1 2.3 ± 0.11 (8.4 ± 0.21) x 10
4
 (1.9 ± 0.01) x 10
-4
 
  C1r 
enzyme 
32 ± 11 (3.9 ± 2.2) x 10
3
 (1.1 ± 0.46) x 10
-4
 
 
The dissociation constant (KD), association rate constant (ka) and dissociation rate 
constant (kd) were calculated by performing kinetic analysis for each interaction. All 
experiments were performed between three and five times and errors are reported as the 
mean ± SEM.  
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chip. Intriguingly, no detectable response was measured when C1 was injected 
over the BBK32-N fragment (Fig. 13C); however, the C-terminal domain of BBK32 
retained a high-affinity for C1 (KD = 2.3 nM) (Fig. 13B, Table 4). Furthermore, 
BBK32-C has a very similar kinetic profile (ka = 8.4 x 104 M-1s-1, kd = 1.9 x 10-4 s-
1) to that measured for C1::BBK32-FL (ka = 7.2 x 104 M-1s-1, kd = 2.8 x 10-4 s-1). 
The interaction of both BBK32-FL and BBK32-C with C1 was strongly dependent 
on calcium as binding was nearly abolished when C1 was injected in a buffer 
containing the calcium chelator ethylene glycol tetraacetic acid (EGTA) (Fig. 13D- 
F). Taken together, these results demonstrate that the C-terminal region of BBK32 
forms a tight calcium-dependent interaction with human complement C1. 
 
The C-terminal domain of BBK32 specifically and potently blocks the 
classical pathway of human complement  
Given the apparent high-affinity interaction between BBK32 and C1 we 
sought to determine if BBK32 modulates complement activation. To this end, we 
evaluated the effect of various concentrations of BBK32-FL, BBK32-N and 
BBK32-C in an ELISA-based assay of complement function. When conditions 
specific for the classical pathway activation were used, both BBK32-FL (IC50, C3b 
= 34 nM, IC50, C4b = 34 nM) and BBK32-C (IC50, C3b = 4.7 nM, IC50, C4b = 5.6 nM) 
potently inhibited the generation of the downstream complement activation 
products C3b and C4b (Fig. 14 A-B, Table 5). In contrast, BBK32-N failed to 
inhibit the classical pathway activation at any concentration used. Importantly,  
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Figure 14. The C-terminal domain of BBK32 specifically inhibits the classical pathway in 
a dose-dependent manner in an ELISA based assay of complement function. classical 
pathway was selectively activated by immobilization of human IgM followed by incubation 
of 1% human serum in GHB++ buffer in the presence of varying concentrations of BBK32 
proteins. Monoclonal antibodies were used to detect the deposition of the complement 
activation products (A) C3b or (B) C4b. While BBK32-FL and the BBK32-C potently inhibit 
the classical pathway in a dose-dependent manner, BBK32-N showed no apparent 
inhibitory activity. In contrast, when conditions were used to select for (C) alternative 
pathway activation (LPS coating, 20% serum, GHB°, Mg-EGTA) or lectin pathway 
activation (mannan coating, 1% serum, GHB++) no significant inhibition was detected for 
up to 1 µM concentrations of any BBK32 protein derivative. Wells containing serum only 
or where serum was replaced with buffer were treated as 100% and 0% signal, 
respectively. All experiments were performed a minimum of three times, errors are 
reported as the mean ± SEM, and calculated IC50 values are reported in Table 5.  
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Table 5. IC50 values for inhibition of the classical pathway by BBK32 proteins. 
 
Inhibitor Assay IC50 
(nM) 
R
2
 
BBK32-FL ELISA: C3b detection 34 ± 2.2 0.997, 0.997, 0.996 
  ELISA: C4b detection 34 ± 3.6 0.948, 0.987, 0.969 
  Hemolytic 110 ± 11 0.995, 0.995 
  C1r enzyme activity 670 ± 280 0.982, 0.976 
BBK32-C ELISA: C3b detection 4.7 ± 2.2 0.970, 0.961, 0.971 
  ELISA: C4b detection 5.6 ± 2.0 0.927, 0.989, 0.983 
  Hemolytic 60 ± 4.9 0.977, 0.987, 0.967, 0.946 
  C1r enzyme activity 540 ± 91 0.983, 0.956, 0.965, 0.998 
BBK32-N ELISA: C3b detection No inhibition NA 
  ELISA: C4b detection No inhibition NA 
  Hemolytic No inhibition NA 
  C1r enzyme activity No inhibition NA 
 
IC50 values were obtained by nonlinear regression analysis using a four-parameter 
variable slope fit and constraining the bottom and top values to 0 and 100 respectively. 
The ‘goodness of fit’ parameter R2 is provided for each individual fit of replicate 
experiments. NA = not applicable. 
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when conditions were used to selectively activate the alternative or lectin pathway, 
no significant effect could be measured at concentrations up to 1 µM of BBK32-
FL or BBK32-C (Fig. 14C). 
To further investigate their complement inhibitory activities, we next 
measured residual complement-mediated hemolysis in the presence of 1 µM 
BBK32 proteins. Strikingly, 1 µM BBK32-FL or BBK32-C conferred nearly 100% 
protection to sensitized sheep red blood cells in the presence of complement (i.e., 
normal human serum) using a standard assay of the classical pathway-mediated 
hemolysis (CP50) (Fig. 15A). Furthermore, BBK32 inhibited the classical pathway 
in a dose-dependent manner with calculated IC50 values of 110 nM and 60 nM for 
BBK32-FL and BBK32-C, respectively (Fig. 15B and Table 5). Similar inhibition 
of the classical pathway could not be detected for the N-terminal BBK32 fragment 
(Fig. 15A-B). Consistent with the ELISA based complement assay (Fig. 14C), 
BBK32 proteins did not have an effect on alternative pathway-mediated hemolysis 
of rabbit blood cells (Fig. 15C). Taken together, these results demonstrate that 
BBK32 acts as a potent and specific inhibitor of the classical pathway of human 
complement and this inhibitory activity locates to the C-terminal globular region of 
BBK32.  
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Figure 15. The C-terminal domain of BBK32 specifically inhibits the classical pathway-
mediated hemolysis. (A) The effect of 1 µM BBK32 proteins on the classical pathway -
mediated hemolysis was assessed using a standard assay of complement hemolytic 
function (CP50). (B) While BBK32-N exhibited no measurable effect, BBK32-FL and 
BBK32-C abrogated nearly all hemolytic activity in a dose-dependent manner. (C) In 
contrast, BBK32 proteins fail to inhibit alternative pathway-mediated hemolysis. 
Measures of statistical significance in (A) and (C) were determined by use of an unpaired 
t test of each experimental series versus buffer control. ** P ≤ 0.01, *** P ≤ 0.001; ns, not 
significant. All experiments were performed between two and four times and errors are 
reported as the mean ± the standard error of the mean (SEM). Calculated IC50 values for 
the dose-dependent inhibition of the classical pathway hemolysis are reported in Table 
5. 
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BBK32 interacts directly with the C1 subunit, C1r protease, in a calcium-
dependent manner  
The data presented above indicate that BBK32 can form a high-affinity 
interaction with C1 and that this interaction results in a specific inhibition of the 
classical pathway of human complement. The calcium-dependence of the 
C1::BBK32 interaction (Fig. 13 D-F) raised the distinct possibility that BBK32 was 
capable of recognizing only the fully formed calcium-mediated C1 complex rather 
than binding to an individual C1 subunit with high-affinity. To determine if this was 
the case we used SPR and monitored the response generated by individual 50 
nM injections of C1q, C1r enzyme, C1s enzyme, and C1s proenzyme over the 
surface of a BBK32-FL or BBK32-C SPR biosensor (Fig. 16 A and B). 
Surprisingly, we found that BBK32 binds specifically to C1r, but not to other C1 
components (Fig. 16 A and B). In agreement with C1/BBK32 binding activity, 
BBK32-C binds C1r with similar affinity to that of full-length BBK32 (KD, C1r/BBK32-FL 
= 15 nM vs. KD, C1r/BBK32-C = 32 nM) (Fig. 16 C, D and Table 4). The ability of 
BBK32 to interact with C1r could also be observed using a Far Western approach 
where B. burgdorferi lysates were probed with biotinylated C1r (Fig. 16E). A band 
corresponding to the 47-kDa BBK32 protein was detected in the parent lysate but 
was absent in the lysate from the bbk32 mutant strain. Intriguingly, two additional 
“non-BBK32” bands were also capable of interacting with C1r using this 
technique. While the identities of these proteins are currently unknown, we note 
the presence of a  
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Figure 16. BBK32 forms a calcium-dependent, high-affinity interaction with the C1 
subunit, complement C1r. SPR analysis was used to evaluate C1 component binding to 
BBK32-FL or BBK32-C. C1 or individual protein constituents of the C1 complex were 
injected at a fixed 50 nM concentration over the surface of immobilized (A) full-length 
BBK32-FL or (B) BBK32-C. As SPR signal is directly proportional to molecular weight, 
the resulting sensorgrams were normalized using the molecular weight of each analyte 
species. Only injection of C1 or C1r enzyme resulted in significant binding. The SPR 
response (black lines) was recorded for a twofold dilution injection series of C1r enzyme 
in a running buffer of HBS-T-Ca2+ over immobilized (C) BBK32-FL or (D) BBK32-C. Five 
independent injection series were collected and sensorgrams shown are from a 
representative experiment. Red traces represent fits from kinetic evaluation of the 
injection series. The derived binding constants and fitting statistics are reported in Table 
1. (E) Far Western Blot analysis was used to assess interaction of B. burgdorferi lysates 
with C1r enzyme. Biotinylated C1r enzyme was used to probe cell lysates from B. 
burgdorferi B31 strain ML23 grown under conventional (pH 7.6) conditions. Proteins of 
apparent molecular weights 28, and 48, and 54 kDa were capable of binding C1r in the 
parent strain, while the 48-kDa band alone was absent from the strain lacking an intact 
bbk32 locus (bbk32::StrR). An arrowhead denotes the band corresponding to BBK32 
while an asterisk denotes a band migrating to a position observed in the C1 Far Western 
(Fig. 12A). 
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28-kDa-reactive band present in the parent strain (denoted with an asterisk) that 
matches the migration position of a C1 reactive band (Fig. 12).  
Kinetic evaluation of the SPR data suggest that both the BBK32-FL and  
the BBK32-C proteins recognize C1 preferentially over C1r with an increased 
affinity being attributed primarily to an increase in the association rate (Table 4). 
Nonetheless, these binding data strongly suggest that the major BBK32 binding 
site on the C1 complex is mediated by C1r. Interestingly, we found that the 
C1r/BBK32 interaction was also dependent on calcium (Fig. 17A, B). C1r itself 
possesses multiple calcium binding sites and the structural and functional 
consequences of C1r/calcium binding are complex (Bally et al., 2009; Busby and 
Ingham, 1990; Major et al., 2010; Thielens et al., 1999). For example, calcium 
binding of C1r results in large-scale conformational changes of the C1r CUB2 
domain from a disordered structure in the absence of calcium to a fully folded 
structure in its presence (Major et al., 2010). The dependence of the BBK32::C1r 
interaction on calcium suggests that BBK32 recognizes a calcium-dependent C1r 
conformation, which further implicates the calcium-dependent C1 complex as the 
physiologically relevant BBK32 ligand.  
 
BBK32 inhibits C1r autoactivation and prevents the enzymatic cleavage of 
C1s proenzyme  
The ability of BBK32 to bind both C1 and C1r and to specifically inhibit the 
classical pathway of complement suggested that BBK32 interfered with the  
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Figure 17. The interaction of BBK32 with C1r is calcium dependent. As was observed for 
the C1 complex, the interaction of C1r with (A) full-length BBK32-FL or (B) BBK32-C is 
strongly dependent on calcium as judged by SPR.  
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enzymatic activity of the C1r protease. To determine if this was the case we first 
measured the effect of various concentrations of BBK32-FL, BBK32-C, and 
BBK32-N on the in vitro conversion of C1s proenzyme by previously activated C1r 
enzyme (Fig. 18A). Indeed, both BBK32-FL and BBK32-C inhibited C1r in a dose-
dependent fashion, while BBK32-N failed to inhibit up to a 10 µM final 
concentration. Quantification of these data by densitometry was performed by 
evaluating the peak intensity of the C1s proenzyme band (Fig. 18B) and 
calculated IC50 values are reported in Table 5. BBK32 proteins do not affect the 
activity of previously activated C1s (C1s enzyme) as C4 is cleaved by C1s in the 
presence of 1 µM BBK32 proteins (Fig. 18C). These results indicate that BBK32 
specifically inhibits C1r enzyme by preventing the processing of its natural 
substrate, the C1s proenzyme.  
When C1 is incubated at 37°C, it becomes activated by the autocatalysis 
of C1r proenzyme and subsequent C1r enzyme cleavage of the C1s proenzyme 
(Ziccardi, 1982). To determine if BBK32 affects C1r and C1s zymogens within the 
C1 complex, we incubated BBK32 proteins (5 µM) with C1 (40 nM) for two hours 
at 37°C and co-immunoprecipitated (co-IP) C1 using a C1q monoclonal antibody. 
Bound fractions were subjected to SDS-PAGE, followed by Western immunoblot 
analysis, and the presence of C1r, C1s, C1q, or BBK32 was then assessed.  
When reactions were probed with C1r antibody (Fig. 19A), a processed 
form of C1r was observed for the buffer only control as indicated by the presence  
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Figure 18. BBK32 inhibits the enzymatic cleavage of C1s proenzyme by C1r enzyme. (A) 
The ability of BBK32 to inhibit the in vitro proteolytic cleavage of C1s proenzyme by 50 
nM of activated C1r enzyme was assessed by monitoring for the presence of C1s 
proenzyme (single 86-kDa chain; asterisk) or activated C1s enzyme (58-kDa chain 1 and 
28-kDa chain 2; arrows) by SDS-PAGE. Overnight reactions were incubated at 37°C in 
HBS-Ca2+ in the presence of various concentrations of BBK32-FL (gel 1), BBK32-C (gel 
2), or BBK32-N (gel 3). In the absence of BBK32, C1r enzyme converts 100% of C1s 
proenzyme to C1s enzyme under the conditions used (see “No BBK32” lanes on gels 1-
3). BBK32-FL and BBK32-C inhibited C1r activity in a dose-dependent manner, whereas, 
BBK32-N failed to inhibit C1r up to a final concentration of 10 µM. All C1r activity assays 
were conducted a minimum of three times and representative gel images are shown. (B) 
Densitometry was performed and the normalized peak intensity of the band 
corresponding to C1s proenzyme was plotted against the concentration of BBK32 present 
in each reaction. IC50 values were calculated and are reported in Table 5 along with 
statistics for individual fits. (C) The ability of 1 µM BBK32 proteins to inhibit the cleavage 
of complement C4 by previously activated and purified C1s enzyme was evaluated in 
vitro by monitoring the conversion of the C4 α-chain to the C4 α’-chain by SDS-PAGE. 
C1s enzyme activity could not be detected under the conditions used for any BBK32 
proteins, indicating that the BBK32 inhibitory activity is specific for C1r. C1s activity 
assays were performed in duplicate and a gel image from a representative experiment is 
shown. 
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Figure 19. BBK32 inhibits the autocatalysis of C1r within the C1 complex. C1 (40 nM) 
was incubated at 37°C for 2 hours in the presence or absence of 5 µM BBK32 or OspC 
proteins. Reactions were co-immunoprecipitated using a C1q monoclonal antibody 
previously adsorbed to protein G beads, and bound fractions were subjected to Western 
immunoblot analysis. (A) Reactions were probed with C1r polyclonal antibody. Previously 
purified activated C1r enzyme is loaded as a reference. Activated C1r is detected in buffer 
only reactions as judged by the presence of C1r enzyme chain 1 (57 kDa) and chain 2 
(35 kDa), denoted by arrowheads. Reactions incubated with BBK32-FL or BBK32-C lack 
processed C1r and contained only the 92 kDa C1r proenzyme form (denoted by an 
asterisk). BBK32-N and a negative control protein (OspC) reactions contain processed 
C1r at levels indistinguishable from the buffer only reaction. (B) Reactions were probed 
with a C1s polyclonal antibody and previously purified activated C1s is loaded for 
reference. As was observed for C1r, reactions incubated with BBK32-FL or BBK32-C lack 
activated C1s and contain only C1s proenzyme (asterisk). Buffer only, BBK32-N, and 
OspC reactions contain equal amounts of activated C1s as judged by the presence of 
C1s enzyme chain 1 (58 kDa) and chain 2 (28 kDa) (denoted with arrowheads). (C) 
Detection with C1q polyclonal antibody indicates equivalent amounts of C1q are pulled 
down in all reactions. (D) Detection with BBK32 polyclonal antibody demonstrates that 
BBK32-FL or BBK32-C but not BBK32-N are pulled down with the C1 complex. The last 
three rightmost lanes contain 100 ng of each form of BBK32 protein as a reference. 
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of C1r chain 1 (57 kDa) and C1r chain 2 (35 kDa). Interestingly, reactions 
containing BBK32-FL or BBK32-C contain only the proenzyme form of C1r (92 
kDa). In contrast, reactions incubated with BBK32-N or an independent negative 
control (recombinant borrelial lipoprotein OspC) were indistinguishable from the 
buffer only reaction. These results demonstrate that BBK32 inhibits the 
autocatalysis of the C1r proenzyme. In agreement with the presence of inactivated 
C1r within the C1 complex, we found essentially only C1s proenzyme (86 kDa) 
when we probed the reactions containing BBK32-FL or BBK32-C with the C1s 
polyclonal antibody (Fig. 19B). As would be expected by the presence of activated 
C1r, we found cleaved C1s in the buffer only, BBK32-N, and OspC reactions. C1q 
was detected at identical levels in all reactions, confirming the validity of the co-
IP approach (Fig. 19C), and importantly, BBK32-FL or BBK32-C but not BBK32-
N were pulled down with the C1 complex (Fig. 19D). Taken together, these results 
show that BBK32 bound C1 is trapped in an inactive form that the autocatalytic 
activation of C1r is inhibited, that C1r cleavage of C1s proenzyme is blocked, and 
that the BBK32 inhibitory effect is specific for the C-terminal half of the protein. 
 
B. burgdorferi binds to C1 and C1r in a BBK32-specific manner  
We were interested in determining if similar activities were also observed 
with native BBK32 produced in B. burgdorferi. To test whether surface exposed 
BBK32 could mediate binding to components of the classical complement 
pathway, we incubated infectious B. burgdorferi parent strain and a bbk32::StrR 
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derivative (strain JS315, grown under conditions that induce bbk32) with 
immobilized C1. Interestingly, both the parent and the bbk32 isogenic mutant 
readily bound C1 and no significant difference in binding could be detected (Fig. 
20). One plausible explanation for this result is a likely layer of functional 
redundancy provided by the presence of additional B. burgdorferi proteins capable 
of C1 recognition as evidenced in the overlay analysis (Fig. 12A). To provide a 
less complex outer surface environment for B. burgdorferi, we used strain B314, 
which is missing linear plasmids (lp) and thus does not synthesize many lp-
encoded borrelial proteins associated with both mammalian and tick infectivity, 
specifically OspAB, DbpBA, and BBK32 (Sadziene et al., 1993, 1995). A shuttle 
vector containing bbk32 with its native promoter (pCD100) was transformed into 
strain B314, along with a vector-only control (pBBE22luc). An equivalent amount 
of protein was loaded from each strain (Fig. 21A) and subsequent immunoblot 
and biotin-labeled C1 overlay analysis showed that, as expected, B314/pCD100 
made detectable levels of BBK32 capable of binding C1 whereas 
B314/pBBE22luc did not (Fig. 21B and C). To determine whether natively 
produced BBK32 mirrored the C1/C1r-binding profile of purified recombinant 
BBK32, we exposed these strains to immobilized C1 and C1r. Unlike the wild-type 
strain, the B314 control strain (B314/pBBE22luc) exhibited very little binding to C1 
or C1r (Fig. 21D). In contrast, the presence of BBK32 in B314/pCD100 
transformed organisms promoted a significant enhancement of spirochete binding 
to both of these targets (Fig. 21D).  
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Figure 20. Infectious B. burgdorferi and the isogenic bbk32 mutant bind to C1 at high 
levels. Strain ML23/pBBE22luc and the bbk32 mutant derivative JS315/ pBBE22luc were 
incubated with immobilized C1 to assess binding. No significant difference was observed 
in binding for both strains tested. Each data point represents spirochetes counted within 
an independent field as scored by dark field microscopy (n = 30 per strain). The horizontal 
bar represents the mean value. Statistical significance was evaluated by use of an 
unpaired t test. ns; not significant. 
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Figure 21. Surface exposed BBK32 promotes binding of a non-infectious variant B314 of 
B. burgdorferi to human C1 and C1r. Strain B314 total cell protein lysates from cells 
containing the vector pBBE22luc (lane 1) and natively expressed bbk32 (plasmid 
construct pCD100; lane 2) were stained with Coomassie blue (A), immunoblotted against 
a monoclonal antibody specific for BBK32 (B), and subjected to Far Western overlay 
analysis with biotinylated C1 (C). B314/pBBE22luc and the bbk32 expressing strain 
B314/pCD100 were incubated with immobilized C1, C1r, and BSA to assess BBK32-
dependent binding to these target proteins (D). Each data point represents the average 
number of spirochetes present on 10 independently read fields as scored by dark field 
microscopy. The horizontal bar represents the mean value. Statistical significance in (D) 
was determined by use of a multiple t test followed by the Sidak-Bonferroni method to 
correct for multiple comparisons. All experiments were performed independently between 
three and five times. Significant differences are reflected in the P values shown. ns; not 
significant.  
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BBK32 promotes resistance to a serum sensitive B. burgdorferi strain  
We were next interested if the production of BBK32 could promote 
resistance to serum. For this purpose, we again utilized B. burgdorferi strain B314, 
which in addition to its avirulent phenotype, is rendered serum sensitive, 
presumably due to its aforementioned loss of lp content (Sadziene et al., 1995). 
We hypothesized that the selective addition of BBK32 would make strain B314 
resistant to complement dependent killing and, to assess this, tested 
B314/pBBE22luc and B314/pCD100 for their relative resistance to serum. 
Consistent with an anti-complement activity, the presence of natively expressed 
BBK32 in B314/pCD100 provided significant protection against serum based 
immobilization relative to strain B314/pBBE22luc that lacked BBK32 (Fig. 22). As 
expected, heat inactivation resulted in limited killing with either strain tested (Fig. 
22). When conditions were used that selectively block the classical/lectin pathway 
but keep the alternative pathway intact (NHS + Mg-EGTA) (Dam et al., 1997) both 
strains exhibited equivalent resistance/sensitivity independent of BBK32 levels 
(Fig. 22). These data imply that a majority of the inactivation observed for serum-
sensitive B314/pBBE22luc is due to the adverse effects of the classical and lectin 
pathways. Furthermore, these data strongly suggest that the BBK32-dependent 
protection observed with untreated serum is due to the ability of BBK32 to 
neutralize either the classical or lectin pathway. Coupled with the C1/C1r-specific 
binding profile (Fig. 12, 13 and 17), the classical pathway-specific inhibition (Fig.   
 
  101 
 
 
Figure 22. Production of BBK32 provides resistance to the serum sensitive strain B314. 
B. burgdorferi strain natively expressing BBK32 (B314/pCD100) is significantly more 
resistant to serum-based inactivation relative to the isogenic parent strain 
B314/pBBE22luc. Conditions that selectively block the classical/lectin pathway but leave 
the alternative pathway intact (NHS+Mg/EGTA) enhanced survival of these cells in a 
BBK32-independent manner. As expected, heat inactivated serum (hiNHS) ablated all 
complement-dependent killing for both strains. Statistical significance was determined by 
use of a multiple t test followed by the Sidak-Bonferroni method to correct for multiple 
comparisons and is depicted as the mean value ± the standard deviation. All experiments 
were performed independently between three and five times. Significant differences are 
reflected in the P values shown. ns; not significant.  
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14 and 15), and C1r inhibitory activity (Fig. 17 and 18) of recombinant BBK32 
proteins along with the classical pathway-specific function of C1r (Thiel et al., 
2000), the serum resistance mediated by BBK32 in this assay is best explained 
by BBK32-dependent inactivation of the classical pathway.  
  
Naïve secreted IgM mediates complement killing of the non-infectious 
variant B314 strain of B. burgdorferi 
 The classical complement pathway is associated with antigen-specific 
antibody dependent killing. However, the NHS used in this study does not contain 
B. burgdorferi specific antibodies (data not shown), indicating that the classical 
pathway dependent killing of the non-infectious B. burgdorferi partially reflects an 
innate immune defense. In fact, in addition to the antigen-specific IgG, the C1 
complex can be also activated by naïve IgM antibodies, which exist as a pentamer 
in the circulation system, and have a 1000-fold greater binding affinity to C1q 
when compared to IgG. (Ehrenstein and Notley, 2010; Ochsenbein and 
Zinkernagel, 2000). Therefore, we tested if the secreted naïve, and non-
immunized IgM in NHS mediates the classical complement dependent killing of 
the serum-sensitive B. burgdorferi B314 strain. A C4b deposition ELISA assay on 
an IgM-coated plate showed that IgM-depleted serum retained the same level of 
the classical pathway activity, when compared to NHS (Fig. 23A). We then 
performed the serum sensitivity assay in NHS and IgM-depleted serum. 
Consistent with prior result (Fig. 22), B314/pBBE22luc that lacked BBK32 was 
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sensitive to NHS, and expression of bbk32 partially restored borrelial serum 
resistance (Fig. 23B). As a comparison, when treated with IgM-depleted serum, 
both strains exhibited similar resistance/sensitivity independent of BBK32 levels 
(Fig. 23B), and the survival rate of both strains was recovered to the same level 
as when they were incubated with Mg-EGTA treated serum that compromises the 
classical pathway (Fig. 22). These data imply that naïve IgM antibodies presented 
in NHS activate the classical complement pathway and kill B. burgdorferi that lack 
serum resistant activity. Furthermore, these data suggest that the classical 
pathway plays a role in the innate immune response to control B. burgdorferi 
infection in an IgM-dependent manner.  
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Figure 23. Naïve secreted IgM mediates complement killing of the non-infectious variant 
B314 strain of B. burgdorferi. A. The classical complement pathway is equally activated 
by immobilization of human IgM followed by incubation of 1% normal human serum or 
IgM-depleted serum in GHB++ buffer. Polyclonal antibodies were used to detect the 
deposition of the complement activation products C4b. Statistical significance was 
determined by use of a student t test and is depicted as the mean value ± the standard 
deviation. B. Non-infectious B. burgdorferi B314 strain expressing BBK32 
(B314/pCD100) is significantly more resistant to serum-based killing, compared with the 
isogenic parent strain B314/pBBE22luc. Depletion of IgM from the serum enhanced 
survival of these cells in a BBK32-independent manner. Statistical significance was 
determined by use of a multiple t test followed by the Sidak-Bonferroni method to correct 
for multiple comparisons and is depicted as the mean value ± the standard deviation. All 
experiments were performed independently three times. Significant differences are 
reflected in the P values shown. ns; not significant.  
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Discussion 
 In order to survive the destructive forces of the human complement 
cascade, successful microbial pathogens have evolved a number of sophisticated 
evasion strategies. Although specific modes of complement recognition and 
inactivation are widely varied, these inhibitory mechanisms can be conceptually 
grouped into three forms: direct recruitment or mimicry of host regulators of 
complement activity such as complement factor H, enzymatic degradation of 
complement components by direct or indirect means, or inhibition through direct 
interaction with complement proteins (Lambris et al., 2008). In addition to 
employing each of these evasion strategies, B. burgdorferi takes advantage of its 
complex mammalian-tick lifestyle by exploiting anti-complement molecules 
produced by the tick salivary glands during tick feeding (de Taeye et al., 2013). 
Recruitment of factor H related molecules by the borrelial CspA, CspZ, and 
the OspE/F proteins has been studied extensively (Kraiczy and Stevenson, 2013; 
de Taeye et al., 2013) and C4b-binding protein has been reported to interact with 
B. burgdorferi, B. afzelii, and B. garinii (Pietikäinen et al., 2010), while the 
relapsing fever spirochetes have been shown to bind factor H (McDowell et al., 
2003b; Hovis et al., 2004) C4b-binding protein and C1-INH (Grosskinsky et al., 
2010; Meri et al., 2006). In addition to their direct recruitment, an example of host 
complement regulator mimicry has also previously been reported for B. 
burgdorferi (Pausa et al., 2003). To our knowledge, the only previously reported 
example of a borrelial factor possessing direct and novel complement inhibition 
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activity is the recently described terminal complement complex inhibition function 
of CspA (Hallström et al., 2013; de Taeye et al., 2013). CspA along with its ability 
to bind factor H/factor H like-1 and plasminogen also acts a direct inhibitor of the 
terminal complement complex by binding complement components C7 and C9 
and interfering with C5b-9 complex assembly (Hallström et al., 2013).  
All three pathways of complement can be activated by B. burgdorferi and 
all result in direct complement-mediated killing of the spirochete (Hallström et al., 
2013; de Taeye et al., 2013). In addition to becoming activated by immune 
complexes, the classical pathway has also been shown to kill B. burgdorferi in the 
absence of specific antibodies (Dam et al., 1997). The requirement for protection 
from complement attack for B. burgdorferi is evidenced by the production of a 
number of virulence factors (now to include BBK32) that specifically target and 
inactivate complement (Hallström et al., 2013; de Taeye et al., 2013). In this study 
we determined that the C-terminal globular region of the borrelial lipoprotein 
BBK32 exhibits a potent classical pathway-specific inhibitory activity that confers 
serum resistance to a normally serum-sensitive B. burgdorferi strain. While the 
focus of this study was on elucidating the anti-complement activity and 
mechanism of BBK32, our probe of lysates with C1 and C1r suggest a robust 
interaction between B. burgdorferi and the classical pathway may exist. Despite 
the linkage of B. burgdorferi to complement resistance, the small number of 
experimental infectivity studies employing mice deficient in key components of 
complement has shown a surprisingly limited role for complement in controlling B. 
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burgdorferi burden (Bockenstedt et al., 1993; Lawrenz et al., 2003; Woodman et 
al., 2007). Thus, it is of interest to consider potential roles for the inhibition of the 
classical pathway beyond protection from complement-mediated attack. For 
example, upon colonizing lymph tissue B. burgdorferi disrupts the normal 
formation of germinal centers (GC) (Elsner et al., 2015; Hastey et al., 2012). Lack 
of normal GC development ultimately results in reduced antibody titers against B. 
burgdorferi in experimental infection (Elsner et al., 2015). Local complement C4 
deposition on follicular dendritic cells (FDC) is significantly reduced in B. 
burgdorferi infected lymph nodes and this is speculated to be responsible for the 
premature collapse of GC responses due to diminished antigen presentation by 
FDCs (Elsner et al., 2015). In this regard, it is of interest to determine if BBK32 
mediates this lymphoid specific effect, resulting in the observed reduction in the 
humoral immune response to borrelial antigens. It would be of additional interest 
to understand the potential role of BBK32 anti-complement activity in the context 
of spirochetal persistence in a natural reservoir animal such as Peromyscus 
leucopus (Cook and Barbour, 2015). Studies to address some of these 
possibilities are currently underway. 
In the current study we show that BBK32 acts directly by binding to and 
inhibiting C1 via a novel mechanism involving the noncovalent inhibition of C1r 
enzymatic activity. A model for the inhibition of C1 by BBK32 is depicted in Fig. 
24. When C1 engages a surface via C1q binding, this information is transmitted 
by coordinated conformational changes within the C1 complex ultimately 
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triggering autocatalysis of C1r and subsequent activation of C1s (Venkatraman 
Girija et al., 2013). Under physiological conditions this activation is extremely rapid 
(Ziccardi, 1981) and controlled on the surface of host cells by the only known 
endogenous inhibitor of C1, C1-INH. C1-INH covalently modifies the C1r and C1s 
active sites and promotes their release from ligand-bound C1q (Davis et al., 2008). 
C1-INH is a member of the serpin family of protease inhibitors and along with 
inhibiting both C1r and C1s it also inactivates a number of blood proteases 
involved in the complement, contact, fibrinolytic, and coagulation systems (Davis 
et al., 2008). The broad protease-binding specificity and covalent inhibitory 
mechanism of C1-INH stands in stark contrast to that of BBK32, which specifically 
binds and inhibits C1r and had no detectable effect on the homologous C1s 
protease. It has been shown that serum deficient in C1r is unable to undergo 
classical pathway activation while retaining a fully functional lectin pathway (Thiel 
et al., 2000). In our studies BBK32 did not block the lectin or alternative pathway, 
suggesting it is unable to inhibit the primary serine proteases of these pathways 
(i.e., MASPs and factor D, respectively). Instead, BBK32 specifically inactivates 
the classical pathway by preventing the autocatalysis of C1r proenzyme and 
subsequent cleavage of C1s proenzyme ultimately rendering C1 entrapped in a 
zymogen form.  
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Figure 24. Model of C1 inactivation and the classical pathway inhibition by BBK32. C1 
circulates as an inactive zymogen composed of one C1q molecule, two C1r proenzyme 
molecules, and two C1s proenzyme molecules. The pathway on the left depicts the 
normal uninhibited activation of C1 that proceeds by binding of the pattern recognition 
molecule C1q to a bacterial surface (1). C1q binding triggers the autocatalysis of the C1r 
proenzymes (2) that subsequently cleave and activate C1s (3). C1s then cleaves 
downstream the classical pathway components (4), which ultimately lead to many 
downstream the classical pathway effector functions. The pathway on the right side 
depicts the situation in the presence of the BBK32 lipoprotein. Following C1q binding to 
the borrelial surface the C-terminal domain of BBK32 recognizes C1 by binding directly 
to C1r. BBK32 blocks the autocatalytic and C1s proenzyme proteolysis functions of C1r 
(denoted in both instances by a red X). Thus, BBK32 effectively renders C1 in the 
zymogen form leading to abrogation of the classical pathway activation (denoted by a red 
bar).  
  
  110 
Since its discovery as a fibronectin and glycosoaminoglycan-binding 
protein expressed on the surface of B. burgdorferi (Fischer et al., 2006; Probert 
and Johnson, 1998), BBK32 has been the subject of intense study (Fikrig et al., 
2000; He et al., 2007; Hyde et al., 2011a; Kim et al., 2004; Lin et al., 2014; Raibaud 
et al., 2005; Seshu et al., 2006), including a recent report indicating a role in 
bloodstream survival (Caine and Coburn, 2015). In this regard, BBK32 has been 
shown to be critical for borrelial pathogenesis (Hyde et al., 2011a; Seshu et al., 
2006), capable of exploiting host fibronectin function (Harris et al., 2014; Kim et 
al., 2004; Moriarty et al., 2012; Norman et al., 2008; Prabhakaran et al., 2009; 
Raibaud et al., 2005), shown to be involved in borrelial vascular adhesion 
mechanisms (Caine and Coburn, 2015; Moriarty et al., 2012; Norman et al., 2008), 
and in promoting joint colonization (Lin et al., 2014). Surprisingly then, B. 
burgdorferi bbk32 mutant shows a limited infectivity phenotype when experimental 
infection is done at a high inoculum dose (i.e., 105) (Hyde et al., 2011a; Li et al., 
2006; Seshu et al., 2006). However, this effect is restricted to high doses, as lower 
inoculum doses (e.g., 103) exhibit a significant reduction in colonization (Seshu et 
al., 2006) that is most apparent using in vivo imaging for detection (Hyde et al., 
2011a). Furthermore, bbk32 mutant strains exhibit a delay in the ability to 
disseminate (Hyde et al., 2011a). Nonetheless, one potential explanation for the 
relatively mild phenotype of the bbk32 mutant is a layer of functional redundancy 
present in the spirochete. For example, several borrelial proteins besides BBK32 
are now known to bind directly to fibronectin (Brissette et al., 2009c; Gaultney et 
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al., 2013; Hallström et al., 2010), and although much remains to be known about 
their specific functional activities, it is possible that these proteins could overlap 
with BBK32’s fibronectin related functions. It seems a similar situation may exist 
for the BBK32 anti-complement activities described here. The presence of 
multiple bands in the Far Western lysate probes (Fig 12 and Fig 16 E) suggest 
that B. burgdorferi may express one or more “non-BBK32” proteins capable of 
interacting with both C1 and C1r. The existence of additional borrelial proteins 
able to compensate a loss of BBK32 may further explain the muted bbk32 mutant 
phenotype. Determining the identity of these proteins along with evaluating their 
potential to interfere with the classical pathway remains an important next step.  
Orthologs of BBK32 are found not only in Lyme disease spirochetes, but 
also in relapsing fever spirochetes where they have been divided into three groups 
based on phylogenetic relationships (Lewis et al., 2014). Interestingly, the Lyme 
disease spirochete B. valaisiana strain ZWU3 Ny3 was shown to possess a novel 
mechanism of complement inhibition independent of host complement regulator 
recruitment/mimicry (Schwab et al., 2013). Although a molecular mechanism has 
not been elucidated, the authors hypothesize that the inhibitory mechanism 
present in this strain of B. valaisiana relies on direct interaction with complement 
components (Schwab et al., 2013). We note that a BLASTP search of BBK32 from 
B. burgdorferi B31 reveals a gene located on linear plasmid 28 of B. valaisiana 
strain VS116 that encodes a 113 amino acids residue hypothetical protein that 
contains 60% identity and 72% similarity with the C-terminus of BBK32 (residues 
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181 to 303). While it is not known if this is a functional gene product possessing 
BBK32 anti-complement activity, it is intriguing that the hypothetical protein lacks 
the GAG and Fn-binding sequences that are the hallmark of BBK32. Nonetheless, 
future studies are required to understand if the complement inhibitory activity of 
the BBK32 C-terminal domain is conserved across borrelial species.  
In the same light, it remains to be seen if BBK32 anti-complement 
mechanisms are found in other human pathogens that are known to have evolved 
similar molecular mechanisms of host interaction. For instance, BBK32 itself 
shares nearly identical modes of fibronectin interaction with a group of fibronectin-
binding proteins from staphylococcal and streptococcal bacterial species 
(Bingham et al., 2008; Marjenberg et al., 2011; Meenan et al., 2007; Raibaud et 
al., 2005; Schwarz-Linek et al., 2003). While these Gram-positive encoded 
proteins lack sequence conservation with C-terminal BBK32 sequences, it may 
be important to assess their potential role in complement interaction. The 
possibility is raised that an underlying benefit to the microorganism exists in 
producing proteins capable of simultaneously interacting with host extracellular 
matrix molecules like fibronectin and components of the complement system. 
Such an example of a synergistic mode of interaction exists for the extracellular 
fibrinogen-binding (Efb) protein expressed by Staphylococcus aureus. A 
disordered N-terminal region of Efb binds directly to human fibrinogen, while a 
highly basic globular domain originating from the C-terminal region of the protein 
binds with high affinity to complement component C3 (Hammel et al., 2007; Ko et 
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al., 2011; Lee et al., 2004). Although each molecular interaction individually 
contributes to virulence, a ternary fibrinogen-Efb-C3b complex can form, 
encapsulating the bacteria in a ‘fibrinogen-shield’, which results in direct inhibition 
of phagocytosis (Ko et al., 2013). While the similarity of the BBK32 molecular 
architecture to that of staphylococcal Efb is striking, it is currently unknown how 
BBK32/fibronectin binding affects BBK32 anti-complement activities or if an 
analogous functional synergism exists. The work presented here provides the 
conceptual framework to explore this and related questions on complex host-
pathogen interactions involving extracellular matrix and complement proteins. 
 
Experimental procedures 
Bacterial strains and plasmids  
B. burgdorferi B31 strains ML23 (Labandeira-Rey et al., 2001), JS315 
(ML23 bbk32::StrR; (Seshu et al., 2006)), and B314 were grown in BSK-II media 
supplemented with 6% normal rabbit serum (Pel-Freez Biologicals, Rogers, AR) 
under microaerobic conditions at 37°C, 5% CO2 atmosphere, at either a pH of 6.8 
or 7.6. The serum sensitive strain B314 (kindly provided by Tom Schwan) is a 
non-infectious variant of strain B31 that lacks most linear plasmids (Fischer et al., 
2006; Lin et al., 2014; Sadziene et al., 1993, 1995). All B. burgdorferi cells were 
enumerated by dark field microscopy.  
Native bbk32 was cloned into the shuttle vector pBBE22luc (Hyde et al., 
2011a) using the following approach. The oligonucleotide primers BBK32Comp-
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BamHI-F (5’-ACGCGGATCCGTACTTTGTTCACCCTCTTGATAGC-3’; BamHI 
site is in bold) and BBK32Comp-SalI-R (5’-
ACGCGTCGACATATTATGTAGCCTGTTTTAAATT-3’; SalI site is underlined) 
were used to PCR amplify bbk32 from strain B31 genomic DNA. The PCR-
amplified product contains 213 bp of upstream sequence and 37 bp downstream 
from the translational start site and stop codon of the 1,062 bp bbk32 gene, 
respectively. The resulting 1.3 kb fragment was cloned into plasmid pCR-Blunt-II-
TOPO and transformed in Mach1-T1R Escherichia coli cells (F– ∅80lacZΔM15 
ΔlacX74 hsdR(rK–, mK+) ΔrecA1398 endA1 tonA; ThermoFisher). The resulting 
construct was digested with BamHI and SalI and the 1.3 kb fragment subsequently 
cloned into BamHI and SalI cut pBBE22luc. The resulting construct, which 
contained bbk32 expressed from its native promoter, was designated pCD100.  
Transformation of strain B314 with pCD100 and pBBE22luc was done as 
previously described (Samuels, 1995). Transformants were selected for 
resistance to kanamycin and screened by PCR to confirm the presence of 
pCD100 using primers BBK32Comp-BamHI-F and BBK32Comp-SalI-R.  
 
Proteinase K accessibility assay 
 B. burgdorferi strain ML23 was grown under inducing conditions (37˚C, 5% 
CO2, pH 6.8) and harvested by centrifugation at 5,800 x g, and washed twice with 
PBS. The cell pellet was resuspended in 0.5 ml of either PBS alone, or PBS with 
proteinase K (to a final concentration of 200 µg ml-1). All samples were incubated 
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at 20°C for 40 min. Reactions were terminated by the addition of 
phenylmethylsulfonyl fluoride (PMSF) to a final concentration of 1 mM. Cells were 
again pelleted by centrifugation (9,000 x g for 10 min at 4°C), washed twice with 
PBS containing 1 mM PMSF, and resuspended in Laemmli sample buffer 
(Laemmli, 1970). Samples corresponding to 5 x 107 whole cell equivalents were 
run on SDS-PAGE gel, transferred to PVDF membranes and probed with 
biotinylated C1 in a Far Western analysis or immunoblotted with a monoclonal 
antibody to borrelial FlaB (Affinity BioReagents, Inc.), as described below. 
 
Proteins  
DNA fragments encoding residues 21 to 205 or 206 to 354 of BBK32 (B. 
burgdorferi B31 strain) were PCR-amplified from pQE30-BBK32-FL plasmid DNA 
(Kim et al., 2004) using oligonucleotide primers that appended BamHI and NotI 
sites at the 5’ and 3’ ends, respectively. Restriction digested DNA fragments were 
then sub-cloned into the pT7HMT vector (Geisbrecht et al., 2006). Sequence 
confirmed plasmids were transformed into E. coli strain BL21(DE3) for protein 
production.  
Expression and purification of recombinant BBK32-FL was performed as 
previously described (Kim et al., 2004). Recombinant BBK32-N and BBK32-C 
were overexpressed by inoculating 1 liter of Terrific Broth with 10 ml of an 
overnight BL21(DE3) at 37°C, induced with 1 mM isopropyl-D-
thiogalactopyranoside upon reaching an optical density at 600 nm of 0.6-0.8, 
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shifted to 18°C shaking, and allowed to express overnight. Overnight cultures 
were harvested by centrifugation at 5,000 x g for 10 min and resuspended in Ni-
NTA-binding buffer (20 mM Tris (pH 8.0), 500 mM NaCl, 10 mM Imidazole (pH 
8.0)) and lysed by microfluidization. A clarified cell extract was obtained by 
centrifugation at 25,000 x g for 35 min and the supernatant was applied to a nickel 
agarose (Gold Bio) column previously equilibrated in Ni-NTA buffer, washed with 
5 column volumes (CV) of Ni-NTA-binding buffer, and eluted with 2 CV’s of Ni-
NTA elution buffer (20 mM Tris (pH 8.0), 500 mM NaCl, 500 mM imidazole (pH 
8.0)). The HIS-myc affinity tag was removed by enzymatic digestion with tobacco 
etch virus (TEV) protease in the presence of 5 mM β-mercaptoethanol at room 
temperature for 2 h. The digestion reaction was allowed to continue overnight at 
4°C while being dialyzed against Ni-NTA-binding buffer. The TEV digested 
sample was then incubated with a nickel agarose column and the flow through 
fraction was collected and subjected to gel filtration chromatography using a 
HiLoad Superdex 200 PG column (GE Healthcare) equilibrated in 20 mM Tris 
(8.0), 200 mM NaCl. Peaks were analyzed by SDS-PAGE and fractions 
corresponding to BBK32 proteins were pooled and concentrated using Amicon 
centrifugal filters (EMD Millipore), aliquoted, and stored at -80°C until use.  
Purified C1, C1r enzyme, C1q, C1s enzyme, C1s proenzyme, and C4 were 
obtained from Complement Technology (Tyler, TX). Human C1 or C1r proteins 
were biotinylated using EZ-link Sulfo-NHS-LC-Biotin (Thermo Fisher Scientific) at 
the molar ratio suggested by the manufacturer. The labeling reaction was 
  117 
quenched by the addition of Tris HCl pH 7.6 to a final concentration of 20 mM. 
The sample was diluted in protein-binding buffer (100 mM NaCl, 20 mM Tris pH 
7.6, 1 mM EDTA, 10% glycerol, 0.2% Tween-20, 2% non-fat milk) (Wu et al., 
2007) and used below in the Far-Western assay. 
 
Far-Western immunoblotting and conventional immunoblotting  
For Far Western analyses, B. burgdorferi protein lysates were resolved by 
SDS–PAGE (Laemmli, 1970) and gels were transferred to PVDF membranes as 
described (Weening et al., 2008). The membrane was blocked in 10% non-fat 
milk, washed with PBS, 0.2% Tween-20, and then 20 µg biotinylated C1 or C1r 
(both from CompTech), at 1 µg/ml in protein binding buffer (Wu et al., 2007), was 
incubated with the membrane overnight at 4°C. The membrane was washed 
extensively in PBS, 0.2% Tween-20, and then incubated with Vectastain solution 
(Vectastain Elite ABC Kit, Vector Laboratories), as instructed by the manufacturer, 
to enhance the signal. The membrane was then washed and developed using the 
Western Lightning Chemiluminescent Reagent plus system (Perkin Elmer, 
Waltham, MA, USA). 
Conventional immunoblotting was done as previously described [94]. 
Production of BBK32 in B314/pCD100 was evaluated using either a monoclonal 
antibody to BBK32 (a generous gift from Seppo Meri, University of Helsinki) 
diluted to 1:4000 or, in the case of the co-immunoprecipitations (see below), a 
polyclonal antibody against BBK32 diluted 1:1500. Immunoblots to detect the 
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endoflagellar antigen FlaB were done using a monoclonal to B. burgdorferi FlaB 
(Affinity BioReagents) diluted 1:20,000. Appropriate anti-rabbit Ig or anti-mouse 
Ig HRP conjugates (Life Technologies) were diluted 1:5000 and used to detect 
primary antibodies on the PVDF membranes. Immune complexes were detected 
using the Western Lightning Chemiluminescent Reagent plus system (Perkin 
Elmer, Waltham, MA, USA). 
 
SPR  
Direct binding of C1 and subunits of the C1 complex to BBK32 was 
assessed by SPR using a Biacore 3000 instrument (GE Healthcare) at 25°C. 
HBS-T-Ca2+ (20 mM HEPES (pH 7.3), 140 mM NaCl, 0.005% (v/v) Tween 20, 5 
mM CaCl2) was used as the running buffer and a flowrate of 10 µl min-1 was used 
in all experiments. A BBK32 biosensor was created by immobilizing recombinant 
BBK32 proteins on separate flowcells of a C1 sensor chip (GE Healthcare). In all 
cases immobilization was achieved using standard amine coupling chemistry by 
activating the flowcell surface for 7 min at 5 µl min-1 with an equal volume mixture 
of 0.1 M N-hydroxysuccinimide and 0.4 M ethyl(dimethylaminopropyl) 
carbodiimide. Next, BBK32-FL at 20 µg ml-1 in 10 mM sodium acetate (pH 4.0), 
BBK32-N at 25 µg ml-1 in 10 mM sodium acetate (pH 4.5), or BBK32-C at 5 µg ml-
1 in 10 mM sodium acetate (pH 5.5) were injected and allowed to react until the 
desired surface density was reached. Finally, 1 M ethanolamine (pH 8.5) was 
injected for 7 min at 5 µl min-1 to quench remaining reactive groups. A reference 
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flowcell was generated by activating the surface followed by immediate 
quenching. Final immobilization densities reported in resonance units (RU) were 
as follows: BBK32-FL (165 RU), BBK32-N (150 RU), and BBK32-C (240 RU). All 
solution phase analytes were exchanged into running buffer just prior to injection.  
Purified C1 was injected as a twofold concentration series in triplicate 
consisting of 0.20, 0.39, 0.78, 1.6, 3.1, 6.3, 13, 25, 50, and 100 nM for 3 min 
followed by 5 min of dissociation. The surface was regenerated to baseline by 
injecting HBS-T-EGTA (20 mM HEPES (pH 7.3), 140 mM NaCl, 0.005% Tween-
20, and 10 mM EGTA) for 1 min followed by a 30 s injection of a solution 
containing 0.1 M glycine (pH 2.2) and 2.5 M NaCl. Direct interaction of C1r 
enzyme with BBK32 proteins was assessed using an identical protocol to C1 
except for a concentration series consisting of 0.39, 0.78, 1.6, 3.1, 6.3, 13, 25, 50, 
100, and 200 nM was used and the injection time was increased to 5 min followed 
by 10 min of dissociation. Binding of C1r enzyme to active BBK32 proteins was 
assessed on a second C1 biosensor with different coupling densities BBK32-FL 
(80 RU) and BBK32-C (330 RU). A separate concentration series consisting of 
2.0, 3.9, 7.8, 16, 31, 63, 125, 250, 500, and 1000 nM was injected in duplicate for 
5 min followed by 15 min of dissociation. Kinetic analysis was performed for each 
set of sensorgrams resulting from C1 or C1r enzyme injections using 
BIAevaluation software 4.1.1 (GE Healthcare) using a 1:1 (Langmuir) binding 
model and fitting Rmax locally. To determine the effect of calcium on the interaction 
of BBK32, a single concentration of C1 (50 nM) or C1r enzyme (200 nM) was 
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injected in triplicate in a running buffer of HBS-T-Ca2+ or HBS-T-EGTA. To 
evaluate relative binding of individual C1 complex components to BBK32, 
triplicate injections were performed at a fixed 50 nM concentration in HBS-T- Ca2+ 
running buffer. Response was corrected for the molecular weight of each 
component (C1 = 790 kDa, C1q = 410 kDa, C1r enzyme = 92 kDa, C1s 
proenzyme and C1s enzyme = 86 kDa).  
 
Complement Inhibition ELISA  
To delineate the effect of BBK32 proteins on the classical, lectin, and 
alternative pathway, we adopted an ELISA based assay previously described 
(Roos et al., 2003). Costar EIA/RIA plates (Fisher Scientific) were incubated 
overnight at room temperature with 3 µg ml-1 human IgM (the classical pathway 
initiator) (Athens Research & Technology), 25 µg ml-1 Salmonella enteriditis LPS 
(the alternative pathway initiator) (Sigma Aldrich), or 20 µg ml-1 of mannan from 
Saccharomyces cerevisiae (the lectin pathway initiator) (Sigma Aldrich) in a 
coating buffer consisting of 100 mM Na2CO3/NaHCO3 (pH 9.6). All subsequent 
steps were preceded by three consecutive washes with TBS-T buffer (50 mM Tris 
(pH 8.0), 150 mM NaCl, 0.05% (v/v) Triton X-100) and all reaction volumes were 
100 µl. Plates were blocked in PBS-T-BSA (137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4, 1% (w/v) bovine serum albumin, and 0.05% (v/v) 
Tween-20) for 1 h. Reactions consisted of pooled complement human serum 
(Innovative Research), at 1% (the classical and lectin pathway) or 20% (the 
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alternative pathway) final concentration, various concentrations of BBK32 
proteins, and classical/lectin pathway buffer (20 mM HEPES (pH 7.3), 0.1% (w/v) 
gelatin, 140 mM NaCl, 2 mM CaCl2, 0.5 mM MgCl2) or alternative pathway buffer 
(20 mM HEPES (pH 7.5), 0.1% (w/v) gelatin, 140 mM NaCl, 5 mM MgCl2, 10 mM 
EGTA). Serum/BBK32 mixtures were then added to wells and incubated at 37°C 
for 1 h. Downstream complement activation was measured by detecting C3b 
deposition using a 1:300 dilution of an anti-C3d monoclonal antibody (030-08, 
Santa Cruz Biotechnology) or 1:300 dilution of an anti-C4d monoclonal antibody 
(C4-1, Cell Sciences) incubated at room temperature for 1 h, and subsequent 1 h 
room temperature incubation with a 1:5000 dilution of goat anti-mouse HRP 
secondary antibody (Thermo Scientific). HRP-labeled antibody was detected 
using 1-step Ultra TMB (Thermo Scientific) for 10 min. The reaction was stopped 
by addition of 2 M sulfuric acid and the absorbance was measured at 450 nm 
using a VersaMax microplate reader (Molecular Devices). Wells containing serum 
only or where serum was replaced with buffer were treated as 100% and 0% 
signal, respectively. All experiments were performed a minimum of three times. 
IC50 values were evaluated by variable slope four-parameter nonlinear regression 
analysis performed using GraphPad Prism 5.0. 
 
Hemolytic Assays  
Inhibition of classical pathway-mediated hemolysis by BBK32 proteins was 
assessed using a modified classical pathway hemolytic assay (CP50). Sheep 
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erythrocytes (5 x 108 cells ml-1) sensitized with human IgM (Complement Tech) 
were centrifuged at 500 x g at 4°C for 3 min and resuspended in GHB++ buffer (20 
mM HEPES (pH 7.3), 140 mM NaCl, 0.1% gelatin (w/v), 0.15 mM CaCl2, and 0.5 
mM MgCl2). Final volumes were 100 µl and reactions began by mixing 35 µl 
GHB++ with 20 µl of BBK32 proteins previously diluted into GHB++ at various 
concentrations, followed by 20 µl NHS (1% v/v) final concentration, and 25 µl 
sheep erythrocytes sensitized with human IgM. Reactions were incubated at 37°C 
for 1 h with intermittent shaking and clarified by centrifugation at 1000 x g for 3 
min. 50 µl of each reaction were transferred to a 96-well flat-bottom half-area 
microplate and absorbance was measured at 541 nm using a VersaMax 
microplate reader (Molecular Devices). A well containing no BBK32 was 
considered as 100% lysis and background absorbance was measured by 
replacing NHS with buffer. Percent lysis was calculated by subtracting 
background readings from each well and comparing each reading to 100% 
controls.  
Inhibition of alternative pathway-mediated hemolysis by BBK32 proteins 
was assessed using a modified alternative pathway hemolytic assay (APH50). 
Rabbit erythrocytes (Complement Tech) at 5 x 108 cells ml-1 were washed by 
centrifugation at 500 x g at 4°C for 3 min and resuspension in GHBS° buffer (20 
mM HEPES (pH 7.5), 140 mM NaCl and 0.1% gelatin (w/v)). Reactions began by 
diluting 5 µl of 0.1M MgCl2-EGTA into 30 µl GHBS°, followed by 20 µl of BBK32 
proteins, followed by 20 µl of NHS, and finally 25 µl rabbit erythrocytes. Reactions 
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were allowed to incubate at 37°C for 30 min with intermittent agitation, clarified, 
and diluted 1:10 in a 96-well plate. Absorbance was measured at 412 nm and % 
lysis was computed as described for the CP50 assay. All experiments were 
repeated between two and four times. IC50 values were evaluated by variable 
slope four-parameter nonlinear regression analysis performed using GraphPad 
Prism 5.0. 
 
C1r/C1s Enzyme Activity Assays  
The ability of BBK32 proteins to inhibit the enzymatic cleavage of C1s 
proenzyme by C1r enzyme in vitro was performed as follows. Reactions were 
carried out in HBS-Ca2+ (20 mM HEPES (pH 7.3), 140 mM NaCl, 5 mM CaCl2). 
Reaction volumes were 10 µl and consisted of 5 µl BBK32 protein previously 
diluted into water, 1 µl C1s proenzyme (1 µg µL-1), 1.5 µl C1r enzyme (333 nM), 
and 2.5 µl of 4x HBS-Ca2+. Following overnight incubation at 37°C, each reaction 
was mixed with 5 µl reducing SDS-PAGE Laemmli sample buffer, boiled for 5 min, 
and 7.5 µl of each reaction were separated on a 10% Tris-tricine SDS-PAGE gel. 
Following Coomassie blue staining, digital images of destained gels were 
captured using a FluorChem M imaging system (ProteinSimple). Densitometry 
was performed using AlphaView SA 3.4.0 software (ProteinSimple) and the 
normalized peak height of the band corresponding to C1s proenzyme was plotted 
against the concentration of BBK32 present in each reaction. IC50 values were 
evaluated with GraphPad Prism 5.0 using four parameter variable slope nonlinear 
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regression analysis and constraining the top and bottom values to 100 and 0 
respectively. All experiments were repeated between two and four times.  
 The ability of BBK32 proteins to inhibit the enzymatic cleavage of C4 by 
C1s enzyme in vitro was performed as follows. Reaction volumes were 10 µl and 
consisted of 2.5 µl C4 (1 mg ml-1), 1 µl C1s enzyme (1 mg ml-1), 1.5 µl PBS, and 
5 µl of BBK32 proteins previously diluted into PBS. Reactions were incubated at 
37°C for 30 min and stopped by the addition of 5 µl SDS-PAGE reducing buffer, 
boiled for 5 min, and evaluated by SDS-PAGE.  
 
C1q Co-immunoprecipitation  
Monoclonal antibodies to human C1q were captured by Protein G beads 
(Thermo Scientific) at room-temperature for 2 h as instructed by the manufacturer. 
Purified C1 complex (40 nM) was incubated at room temperature for 2 h with either 
5 μM BBK32-FL, BBK32-N, BBK32-C, or full-length recombinant OspC. All 
reactions were performed in HEPES++ buffer (20 mM HEPES, 140 mM NaCl, 0.15 
mM CaCl2 and 0.5 mM MgCl2, pH 7.3). Subsequently, C1, pre-incubated with 
borrelial recombinant proteins, was added to Protein G beads pre-loaded with C1q 
monoclonal antibodies and incubated at 37˚C for 2 hr. The beads were then 
washed 5 times with HEPES++ buffer containing 0.2% Tween-20, followed by the 
addition of 50 μl Laemmli sample buffer. Samples were then boiled for 10 min, 
separated by SDS-PAGE, transferred to PVDF membranes, and subjected to 
Western immunoblot analysis. The components of the C1 complex or BBK32 were 
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detected with polyclonal goat anti-human C1q (diluted 1:5000), goat anti-human 
C1r (diluted 1:3000), sheep anti-human C1s (diluted 1:3000), or rabbit polyclonal 
antibody to BBK32 (diluted 1:1500) followed by incubation with either HRP-
conjugated TrueBlot (Rockland Antibodies) directed against goat or sheep 
immunoglobulin (diluted 1:2000) (for the C1 proteins) or goat anti-rabbit Ig/HRP 
(Life Technologies) diluted 1:5000 (for BBK32). The membranes were washed 
extensively in PBS, 0.2% Tween-20, and developed using the Western Lightning 
Chemiluminescent Reagent plus system (Perkin Elmer, Waltham, MA, USA). 
 
B. burgdorferi whole cell adherence assays 
The B. burgdorferi adherence assay was done as previously described with 
slight modifications (Zhi et al., 2015). Briefly, poly-D-lysine pre-coated coverslips 
(Corning Biocoat) were coated with 1 µg human C1 (Comptech), C1r (Comptech), 
or BSA respectively and incubated at 4°C overnight. The coverslips were washed 
thoroughly in PBS to remove excess unbound proteins. The coverslips were then 
blocked with 3% BSA at room temperature for 1 hr. B. burgdorferi strains 
ML23/pBBE22luc and JS315/pBBE22luc were grown to mid-logarithmic phase at 
37°C, 5% CO2, pH 6.8 to induce expression of bbk32. Strains B314/pBBE22luc 
and B314/pCD100 were grown to mid-logarithmic phase at 32°C, 1% CO2, pH 7.6 
since the production of BBK32 in B314/pCD100 was high independent of growth 
condition. All B. burgdorferi strains were subsequently diluted to 107 organisms/ml 
in BSK-II medium without serum. The resulting B. burgdorferi samples, in 0.1 ml 
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volumes, were applied onto the coverslips and incubated for 2 hr at 32 °C. 
Unbound bacteria were removed from the coverslips by gentle washing with PBS; 
this wash step was repeated 7 times. The coverslips were applied to a glass slide 
and attached spirochetes were counted by dark field microscopy. 
 
Serum complement sensitivity assay  
Complement sensitivity assays were performed as previously described 
(Dam et al., 1997; Kurtenbach et al., 1998). Briefly, B. burgdorferi strains were 
grown to exponential phase at 32°C, 1% CO2, pH 7.6, and 106 cells suspension 
in 80 µl of BSK-II medium was added to 20 µl of normal human serum (NHS) or 
10 mM Mg/EGTA treated NHS, or IgM depleted human serum, to give a final 
volume of 100 µl with 20% serum. The samples were placed in microtiter plates 
and the suspensions were sealed and incubated at 32 °C for 2 h. Heat-inactivated 
normal human serum (hiNHS) was used as a control. After incubation, B. 
burgdorferi suspensions were scored under dark field microscope and the 
percentage of viable B. burgdorferi cells were calculated from randomly chosen 
fields and based on immobilization, loss of cell envelope integrity, and overt lysis. 
 
IgM depletion  
1 ml NHS was incubated with 100 µl anti-human IgM (μ-chain specific) 
agarose (Sigma) at 4°C for 1 hour. Then the agarose was gently centrifuged at 
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300xg for 3 minutes, the serum supernatant collected, and directly used for 
subsequent C4b deposition assay and serum sensitivity assays.  
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CHAPTER IV  
CONCLUSIONS AND DISCUSSION 
 
B. burgdorferi surface lipoproteins are crucial for borrelial pathogenesis  
The causative agent of Lyme disease, Borrelia burgdorferi, is a unique 
pathogenic spirochetal bacterium. Borrelia species are organized as a Gram-
negative like bacterium due to the existence of a double membrane envelope 
structure (Samuels, 2010). The composition of the borrelial outer-membrane is 
distinct from other Gram-negative bacteria in that it lacks lipopolysaccharides 
(LPS) (Takayama et al., 1987). Instead, Borrelia species produce abundant 
lipoproteins that are displayed on their outer surface and assist in the survival, 
colonization, and dissemination within the hosts they infect (Garcia et al., 2016; 
Hallström et al., 2013; Kenedy et al., 2009; Radolf et al., 2012; Seshu et al., 2006; 
Tilly et al., 2006; Weening et al., 2008; Zhi et al., 2015). During the transmission 
between the arthropod vector and vertebrate host, the surface protein profile of 
Borrelia burgdorferi changes dramatically in a manner that is largely RpoS-
dependent (Burtnick et al., 2007; Caimano et al., 2004; Hubner et al., 2001; 
Lybecker and Samuels, 2007; Yang et al., 2000). Indeed, some of the up-
regulated lipoproteins are important to the pathogenic potential of B. burgdorferi 
as they affect different aspects of the infectivity process, including immune 
evasion, colonization, and trafficking in blood vessels (Coburn et al., 2013; Garcia 
et al., 2016; Hallström et al., 2013; Kenedy et al., 2009, 2012; Moriarty et al., 2008; 
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Pal et al., 2004a; Seshu et al., 2006; Tilly et al., 2006, 2007; Weening et al., 2008; 
Zhang and Norris, 1998; Zhi et al., 2015). Specifically, BBK32 binds to fibronectin 
and GAGs through its N-terminal domain, and mediates borrelial adhesion as well 
as trafficking in blood vessels, whereas its C-terminal domain blocks the activation 
of classical complement pathway (Garcia et al., 2016; Lin et al., 2014; Moriarty et 
al., 2008; Seshu et al., 2006). DbpA/B binds to decorin and the loss of dbpA leads 
to a significantly attenuated infectivity (Weening et al., 2008). In addition, B. 
burgdorferi VlsE provides antigenic variation to avoid immune-recognition by the 
mammalian hosts (Zhang and Norris, 1998), while CspA, BBK32, and other 
proteins provide serum-resistance to complement-dependent killing (Garcia et al., 
2016; Hallström et al., 2013; Kenedy and Akins, 2011; Kenedy et al., 2009). These 
studies have provided insight into mechanisms utilized by B. burgforferi to evade 
the host immune system, disseminate, and interact with different components 
enriched within the colonized tissues. In spite of these knowns, there are many 
genes encoding putative lipoproteins that have no known function(s). Many of 
these genes are regulated by RpoS as well, suggesting that they also play a role 
during mammalian infection. As such, it is possible that the function of some of 
these lipoproteins may provide additional clarity into our understanding of the 
pathogenesis of B. burgdorferi.  
In Chapter II, I first focused on a previously uncharacterized lipoprotein-
encoding gene bba33, which is up-regulated in both feeding ticks and mammalian 
conditions in a RpoS-dependent manner (Boardman et al., 2008; Caimano et al., 
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2007; Kumar et al., 2010). I then showed that the loss of bba33 renders B. 
burgdorferi essentially non-infectious, as determined by the clearance of the 
bba33 mutant at early stages of experimental infection (Zhi et al., 2015). This 
observation suggests that BBA33 is essential for borrelial infection and possibly 
involved in initial colonization or survival in mammalian hosts. Using a phage 
display experiment, we found that BBA33 specifically targets a peptide sequence 
that matches to the collagen VI triple-helix region. In an ELISA based assay, I then 
determined that BBA33 binds type IV and type VI collagens in a dose-dependent 
manner. In addition, synthesis of BBA33 on the surface of B. burgdorferi mediates 
attachment to collagen VI, suggesting that BBA33 functions as an adhesin and 
promotes borrelial colonization within collagen enriched tissues (Zhi et al., 2015). 
The bbk32 gene of B. burgdorferi encodes a surface lipoprotein that is up-
regulated in both feeding ticks and following experimental infection in mice. 
BBK32 binds to fibronectin and GAGs, mediates borrelial trafficking in blood 
vessels (Fischer et al., 2006; Kim et al., 2004; Moriarty et al., 2012; Norman et al., 
2008; Probert and Johnson, 1998; Seshu et al., 2006), and is required for optimal 
infection of B. burgdorferi (Hyde et al., 2011a; Seshu et al., 2006). In Chapter III, 
we identified a novel function for BBK32; specifically, that BBK32 binds to the 
complement C1 complex, and inhibits the activation of the classical complement 
pathway by specifically blocking the activation of the C1r pro-enzyme. 
Subsequently, we determined that the production of BBK32 in an avirulent B. 
burgdorferi B31 isolate resulted in binding to both C1 and C1r, and provided partial 
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resistance to classical pathway-dependent complement killing (Garcia et al., 
2016).  
 
BBA33: An essential collagen-binding protein 
The interaction of B. burgdorferi and collagens is presumed to be a critical 
process during infection (Barthold et al., 1991). After the bite by infected ticks, B. 
burgdorferi is injected into the dermal layer of the skin and is deposited within the 
host extracellular matrix (ECM), which is enriched for collagens and other 
structural components (Cabello et al., 2007; Radolf et al., 2012). The observations 
that BBA33 promotes binding of B. burgdorferi to collagen VI and that bba33 
mutant is completely non-infectious suggests that this interaction is a key 
colonization event during the early stages of mammalian infection (Zhi et al., 
2015). 
The complete non-infectious phenotype of the bba33 mutant is striking. 
Multiple borrelial lipoproteins (BBK32, DbpA/B, ErpX, etc) bind ECM components 
such as fibronectin (BBK32), laminin (ErpX), and decorin (DbpA/B) (Brissette et 
al., 2009a; Kenedy et al., 2012; Probert and Johnson, 1998; Weening et al., 
2008). Nevertheless, several mutants of B. burgdorferi that lose a single adhesin, 
such as, Rev A (binds Fn), RevB(binds Fn), Bgp (binds GAGs), and ErpX (binds 
Laminin), do not exhibit a dramatically attenuated infectivity phenotype (Coburn 
et al., 2013). One hypothesis for this observation is that some of the binding 
activities for these putative adhesins may be partially overlapping and redundant. 
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The non-infectious phenotype of the bba33 mutant implies that no other B. 
burgdorferi proteins can compensate for BBA33 or that such a homologue is not 
expressed under our experimental conditions. 
Based on results obtained through the use of a peptide phage display 
library, we found that BBA33 binds to both type IV and type VI collagens. Type IV 
collagen is mainly found in the skin while type VI is enriched in skeletal muscle, 
the papillary dermis immediately below the dermal-epidermal junction, and 
around blood vessels (Watson et al., 2001). Indeed, some of the first micrographs 
of B. burgdorferi from infected tissues showed B. burgdorferi preferentially 
colonize these type IV and VI collagen enriched tissues (Barthold et al., 1991; 
Cadavid et al., 2003; Barthold et al., 2006; Cabello et al., 2007). Despite the 
known interaction between B. burgdorferi and collagen, no collagen adhesin has 
yet to be identified until our identification and characterization of BBA33 in this 
context (Zhi et al., 2015). New possible explanations as to why bba33 is crucial 
for borrelial infectivity include the following: (1), the interaction of BBA33 and 
collagens may facilitate the initial colonization of B. burgdorferi under skin, which 
is an essential step for B. burgdorferi to invade the host tissues by binding and 
breaking down ECM components; (2), this interaction may “cloak” B. burgdorferi 
and hide it from the host immune response. Accordingly, the loss of BBA33 may 
expose the bacteria to immune system at the early stage and lead to the 
clearance; and/or (3), the BBA33-mediated interaction of B. burgdorferi with 
collagens may promote spirochetal colonization and penetration of blood vessels 
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under the skin, which would promote further dissemination through the blood 
circulation system. To test the first hypothesis, one could ask whether B. 
burgdorferi adheres to collagens in a dermal fibroblast model. Dermal fibroblasts 
are major collagen-producing cells in skin (Olsen et al., 1989). B. burgdorferi 
recognizes in vitro cultivated primary dermal fibroblasts (Georgilis et al., 1992; 
Klempner et al., 1993; Wu et al., 2011); however, no specific adhesin has been 
linked to this interaction. If the bba33 mutant exhibits decreased binding to dermal 
fibroblasts relative to the parent and complement strains, then this would imply 
that BBA33 is needed for binding to these cell types. Purified collagen type VI (or 
peptide derivative thereof) could be used to test whether they can competitively 
inhibit this binding. In addition, B. burgdorferi is able to invade fibroblasts to 
prevent the killing by antibiotics and blood cells (Chmielewski and Tylewska-
Wierzbanowska, 2010; Georgilis et al., 1992; Wu et al., 2011). Using the bba33 
mutant, we could ask whether invasion requires BBA33.  
To test the third hypothesis that B. burgdorferi colonizes around blood 
vessels in a BBA33 dependent manner, an in vivo imaging system such as 
intravital confocal microscopy (IVM) could be used to observe the behavior of 
bba33 mutant under the skin and around blood vessels (Moriarty et al., 2008). 
IVM has been used extensively to monitor and quantify the motility, adhesion, and 
trafficking of B. burgdorferi in live mouse tissues and blood vessels (Moriarty et 
al., 2008, 2012; Norman et al., 2008). One can observe the interactions of B. 
burgdorferi with host cells and tissues as well as the dynamics of these 
  134 
interactions. To take the advantage of this technology, we could monitor if the 
bba33 mutant is able to colonize tissues around the blood vessels under IVM and 
whether this interaction benefits borrelial transmission through blood vessel walls. 
In summary, collagens are ubiquitous in mammalian tissues that B. burgdorferi is 
known to align with during infection (Barthold et al., 1991; Zambrano et al., 2004). 
The interaction between collagens and B. burgdorferi may directly contribute to 
the colonization, tissue tropism, and dissemination of this bacteria. Therefore, 
characterization of the BBA33-collagen interaction may provide important 
mechanistic insight into borrelial pathogenesis.  
In addition to collagen binding, the in vivo imaging data showed that the 
∆bba33 mutant was cleared early during infection, before dissemination begins, 
suggesting that BBA33 may assist in the evasion of the innate immune response. 
It is intriguing that the complement protein C1q contains a collagen-like triple-
helical motif (Kishore and Reid, 2000), which is similar to the binding ligand of 
BBA33 on collagen VI. The interaction of bacterial collagen-binding protein with 
C1q is not unprecedented and may play a role in evading the innate and adaptive 
immune response. For instance, Staphylococcus aureus collagen-binding protein 
Cna binds C1q and, in doing so, inhibits the activation of the classical pathway 
(Kang et al., 2013). Although we found that BBA33 did not inhibit the activation of 
the classical pathway in an IgM dependent C4b deposition and a hemolysis assay 
(data not shown), the interaction of BBA33 and C1q may leads to the suppression 
of other innate immune response mediated by C1q.  
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A number of studies indicate that C1q binds to different cell types and 
triggers a variety of cellular response, including enhanced microbial killing by 
phagocytosis, induction of chemotaxis, and stimulation of oxidative metabolism 
(Eggleton et al., 2000). Both the C1q globular head and collagen-like tail are 
possible ligands for cell surface C1q receptors and binding proteins (Eggleton et 
al., 1998). Therefore, BBA33 may mimic or compete with the host C1q receptors 
and interfere with the innate immune response if it recognizes the collagen-like 
region of C1q. The collagen-like region of C1q is recognized by the α-2-
macroglobulin receptor (also known as CD91), CD18, calreticulin and CR1 
(Eggleton et al., 2000; Nayak et al., 2010), each of which triggers different 
responses. For instance, CD91 enhances C1q-mediated phagocytosis of 
apoptotic cells by macrophages and epithelial cells (Duus et al., 2010; Monks et 
al., 2005), while CD18 mediates C1q-dependent neutrophil superoxide production 
(Goodman et al., 1995). BBA33 could promote borrelial entry into epithelial cells 
by binding to C1q; or it may interfere with the neutrophil superoxide production 
and promote borrelial evasion of neutrophil dependent killing as a result of 
competing with CD18 (Goodman et al., 1995). Based on these possibilities, B. 
burgdorferi could benefit from recruiting C1q on its surface during the early stage 
of infection.  
Taken together, BBA33 is an essential lipoprotein for B. burgdorferi to 
establish successful mammalian infection. In the work presented herein, we show 
that BBA33 promotes borrelial binding to collagen type VI in vitro and may 
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promote borrelial initial colonization and/or dissemination in vivo. In addition, it is 
worth noting that BBA33 may be involved in evading the host immune response 
as well, potentially by mitigating the innate immune response.  
 
BBK32: A novel complement regulator  
BBK32 is an extensively studied borrelial lipoprotein that is involved in 
borrelial pathogenesis (Hyde et al., 2011a; Seshu et al., 2006). Previous studies 
have focused on the role of BBK32 as an adhesin specific for binding to fibronectin 
and GAGs via its N-terminal domain (Fischer et al., 2006; Kim et al., 2004; 
Moriarty et al., 2012; Norman et al., 2008; Probert and Johnson, 1998; Seshu et 
al., 2006). In Chapter III, we reported that BBK32 recognizes the human 
complement protein C1r, a modular serine protease, which is essential for the 
activation of the classical complement pathway. The binding of BBK32 to C1r 
exhibits a high affinity (KD ~ 10 - 20 nM) that inhibits its enzymatic activation, 
blocks the activation of the classical pathway in vitro, and impairs classical 
pathway-dependent killing of B. burgforferi (Garcia et al., 2016). Furthermore, we 
show that the inhibitory effect of BBK32 is mediated by its previously 
uncharacterized C-terminal domain. To our knowledge, BBK32 is the first bacterial 
protein that specifically targets complement C1r and subsequently inhibits its 
enzymatic activity. 
It is of interest that a single borrelial lipoprotein, here BBK32 could perform 
two disparate functions via distinct domains. B. burgdorferi has a relatively small 
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genome and is an obligate parasite that must scavenge many nutrients from the 
hosts they infect. Hence, B. burgdorferi needs to be economical with its limited 
resources. By producing proteins with multiple functions, B. burgdorferi is able to 
efficiently utilize its energy pools and maintain survival within the hosts it occupies. 
Since bbk32 is up-regulated in both feeding ticks and the mammalian 
environment, the function of this protein as both an adhesin and a complement 
regulator would seem to simultaneously contribute to the bacterial survival during 
transmission and colonization. The N-terminal GAG and fibronectin binding 
domains of BBK32 mediate vascular adhesion and promote borrelial penetration 
through vascular walls during blood borne dissemination (Moriarty et al., 2012). 
At the same time, B. burgdorferi encounters complement-dependent killing in both 
feeding ticks where the bacteria confront blood initially, and later in the 
mammalian circulatory system. Our findings suggest that BBK32 may protect B. 
burgdorferi from the classical pathway-dependent killing by directly binding and 
neutralizing C1r.  
The classical complement pathway is involved in antibody-dependent 
killing. Thus, the blockage of the classical pathway may not only increase the 
survival capacity of B. burgdorferi in the blood circulating system at early stage of 
infection, but may also delay antibody mediated neutralization and promote 
borrelial survival after the humoral immune response develops. B. burgdorferi 
infected mice and humans generate a robust humoral immune response, yet 
these antibodies are incapable of clearing the infection. In addition, although B. 
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burgdorferi specific antibodies are sufficient to prevent infection and to reduce 
pathogen burden when passively-transferred to infected antibody-deficient mice 
(Fikrig et al., 1996; McKisic and Barthold, 2000), protection wanes over time 
following antibiotic treatment, suggesting that protective adaptive immunity is not 
long-lived (Elsner et al., 2015; Fikrig et al., 1994; Piesman et al., 1997). It was 
further shown that B. burgdorferi infection disrupts the normal formation of 
germinal centers (GC), which results in reduced antibody titers, as well as local 
C4 deposition on follicular dendritic cells (Elsner et al., 2015; Hastey et al., 2012). 
In this regard, blockage of the classical pathway by BBK32 may be involved in 
this process by reducing C4 deposition. In addition, disruption of the classical 
pathway activation may also lead to incompetent complement-dependent 
antibody killing of B. burgdorferi. 
Since BBK32 blocks the activation of C1 complement complex in vitro, it is 
important to determine if BBK32 also provides borrelial resistance to complement 
dependent killing. Wild-type B. burgdorferi is intermediately resistant to the 
complement killing when the spirochetes are incubated with normal human serum 
(NHS) (Dam et al., 1997; Kochi and Johnson, 1988), possibly due to the presence 
of BBK32, CspA, and other uncharacterized inhibitors of the complement system 
(Garcia et al., 2016; Hallström et al., 2013; Kenedy et al., 2009). In contrast, some 
B. garinii strains are sensitive to the killing by NHS; however, depletion of C1q or 
properdin completely abolished the lethality observed (Dam et al., 1997; Kochi 
and Johnson, 1988). These data suggest that both activation of the classical and 
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alternative pathways are involved in complement-mediated killing of serum-
sensitive Lyme spirochetes in the absence of Borrelia specific antibodies (Dam et 
al., 1997). As such, resistant isolates, such as B. burgdorferi, have developed 
strategies to evade or inhibit the classical and the alternative pathways to reduce 
clearance. However, despite the observation that BBK32 potently binds to C1 and 
C1r and inhibits the classical pathway, we found that the bbk32 mutant was still 
able to bind to the C1 complex, and was resistant to complement killing by NHS. 
This can be explained by the presence of redundant C1 and C1r binding proteins 
produced on borrelial surface, as well as other unknown complement inhibitors 
that could compensate for BBK32. 
To better characterize the function of BBK32 on B. burgdorferi cells, we 
used a gain-of-function strategy, and cloned full-length BBK32 into the serum-
sensitive B. burgdorferi strain B314. B314 is missing many borrelial plasmids 
(including lp36 and lp54 that encode for bbk32 and bba33, respectively) that 
encode one or several classical complement pathway inhibitors or regulators, 
which may function with BBK32 together to provide a full-scale resistance to 
classical pathway-dependent killing. Therefore, the production of BBK32 on B314 
cells allows the characterization of BBK32-specific functions. We showed that 
BBK32 production on the surface of B314 increased borrelial survival of this strain 
in NHS, but did not provide full-scale protection against complement killing. This 
can be explained from the standpoint of the pathogen and mammalian host, 
respectively. First, from the standpoint of the bacterium, the redundancy of B. 
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burgdorferi proteins exists. B. burgdorferi produces multiple proteins with similar 
functions, such as the borrelial proteins binding to C1, and those binding to factor 
H (Garcia et al., 2016; Kraiczy et al., 2004; Stevenson et al., 2002), to block 
different stages of complement activation, and ensure an effective inhibition to 
killing. Therefore, production of a single complement inhibitor such as BBK32 in 
the B314 background provides incomplete protection. Second, from the 
perspective of the host, the complement system is also redundant and 
complicated. Both the classical and alternative pathway are needed for borrelial 
killing, as the classical pathway recognizes the spirochetes and initiates the 
activation, while the alternative pathway amplifies the effects of classical pathway. 
As such, B. burgdorferi presumably needs to inhibit both pathways to survive. The 
lost linear plasmids missing in B314 encode several alternative and terminal 
pathway regulators, including CspA (Brooks et al., 2005; Hallström et al., 2013; 
Kenedy et al., 2009; Kraiczy et al., 2000; McDowell et al., 2003a; de Taeye et al., 
2013). Therefore, strain B314 fails to inactivate alternative pathway or the final 
steps of MAC formation. Even when BBK32 is produced in the B314/pCD100 
strain to dampen the classical complement pathway activation, the alternative and 
the terminal pathways are still activated and are lethal to the spirochetes. This 
could explain why bbk32 expression in B314 only restored the survival rate to 
about 40%. To better address the importance of BBK32 in a more physiologically 
relevant background, we propose to express bbk32 in a serum-sensitive B. garinii 
strain, which is an infectious Lyme disease spirochete found mainly in Europe. 
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This strain is sensitive to the classical pathway dependent killing (Dam et al., 
1997). The resulting strain could then be tested to determine if the orthologous 
bbk32 could partially restore the serum-resistance of this strain to the classical 
pathway.  
Innate immunity is critical for controlling the invasion of pathogenic 
microbes, since it serves as the first line of host defense. Although the classical 
pathway was considered as an important adjunct to adaptive immunity since it is 
best associated with antibody-antigen complex dependent killing, in fact, this 
pathway is also involved in innate immune defense (Ochsenbein and Zinkernagel, 
2000). In addition to the antigen-specific IgG, the C1 complex can be activated by 
multiple factors including IgM, C-reactive protein (CRP) and serum amyloid P 
component (SAP), which is the murine counterpart to CRP (Kishore and Reid, 
2000). CRP is a major acute phase protein in circulation with dramatically 
increased levels from less than 10 mg/L in the serum of a healthy human to more 
than 200 mg/L following the interleukin-6 secretion by macrophages and T cells 
during acute infections (Ansar and Ghosh, 2013; Thompson et al., 1999). CRP 
recognizes and bind to lysophosphatidylcholine expressed on the surface of 
apoptotic cells and some bacteria in order to activate the classical pathway via 
the C1 complex. Therefore, CRP serves as a potent activator of the classical 
pathway during bacterial infection.  
In addition to CRP, IgM is also a potent activator of the classical pathway. 
Circulating, naive IgM antibodies (for our purposes, relative to B. burgdorferi), 
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CRP, and SAP all undergo a conformational change when bound to apoptotic 
cells and foreign structures to reveal a C1q binding site (Agrawal et al., 2001; 
Chiang and Koshland, 1979). Infection of secreted IgM (sIgM)-deficient mice with 
different pathogens, including viruses, parasites, and bacteria, has revealed that 
IgM can mediate innate immune response by either facilitating interactions 
between pathogens and phagocytic cells, activating the classical complement 
pathways to lyse the cell, or blocking the pathogen binding to host cells (Boes et 
al., 1998; Brown et al., 2002; Ehrenstein and Notley, 2010; Hook et al., 2006; 
Jayasekera et al., 2007; Ochsenbein and Zinkernagel, 2000). After infection, B. 
burgdorferi is able to disseminate to distant tissues through the lymphoid and 
circulation system, indicating that the spirochetes are able to avoid the lethal 
effects from these immune responses. The capability of B. burgdorferi to resist 
the serum killing and to survive in NHS is one way to achieve the successful 
evasion of the innate immune response. The observation that the B. burgdorferi 
strain B314 isolate used in our study, as well as the serum-sensitive B. garinii, are 
susceptible to classical pathway dependent killing in normal human serum that is 
free of Borrelia specific antibody (Dam et al., 1997; Garcia et al., 2016), suggests 
that the killing is likely mediated by native and immunologically naïve IgM. 
Previous studies showed that infected ticks that feed on B-cell deficient mice 
(B6Igh-/-) harbor more spirochetes than those that feed on wild type mice and 
passive transfer of either normal mouse serum or natural mouse IgM into B6Igh-/- 
mice reduces spirochete burden in feeding ticks, whereas IgG antibodies have no 
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effect (Belperron and Bockenstedt, 2001). In addition, we showed that depletion 
of IgM from NHS restored borrelial survival to similar level of that in EGTA-treated 
serum (that neutralizes the classical and lectin pathways), suggesting that sIgM 
and the classical pathway activity are both essential for the killing of serum-
sensitive B. burgdorferi strain B314. As such, the classical pathway/IgM mediated 
innate immune response to B. burgdorferi may be a key factor to control systemic 
dissemination and infection following a tick bite. To further understand the role of 
IgM-mediated classical pathway for controlling B. burgdorferi infection in vivo, we 
can determine the infectivity of B. burgdorferi in RAG-1-/- mice and C1q-/- mice, 
respectively. These data may provide additional insight into how B. burgdorferi 
succeeds in disseminating to multiple organs and causes systemic symptoms. 
Through use of appropriate mutant strains of B. burgdorferi, it may be possible to 
decipher the functions of BBK32 and other putative classical pathway inhibitors 
involved in this process.  
In conclusion, Lyme disease is a significant and re-emerging disease that 
is a major public health issue in endemic areas. The etiologic agent of Lyme 
disease, B. burgdorferi, produces lipoproteins on the bacterial surface under 
conditions that simulate the mammalian host, many of which play a role in borrelial 
pathogenesis. BBA33 and BBK32 are both borrelial surface lipoproteins and 
contribute to B. burgdorferi pathogenesis but in entirely different ways: BBA33 
mediates the bacterial colonization and potentially interacts with collagen and 
collagen-like proteins (C1q), while BBK32 promotes borrelial resistance to the 
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classical complement cascade and provides an adhesive function to host 
structures. Since BBA33 is essential for the experimental infection of B. 
burgdorferi in the mouse model, further investigation is warranted to determine 
how BBA33 functions in borrelial colonization in the skin and dissemination from 
the skin to distant tissues. BBA33 may also be involved in evasion of the innate 
immune response based on its ability to bind to host structures that may “cloak” 
B. burgdorferi from the innate and adaptive immne responses. On the other hand, 
to our knowledge, BBK32 is the first borrelial lipoprotein that specifically inhibits 
the classical complement pathway via binding to the C1r protein and blocks its 
enzymatic activity. The ability of the BBK32 C-terminal fragment to inhibit the C1 
activation is particularly intriguing given that several pathogenic conditions are (in 
part) the result of enhanced activation of C1. Assuming that a structure can be 
resolved for the BBK32::C1r interaction, it may be possible to develop an inhibitor 
that mirrors this interaction. Taken together, this dissertation has extended our 
understanding of borrelial lipoproteins in B. burgdorferi pathogenesis and, in 
regard to the BBK32 components, provides a potential tool to target pathologies 
that involve C1 activation. 
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